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Abstract 
Introduction 
With the worldwide prevalence of diabetes continuing to increase, and current 
treatments aimed at increasing insulin secretion often losing effectiveness over time, 
it is imperative to develop new therapeutic strategies that function through 
independent mechanisms to those already developed. 
Methods and aims 
Isolated CD1 mouse islets, INS-1 β-cells and C2C12 skeletal muscle cells were cultured 
in control or glucolipotoxic environments as a model of type 2 diabetes. Using a 
combined approach of transcriptomics, PCR analysis, protein expression, fluorescent 
probes, in silico modelling, and cellular function assays, new therapeutic targets and 
treatments to augment insulin secretion in type 2 diabetes have been identified. 
Results 
Carnosine and β-alanine supplementation was shown to inhibit reactive species 
generation and to increase stimulated insulin secretion. Importantly it was also able 
to reverse glucolipotoxicity-associated inhibition of insulin secretion typically seen in 
type 2 diabetes. However, due to rapid hydrolysis of carnosine by carnosinase 
enzymes in the body, these treatment strategies are likely to be of only modest 
benefit to patients. In silico derived compounds designed to inhibit carnosinase-2 
activity had surprisingly little effect on reactive species scavenging or cellular 
function in β-cells however. Nevertheless, carnosinase inhibitors may still offer a 
 III 
 
realistic treatment strategy in patients, as β-cells are limited by carnosine 
concentrations ~1,000 fold lower than those observed in tissues linked to insulin 
resistance, such as skeletal muscle.  
Illumina HiSeq gene expression analysis identified trace amine associated receptor 
(TAAR) expression as being significantly downregulated by glucolipotoxicity. 
Furthermore, TAARs were shown to regulate insulin secretion through adenylyl 
cyclase activation and cAMP mediated enhanced insulin secretion. Addition of 
physiological TAAR ligands was also shown to be able to amplify secretagogue-
stimulated insulin release. 
Conclusion 
This body of work will pave the way for future studies seeking to develop and further 
characterise carnosine and novel carnosine derived analogs as potential therapeutic 
agents to reverse glucolipotoxic cellular dysfunction. Modulation of heterotrimeric 
G-protein coupled receptor signalling through TAAR agonists may also represent a 
new therapeutic strategy to combat type 2 diabetes.  
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1. INTRODUCTION 
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1.1. β-cell characterisation 
1.1.1. Islet of Langerhans Composition 
The pancreas is an endocrine organ that develops from the foregut endoderm as 
ventral and dorsal buds in gestation and in maturation sits behind the stomach on 
top of the large intestine (Ackermann and Gannon 2007).  The pancreas constitutes 
primarily of cell aggregates named after their discoverer and shape. These so-called 
Islets of Langerhans contain five major cell types; Alpha (α) cells that secrete 
glucagon, Beta (β) cells that secrete insulin, Delta (δ) cells that secrete somatostatin, 
Ghrelin positive cells that secrete ghrelin and F cells that secrete pancreatic 
polypeptides that account for 15-20%, 65-90%, 3-10%, 1% and 1% of the total islet 
populations respectively. Two further islet cell types have been identified; 
enterochromaffin cells that secrete serotonin, and G-cells that secrete gastrin (Elayat, 
el-Naggar and Tahir 1995; Da Silva Xavier 2018). Islets are typically oval and share a 
common arrangement of cells amongst mammals typically exhibited as a core of β-
cells enclosed within non β-cell types (Kulkarni 2004). In humans, β-cells have been 
shown to be sandwiched between two α-cell enriched layers and folded, to allow 
increased blood vessel contact (Bosco, et al. 2010). The concentration of pancreatic 
islets is also reportedly more than two fold higher in the tail of the organ compared 
to the head and body region that share a similar concentration (Wittingen and Frey 
1974; Wang, et al. 2013).  
1.1.2. Insulin Biosynthesis, Maturation, Structure and Storage 
Insulin is a key hormone in controlling glucose homeostasis through its action at 
target tissues. β-cells monitor and respond to dietary nutrients in the blood such as 
 2 
 
glucose, amino acids, fatty acids and monosaccharides and maintain a healthy blood 
glucose concentration by secreting insulin. The insulin gene encodes a 110 amino 
acid, pre-proinsulin, that after translocation through the rough endoplasmic 
reticulum (ER) through the interaction of its hydrophobic N-terminal with cytosolic 
ribonucleoprotein signal recognition particles (SRP) (Egea, Stroud and Walter 2005) 
is cleaved to proinsulin by a peptidase removing the N-terminal (Patzelt, et al. 1978). 
The proinsulin is then folded into a three-dimensional structure by the formation of 
three disulphide bonds (Huang and Arvan 1995) and packed into immature secretory 
granules at the trans-Golgi network. During granule maturation, proinsulin is cleaved 
to mature 51 amino acid insulin by removal of the C-peptide through proteolysis by 
the endoproteases PC1/3 and PC2, and trimming of the C-terminal by 
carboxypeptidase E (Hou, Min and Pessin 2009). Conversion of immature insulin to 
mature insulin is optimal at acidic pH concentrations due to the pH optimum of the 
endoproteases enzymes. Granules become acidic as they mature due to an ATP-
dependent proton pump that ensures the acidic environment optimally facilitating 
insulin conversion from proinsulin (Orci, et al. 1986; Davidson, Rhodes and Hutton 
1988).  
Mature monomeric insulin consists of a 21-amino acid A chain and a 30 amino acid B 
chain linked by the aforementioned disulphide bonds; two between chain A and B 
and one within chain A itself. Chain A is formed of two antiparallel α-helices between 
amino acid residues A2-A8 and A13-A19. The confirmation of these bring the two 
ends of the A chain into close proximity of one another and bind the helices at amino 
acids A9-A12. Chain B is comprised of both α-helices and β-sheets allowing the chain 
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to fold into a V shape. The two chains are linked by disulphide bonds derived from 
cysteine residues at amino acid A7-B7 and A20-B19 with an internal sulphide bond 
between chain A at residue A6 to A11 as shown in figure 1.1. These bonds facilitate 
the high stability of the three dimensional structure (Murray, et al. 2003; Weiss, 
Steiner and Philipson 2000; Pittman, Philipson and Steiner 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1; Structure of human insulin and proinsulin.  
The A chain consists of 21 amino acids and the B chain 30 amino acids. Two disulphide 
bridges at Cys7A-Cys7B and Cys20A-Cys19B bind chains A and B. C-peptide is cleaved 
in maturation (Murray, et al. 2003). 
 
At micromolar concentrations, mature insulin dimerises, maintained by the 
antiparallel β-sheets of the B chain. However due to the hydrophobic nature of the 
amino acid residues, insulin aggregates to form a higher ordered structure, with 6 
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molecules of insulin arranged as 3 dimers around a central Zn2+ ion at a concentration 
of ~40mM (De Meyts 2004). The total amount of granules per β-cell is disputed with 
some reports suggesting a typical mouse β-cell contains ~13,000 insulin granules 
containing ~200,000 insulin molecules each, accounting for ~11.5% of the total cells 
volume (Howell 1984; Dean 1973). Studies that are more recent suggest that this is 
actually much lower due to a reduced estimation in β-cell volume and only 5000-
6000 granules that contain two-fold more insulin than previously thought (Fava, et 
al. 2012). 
1.1.3. Regulation of Insulin Transcription and Translation 
Insulin biosynthesis is regulated at both a transcription and a translation level. The 
former is generally responsible for β-cells ability to respond to intracellular signals 
allowing insulin concentrations to fluctuate in response to high and low levels of 
nutrients. Five sequence elements named A, C, E, Z and CRE (cAMP response 
element), found within the promoter region of the insulin gene, act as binding sites 
for transcription factors enabling the regulation of gene expression (Hay and 
Docherty 2006).   
The A elements, found in the control region of the insulin gene are rich in A/T base 
pairs, with a conserved TAAT core that acts as a DNA binding recognition motif for 
the transcription factor proteins PDX-1, Isl-1 and Cdx-2 which all play various roles in 
islet function (German, et al. 1995; Gehring, Affolter and Burglin 1994; Ohlsson, 
Karlsson and Edlund 1993; German, et al. 1992; Karlsson, et al. 1990). There are two 
C-elements within the insulin gene. In rats, one of the C-elements (C1) forms a 
protein-DNA complex with the two factors; rat insulin promoter element 3b 1 and 2 
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(RIPE3b 1/2) (Shieh and Tsai 1991; Zhao, et al. 2000). Ribe3b1 also named MafA, is 
responsible for the enhancement of insulin gene-expression (Olbrot, et al. 2002), 
which is downregulated in response to prolonged fatty acid exposure (Hagman, et al. 
2005). The second C-element termed PISCES (pancreatic islet cell enhancer 
sequence) which was found to contribute to the transcription of insulin, glucagon 
and somatostatin (Knepel, et al. 1991). This element also binds the transcriptional 
factor PAX6 which is essential for islet development and normal insulin gene 
transcription (Sander, et al. 1997). Rodents have two E-elements whilst most other 
mammals only have one (Steiner, et al. 1985). Transcription factors that bind to this 
element contain a helix-loop-helix motif that facilitates protein-protein interactions, 
whilst their amino base terminal facilitates the DNA-protein binding that enhances 
transcription. The Z sequence element is upstream of the A element and is specific 
to the human insulin gene (Sander, et al. 1998). It is believed that PDX-1 and MafA 
regulate insulin transcription via this element as well as others (Pino, et al. 2005). The 
CRE promotor region consists of four sites which are activated by CRE binding 
proteins all of which share a common cluster of amino acids at their N-terminus that 
bind to the CRE sites to initiate the gene transcription (Inagaki, et al. 1992; Metallo, 
Paolella and Schepartz 1997). 
Pancreatic β-cells can also control the speed of proinsulin protein translation in 
response to nutrients such as sugar and fat. This is primarily controlled by a decrease 
in serine-51 phosphorylation of the eukaryotic initiation factory 2a (eIF2a) by protein 
phosphatase 1 activated proportionately to increasing glucose concentrations 
(Mierde, et al. 2007). Pancreatic ER kinases do the opposite and phosphorylate eIF2a 
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thereby also acting as an inhibitory regulator of insulin translation (Shi, et al. 1998). 
Polypyrimidine tract binding proteins also regulate the insulin genes mRNA 
translation as they extend mRNA viability via exon repression whilst the mRNA is 
undergoing splicing in the nuclei, whilst also stimulating translation initiation by 
recruiting ribosomes in the cytosol (Izquierdo, et al. 2005; Spellman and Smith 2006; 
Wollerton, et al. 2004). 
1.1.4. Insulin Exocytosis 
1.1.4.1. Metabolic Signalling for Insulin Exocytosis 
Insulin secretion is instigated via various pathways, ultimately culminating in influx 
of extracellular Ca2+ ions via Lc-type Ca2+ channels, as well as cAMP-dependent 
signalling cascade activation. Whilst insulin secretion is sensitive to amino acids, fatty 
acids and others, glucose is the most studied metabolite triggering insulin exocytosis. 
Insulin exocytosis is important to maintain blood glucose levels within the 
recommended healthy limit (fasting blood glucose level <5.5mM/L, up to 7.6mM/L 2 
hours after eating). 
Glucose stimulated insulin secretion (GSIS) occurs as outlined in Figure 1.2. Upon 
glucose intake into the blood, following food consumption, it enters pancreatic β-
cells through glucose transporter 2 (GLUT2) uptake. GLUT2 is the only glucose 
transporter expressed in β-cells and they have a low affinity for glucose (Km ~17mM) 
ensuring that glucose is transported proportionally into β-cells up to 10mM 
corresponding glucose concentrations in the blood (Suckale and Solimena 2008). 
Upon entry, glucose is phosphorylated by glucokinase and enters the glycolysis 
reaction. Glycolysis results in ATP and pyruvate production, where pyruvate is further 
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metabolised by pyruvate dehydrogenase and pyruvate carboxylase resulting in 
tricarboxylic intermediates that are passed into the mitochondria. These enter the 
tricarboxylic acid (TCA) chain reaction, where aerobic respiration produces further 
ATP molecules. The change in ATP to ADP ratio within β-cells causes ATP-sensitive K+ 
channels (KATP channels) to close, which in turn depolarises the cell membrane. This 
localised membrane depolarisation induces the opening of Lc-type voltage-
dependent Ca2+ channels resulting in a mass influx of extracellular Ca2+. This increase 
in localised free calcium instigates insulin granule fusion and exocytosis through 
mechanisms discussed in section 1.1.4.2. (Komatsu, et al. 2013). 
Figure 1. 2; Mechanism of glucose stimulated insulin secretion.  
Glucose enters β-cells via GLUT 2 receptors before being metabolised. Resultant 
increase in ATP:ADP ratio causes ATP sensitive potassium channels to close causing 
the cell membrane to depolarise. Depolarisation causes voltage dependent calcium 
channels to open causing localised influx of calcium which triggers insulin exocytosis. 
Figure adapted from (Komatsu, et al. 2013) 
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Fatty acids and amino acids also augment glucose stimulated insulin secretion (GSIS). 
In the total absence of free fatty acids, β-cells lose the ability to secrete insulin in 
response to glucose, however if normal physiological concentration of fatty acids are 
replaced normal secretion will resume (Stein, et al. 1996). Free fatty acid (FFA) 
concentration regulates insulin secretion via three proposed mechanisms (Figure 1.3).  
FFAs can freely diffuse across the plasma membranes into the β-cell cytosol where 
they are metabolised to long-chain acyl-CoA by the enzyme acyl-CoA synthase. The 
long-chain acyl-CoA is subsequently transported to the mitochondria by carnitine 
palmitoyl transferase -1 where it enters the β-oxidation pathway. Oxidisation of the 
long-chain acyl-CoA increases ATP production and sustains the basal level of insulin 
secretion via the KATP channel manner described in GSIS (Berne 1975; Hamilton and 
Kamp 1999).  
Upon ingestion of a carbohydrate-containing meal, glucose and amino acids are 
synthesised into malonyl-CoA by acyl-CoA carboxylase. Malonyl-CoA is a regulatory 
compound that inhibits carnitine palmitoyl transferase-1 transport of long chain acyl-
CoA into the mitochondria thereby inhibiting fatty acid metabolism. The resultant 
accumulation of long-chain acyl-CoA in the cytosol increases intracellular Ca2+ 
concentrations, enhances insulin granular fusion at the membrane and changes the 
acylation state of ion channel activity and exocytosis, all of which augment insulin 
secretion (Newsholme and Krause 2012).  
The heterotrimeric enzyme AMP-kinase regulates the level of ATP production from 
FFA oxidation as it inhibits the activation of acyl-CoA carboxylase, decreasing 
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malonyl-CoA inhibition of carnitine palmitoyl transferase-1, increasing FFA entry into 
the mitochondria for metabolism (McGarry, et al. 1991). Increasing glucose 
concentrations dephosphorylate and inactivate β-cell AMP-kinase increasing 
malonyl-CoA inhibition of carnitine palmitoyl transferase-1, increasing insulin 
secretion (Salt, et al. 1998). 
FFAs can also stimulate G-protein coupled receptors such as GPR40 (also known as 
free fatty acid receptor 1) and GPR119. Activation of GPR40 increases intracellular 
Ca2+ concentrations by stimulating Ca2+ release from the endoplasmic reticulum via 
Gαq-phospholipase C pathway activation, resulting in an increase in insulin 
exocytosis (Shapiro, et al. 2005; Kebede, et al. 2008). Similarly stimulation of GPR119 
with the lipid oleoylethanolamide (a product of membrane phospholipid 
metabolism), increases insulin secretion through adenylyl cyclase mediated 
production of cAMP (Winzell and Ahrén 2007; Moran, et al. 2014) 
However, chronic levels of free fatty acids, particularly in conjunction with increased 
glucose concentrations will reduce β-cell insulin biosynthesis and secretion 
capabilities over time until complete β-cell failure (Prentki, et al. 2002; Poitoit, et al. 
2006).  
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Figure 1. 3; Fatty acid regulated insulin secretion.  
FFAs are converted to acyl-coA and either enter the mitochondria for metabolism 
which increases the ATP:ADP ratio maintaining basal insulin secretion via KATP 
channel pathway, or it is blocked by malonyl-CoA production and accumulates in the 
cytosol. This accumulation of acyl-CoA increases Ca2+ causing insulin exocytosis. AMP-
kinase activity is inhibited with increasing glucose concentration thereby blocking 
fatty acid metabolism further increasing insulin secretion. FFA can also stimulate 
GPCRs which increase intracellular Ca2+ via adenylyl cyclase production of cAMP, or 
activation of the Gαq-phospholipase C pathway activation, resulting in an increase in 
insulin exocytosis. Figure inspired by (Nolan, et al. 2006)  
 
Typical physiological concentrations of individual amino acids are poor 
secretagogues of insulin, however, the combination of leucine and glutamine at 
these same concentrations can augment GSIS. Glutamine is firstly converted into 
glutamate by intracellular glutaminase. Secondly, leucine activates glutamate 
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dehydrogenase which in turn converts the recently produced glutamate to α-
ketoglutarate where it can enter the TCA cycle to increase the production of ATP. The 
increase in ATP increases insulin secretion via the GSIS method described previously 
(Sener and Malaisse 1980; Dixon, et al. 2003). 
Similarly, hormones also have the potential to augment GSIS. Glucagon-like peptide 
1 (GLP-1) and gastric inhibitory peptide (GIP) account for roughly 50% of the insulin 
released after ingesting dietary glucose (Nauck, et al. 1993). The incretin hormones 
secreted from L-cells in the small intestine in response to nutrient consumption bind 
to their receptors, (both members of the GIP receptor family (Mayo, et al. 2003)) 
found on β-cell membranes to activate adenylyl cyclases via stimulatory G proteins. 
The subsequent rise in cAMP production from adenylyl cyclase enabled ATP 
conversion can increase insulin secretion via PKA-dependent and PKA-independent 
pathways. cAMP dependent PKA activation results in phosphorylation of voltage 
gated and ATP dependent channels increasing the intracellular concentration of Ca2+. 
PKA also sensitises secretory machinery to Ca2+, whilst increasing secretory vesicle 
mobility for granule replenishment, all promoting enhanced insulin granule 
exocytosis.  
PKA-independent cAMP insulin secretion which is mediated by Epac is much faster 
than PKA-dependent mechanisms (Henquin and Nenquin 2014). Epac has two 
isoforms Epac1 and Epac2, of which the latter is culpable for increases in insulin 
exocytosis. The true mechanism of Epac mediated insulin secretion is still not fully 
understood. Epac2 is thought to stimulate the recruitment of granules to the 
membrane and cause exocytosis via Rap1 interaction and activation of small GTPases 
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which modulate the actin cytoskeleton. Alternatively, Rap1 mobilises intracellular 
calcium via phospholipase C-ε causing exocytosis. In addition, Epac interaction with 
the SUR1 subunit of the KATP channels are a pre-requisite for granule priming whilst 
it also interacts with the t-SNARE and SNAP25 components of the secretory 
machinery crucial for exocytosis. Epac’s interaction with Rim2 at the Rab3 subunit 
has also been implicated as the effector of incretin augmented insulin secretion (Holz 
2004; Lim and Brubaker 2006; Tengholm 2012). 
1.1.4.2. Granule Fusion and Exocytosis 
Once the insulin containing granules have been transported to the membrane, the 
35kDa vesicular v-SNARE (soluble NH2-ethylmaleimide-sensitive fusion protein 
attachments protein receptor protein) VAMP2 (synaptobrevin), forms a complex 
with the target membrane associated receptors syntaxin 1A and SNAP25 (35kDa and 
25kDa respectively) in a ratio of 1:1:2 in specific areas on the membrane called 
excitosomes (Figure 1.4). There are more than 30 SNARE protein family members, all 
of which are 60-70 amino acids in length that form a seven coiled-coil structure 
(Sudhof and Rothman 2009).  
Upon insulin containing granules reaching the membrane, the receptor interaction 
and binding of exocytosis machinery results in a conformational change, forming a 
four-helix coiled-coil complex known as the SNAREpin that is incredibly stable with 
melting temperatures above 95°C (Thurmond 2007). Whilst this complex forms the 
catalytic exocytotic machinery required for granular docking at the membrane, the 
complex alone is not sufficient to induce rapid Ca2+ dependent exocytosis; other 
accessory proteins are required. 
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 The insulin granule membrane proteins synaptotagmins are considered one of the 
most likely contenders to effect Ca2+ dependent insulin exocytosis as they are large 
proteins with two Ca2+ binding domains (Sugita, et al. 2002). Synaptotagmins of which 
there are 15 known mammalian isoforms (Rickman, et al. 2004) have been 
demonstrated to instigate rapid neurotransmitter synaptic vesicle exocytosis 
through complexin displacement. Complexin is a regulatory protein that inhibits 
spontaneous release by blocking the full assembly of the so called SNAREpin by 
clamping to VAMP2. This arresting of complete granular fusion essentially primes the 
vesicles for rapid synchronised exocytosis in response to calcium (Melia Jr 2007; Lai, 
et al. 2014). Calcium binding to synaptotagmins is thought to uncouple complexin 
from VAMP2 enabling full SNARE complex formation allowing granular fusion and 
exocytosis (Tang, et al. 2006).  
The core exocytotic machinery for insulin secretion and neurotransmitter exocytosis 
is the same and whilst they share a similar requirement for increased Ca2+ to instigate 
secretion, the kinetics of exocytosis is very different, indicative of distinct regulatory 
machinery changes between cell types. Because of this, synaptotagmins III, V, and VII 
have all been implicated as mediators for Ca2+ induced insulin secretion in pancreatic 
β-cells (Gao, et al. 2000; Gustavsson, et al. 2008). Conflicting data about 
synaptotagmin IX has also been reported. Iezzi et al (2005) reported that adenovirus- 
mediated silencing of synaptotagmin 9 reduced Ca2+ dependent islet insulin secretion, 
whilst more recently, Gustavsson et al (Gustavsson, et al. 2010) reported that whilst 
synaptotagmin IX is important for rapid neurotransmission, it plays no role in 
glucose-stimulated insulin secretion regulation in β-cells. All these studies however, 
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only demonstrated a partial inhibition of insulin secretion upon inhibition of 
synaptotagmins. This, alongside the differences in kinetics between rapid 
synaptotagmin dependent neurotransmission and the more multiphasic insulin 
exocytosis, would suggest that synaptotagmins may not be the sole Ca2+ sensor 
culpable in insulin secretion and may in fact work in combination with multiple 
isoforms, or with different Ca2+ sensors altogether. 
One such sensor could be the 54KDa isoform of Calpain-10. Calpain-10 has been 
demonstrated to interact directly with SNAP25 during Ca2+ dependent insulin 
secretion (Marshall, et al. 2005). This was successfully inhibited with a calpain 
protease inhibitor suppressing both SNAP25 proteolysis (postulated to be required 
for secretion) and insulin secretion. Calpain-10 expression is also contrastingly high 
in β-cells compared to synaptotagmins (Aganna, et al. 2006) which further suggests 
calpain-10 may perform a central role in Ca2+ secretion coupling in pancreatic β-cells.  
MUNC18 also plays a regulatory role in insulin granule priming and fusing at the 
cellular membrane. MUNC18a is a competitive inhibitor for SNAP25 and VAMP2 
binding to syntaxin and is thought to change the syntaxin conformational shape 
further inhibiting exocytosis (Dong, et al. 2007). However, conflicting research 
suggests that MUNC18 is required for first-phase insulin secretion and encourages 
granule docking (Oh, et al. 2012). One theory is that MUNC18 increases vesicle 
docking but inhibits vesicle priming and it is therefore critical to maintain the correct 
expression to promote adequate granule docking without impeding overall 
exocytosis (Hou, et al. 2009). 
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Figure 1. 4; SNARE complex of insulin exocytosis.  
VAMP2 on the granule membrane form a complex with SNAP25 and syntaxin 1A on 
the intracellular membrane. Complexin inhibits spontaneous exocytosis, priming the 
granules, before Synaptotagmin activation by Ca2+ uncoupled complexin causing 
granular fusion and exocytosis. MUNC18 is also a regulator promoting granule 
docking but inhibiting granular fusion. Figure adapted from (Thurmond 2007). 
 
1.1.4.3. Granule Trafficking to the Cell Membrane 
It is accepted that there are at least two different insulin granule populations within 
pancreatic β-cells. The readily releasable pool which is pre-docked in the SNARE 
protein complex at the cell surface membrane (Daniel, et al. 1999) which accounts 
for roughly <5% (less than 50 granules of the total granule pool ~10,000 granules per 
cell) and is responsible for the first phase of rapid calcium-dependent insulin 
secretion that lasts 1-5 minutes. The second phase of insulin exocytosis is dependent 
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upon the reserve pools of insulin granules that are recruited to the membrane over 
a more prolonged period of time, ~5-60 minutes. The readily releasable pool is 
continually replenished which starts in the first phase of secretion. Docking and 
priming of previously non-releasable granules occurs at ~5-40 granules per minute 
per cell (Barg, et al. 2002) 
 F-actin and microtubule networks are thought to play a significant role in stimulated 
insulin secretion and granule mobilisation in particular (Figure 1.5). F-actin interacts 
directly with syntaxin 1A on the cellular membrane, inhibiting granule-SNARE-
complex formation blocking the movement of insulin granules to the membrane. It 
does however also provide transportation for granules to be trafficked closer to the 
membrane from the cytosol. Upon glucose stimulation, F-actin blocking the syntaxin 
disaggregates, allowing the mobilisation of granules and fusion of VAMP2 on the 
vesicle membrane to SNAP25 and syntaxin at the cellular membrane resulting in 
insulin exocytosis. This remodelling is known to be regulated by the Rho-family of 
GTPases activated by glucose. In the second phase of glucose stimulated insulin 
secretion, microtubules traffic insulin containing granules from the central cell 
cytosol to the F-actin filaments near the cell membrane where they are further 
mobilised along the F-actin tracks to the cell surface to dock with SNARE proteins and 
be released (Wang and Thurmond 2009).  
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Figure 1. 5; Granule recruitment by cytoskeleton. 
Insulin granules are mobilised to F-actin at the cell peripheral by microtubules in the 
second phase of insulin secretion. In response to glucose, F-actin which blocks the 
SNARE complex formation disaggregates and traffics insulin containing granules to 
the membrane where they fuse and are exocytosed. Figure adapted from (Wang and 
Thurmond 2009). 
 
1.1.5. Insulin Signalling 
Briefly, the main function of insulin signalling is to increase glucose transport into fat 
and muscle cells by stimulating GLUT4 translocation from intracellular sites to the 
cellular membrane. However, in truth it has pleiotropic actions ranging from 
controlling glucose, lipid and protein metabolism, cell growth, gene expression and 
glucose transporter expression (Figure 1.6). 
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Insulin binds with high affinity to the tyrosine kinase insulin receptor on the surface 
of skeletal muscle, liver and adipose tissues. The receptor is composed of two 135kDa 
α-subunits (completely extracellular) and two 95kDa β-subunits that span the 
membrane (Jacobs and Cuatrecasas 1981). Insulin binds at the cysteine rich domain 
of the α-subunit, causing the receptor to autophosphorylate six tyrosine residues in 
the β-subunit mediating the signal transduction by increasing the tyrosine kinase 
activity (Zhang and Roth 1991; Cheatham and Kahn 1995).  
The autophosphorylation of the β-subunit mediates non-covalent stable bonding of 
substrate molecules that are rapidly phosphorylated themselves. These include, but 
are not limited to the insulin receptor substrate (IRS) proteins (1-6), Src-homology-
collagen (SHC) proteins, growth factor receptor bound-2 (Grb-2) and the CAP/c-Cbll 
complex (Langlais, Mandarino and Garvey 2015).  
Phosphorylation of the IRS proteins allows its SRC homology 2 (SH2) domains to 
associate and activate phosphoinositide 3-kinase (PI3K) by binding at its regulatory 
subunits. Activated PI3K phosphorylates PtdIns(3,4)P2/PtdIns(3,4,5)P3-dependent 
kinase-1 (PDK-1) at the 3’ position of the inositol ring or serine residues which in turn 
activates the serine kinase PKB/Akt. PKB/Akt deactivates glycogen synthase kinase 3 
(GSK-3), causing glycogen synthesis to increase as well as promoting cell growth and 
survival. Importantly, PKB/Akt also stimulates GLUT4 translocation to the membrane 
allowing increased glucose uptake in response to insulin binding (Bevan 2001).  
Phosphorylation of IRS, Grb2 and SHC also cause interaction with adapter proteins 
which activates Ras. Ras acts as a molecular switch to activate a serine kinase cascade 
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pathway of Raf, MEK and mitogen-activated protein kinase (MAPK) extracellular 
signal regulated kinase (ERK). Activated MAPK/ERK can translocate to the membrane 
where it can phosphorylate transcription factors regulating gene expression and cell 
growth and survival (Saltiel and Kahn 2001). 
Stimulated GLUT4 translocation to the membrane also occurs via another separate 
mechanism. Insulin binding with its receptor and receptor autophosphorylation 
phosphorylates Cbl; a protooncogene that is in a complex with Crk and associated 
with the adapter protein CAP (Ribon and Saltiel 1997; Ribon, et al. 1998). Upon 
phosphorylation the CAP/Cbl/Crk complex, the sorbin homology domain (SOHO) of 
the CAP protein interacts with the lipid raft associated protein flotillin, causing the 
complex to migrate to the membrane (Baumann, et al. 2000; Kimura, et al. 2001). 
This in turn mediates guanyl nucleotide exchange factor, C3G recruitment to protein 
complex at the Crk element, which activates TC10. TC10 activation stimulates 
intracellular reserve pools of GLUT4 to translocate to the membrane enabling 
glucose uptake into the cell (Chiang, et al. 2001; Saltiel and Kahn 2001). GLUT4 
translocation and subsequent granule fusion resulting in increased expression on the 
cell surface is mediated by the same SNARE complex of VAMP2 and syntaxin involved 
in insulin granule exocytosis (Pessin, et al. 1999). 
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Figure 1. 6; Insulin Signalling Transduction Pathway.  
Upon insulin binding to its receptor, the receptor autophosphorylates which 
activates the receptor as a kinase. The receptor binds and phosphorylates and 
activates adapter proteins IRS and CAP/Cbl/Crk complex. IRS phosphorylation 
activates PI3K which phosphorylates PDK-1. This activates PKB/Akt transduction 
pathway which stimulates GLUT4 containing vesicles to translocate to the membrane, 
promotes cell growth and survival and inhibits GSK-3 causing glycogen synthesis and 
secretion to increase. IRS phosphorylation also activates the Ras pathway resulting 
in MAPK driven changes in gene expression and cell growth. The insulin receptor 
kinase also phosphorylates the CAP/Cbl/Crk complex that associates to C3G, 
activating TC10 which further promotes GLUT4 vesicle translocation to the cell 
membrane. Figure adapted from (Saltiel and Kahn 2001). 
1.1.6. Insulin Degradation 
Insulin degradation is the process of removing insulin from its receptor and 
deactivating its signalling cascade that results in glucose uptake, as well as insulin 
hydrolysis by the zinc-metalloproteinase; insulin-degrading enzyme (IDE) removing 
the hormone from circulation. Insulin has a short half-life of 4-6 minutes in the blood 
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(Duckworth, Bennett and Hamel 1998) with the main insulin clearance sites being 
mediated in the liver and kidney in an insulin receptor dependent mechanism.  
In a study by Hovorka et al (1993), 80% of total body insulin was found at the liver, 
where it spent ~60 minutes bound to its receptor, ~6 minutes bound to peripheral 
receptors and ~3 minutes in the blood (Hovorka, et al. 1993). Insulin internalisation 
and degradation primarily occurs in the hepatocytes of this organ tissue. In the 
kidney, ~50% of peripheral insulin is cleared from circulation, however, insulin 
degradation occurs in all insulin sensitive tissues (Rabkin and Kitaji 1983; Duckworth, 
et al. 1998).  
Insulin receptors bound to insulin are internalised by receptor phosphorylation 
mediated events thought to depend on the juxtamembrane region of the receptor 
(Backer, et al. 1990). Internalised insulin receptors with bound insulin is packed into 
endocytotic vesicles called endosomes which rapidly acidify causing insulin to 
disassociate from its receptor. Insulin is then partially or fully degraded by IDE 
(Duckworth, et al. 1998). IDE is a 110kDa zinc-metalloproteinase that consists of two 
55kDa domains in its monomeric form. These domains; IDE-N and IDE-C are 
connected by a 28 amino acid loop that forms a crypt between the two. This charged, 
polar and hydrophilic crypt contains the catalytic site for substrate binding, which 
excludes peptides bigger than 70 amino acids long (Hulse, Ralat and Wei‐Jen 2009). 
IDE hydrolyses insulin initially on the B-chain, followed by hydrolysis of the disulphide 
bond connecting to two different chains (Seabright and Smith 1996). Unbound insulin 
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receptors are subsequently recycled to the plasma membrane via diacytosis where it 
can freely bind to other circulating insulin molecules (Duckworth, et al. 1998). 
1.2. Diabetes Mellitus 
Diabetes mellitus is a polygenic metabolic condition characterised by high circulating 
blood glucose defined as ‘hyperglycaemia’. The disease is characterised by 
diminished insulin secretion or reduced insulin sensitivity at target tissues or a 
combination of both. As these deficiencies frequently coexist and work synergistically 
in an individual, it is often hard to determine the primary cause for the disease onset. 
In addition, there are numerous class types of diabetes all with different causes and 
risk factors (American Diabetes Association 2014). The three most common are: 
 Type 1 Diabetes (T1D) is an autoimmune condition where the immune 
system attacks and destroys the pancreatic β-cells. The resultant loss of 
insulin secreting cells causes hyperglycaemia and further downstream 
complications. There are many contributing factors to the onset of this 
condition such as genetics, epigenetics, immunological and environmental 
factors. The onset occurs with increasing incidence in earlier life (under 10 
years) and accounts for ~10% of all diabetics (Paschou, et al. 2018). 
Treatments for this will typically be insulin injections. 
 Type 2 Diabetes (T2D) is the most common classification accounting for ~90% 
of all diabetics. The condition is characterised by increased hyperinsulinemia, 
loss of insulin sensitivity and β-cell failure and resultant hyperglycaemia. T2D 
has a slow onset developing over many years and has a number of 
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contributing elements; the main risk factor being obesity and high sugar and 
fat diets. A change in lifestyle, diet and oral medication is often used to treat 
T2D, however insulin injection may be necessary if β-cell failure is advanced.  
 
 Gestational Diabetes (GD) occurs in ~5% of all pregnancies and imposes 
pregnancy and birth complications as well as a risk to both mother and child 
of developing T2D in the years following the pregnancy. GD results due to an 
inability for the mother to increase their insulin response by ~200-250% to 
maintain a euglycemic pregnancy, and is thought to be caused by pregnancy 
hormones as well as obesity related insulin resistance (Kampmann, et al. 
2015). 
1.2.1. Diabetes Mellitus Epidemiology 
1.2.1.1. Worldwide Prevalence, Distribution and Cost 
Diabetes is one of the fastest growing global issues of the modern world, affecting all 
countries regardless of economic power and social class (however a lower-socio 
economic status does correlate with a higher prevalence (Rabi, et al. 2006)) and 
continues to grow at an alarming rate. It is estimated that in 2017, 425 million people 
worldwide, (roughly 8.8%) aged between 20 and 79 had diabetes. This is a huge 
increase from the 127-182 million (4.7%) thought to have diabetes in the year 1980. 
This occurrence is set to increase further to a predicted 629 million people aged 20-
79 by the year 2045 (International Diabetes Federation 2017; Danaei, et al. 2011; 
Ogurtsova, et al. 2017). Diabetes has a slightly higher estimated prevalence in males 
than females affecting 9.1% and 8.4% respectively, peaking between the ages 65-69 
years for males and 75-79 years for females.  
 24 
 
Age-adjusted comparative analysis indicates that North America and the Caribbean 
region has the highest prevalence of diabetes of 11%, followed by the middle east 
and North Africa (10.8%), South-East Asia (10.1%), Western Pacific (8.6%), South and 
Central America (7.6%), Europe (6.8%) and lastly Africa (4.4%). These varied 
prevalence percentages are due to many factors such as levels of obesity, nutrition, 
genetics and urbanisation with the concordance of the condition being higher in 
urban environments compared to rural locations. This trend is therefore set to 
continue due to sustained global urbanisation. In terms of individuals with diabetes, 
it’s estimated China has the most (114.4 million) followed by India (72.9 million) and 
the United States (30.2 million) and is therefore a reflection of countries with larger 
populations (International Diabetes Federation 2017).  
A recent study by Bommer et al, (2017) determined that the global diabetes-
associated costs in the year 2015 was as high as 1.31 trillion US dollars ($) accounting 
for 1.8% of the world’s total gross domestic product (GDP). This observably varied 
between countries dependent upon their GDP with the North American region 
having the highest total percentage spent on diabetes, whilst also having the highest 
absolute costs globally. Diabetes is a universally significant economic burden that is 
set to substantially rise in response to increasing incidences with low to middle-
income countries bearing a larger portion of future expenditure burden than high-
income countries (Bommer, et al. 2017; World Health Organisation 2016) 
1.2.1.2. United Kingdom Prevalence, Distribution and Cost 
3.2 million UK nationals have been diagnosed with diabetes as of the year 2013 with 
the actual occurrence rate believed to be much higher. This is estimated at more than 
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one in seventeen, with over half a million people living in the UK that have 
undiagnosed diabetes. Data from the 2012/3 quality and outcomes framework 
indicate that the diagnosed prevalence in England, Northern Ireland, Scotland and 
Wales is 6.0% (2,703,044), 5.3% (79,072), 5.2% (252,599) and 6.7% (173,299) 
respectively, giving an average diabetes prevalence of 6% of the total UK population. 
This is conservatively around 7.5% when taking into consideration diagnosed and 
non-diagnosed individuals. This in agreement with expected global figures is set to 
increase to over five million people by the year 2025 (Diabetes UK 2014). The 
believed cost of diabetes to the National Health Service (NHS) was £23.7 billion in 
2012 with £9.8 billion accounting for direct costs. This accounts for 10% of the whole 
NHS budget and is projected to rise to over 17% in the next 20 years (Hex, et al. 2012). 
1.2.2. Diabetes Mellitus Symptoms and Diagnosis 
Detecting and diagnosing type 2 diabetes is crucial in combatting the onset of the 
condition. Early diagnosis of prediabetes or early stage diabetes can limit further 
damage to important glucose regulating insulin secreting pancreatic β-cells and 
insulin target tissues such as skeletal muscle and adipose tissue. This will allow the 
best possible outcome with multiple treatment options to permit prolonged life and 
avoidance of downstream complications attributed directly to diabetes. Common 
noticeable symptoms arise due to increased circulating blood glucose concentrations 
that the body can no longer manage, in response to diminished insulin secretion or 
diminished insulin sensitivity. The increased circulating blood glucose concentration 
will start to damage peripheral systems; subsequently in response, the body will try 
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to expel the excess glucose in the urine. The following common symptoms are a 
result of this: 
 Urinating more frequently, particularly ay night 
 Increased thirst 
 Fatigue 
 Unexplained weight loss 
 Blurred vision 
 Slow wound healing 
Despite these common symptoms, as the undiagnosed patient data demonstrates it 
is possible to have diabetes for many years without noticing, as the condition 
manifests gradually over time. This can mean that it may not always present itself 
with any clear symptoms or symptoms that make you feel unwell (NHS 2017). 
In 2011 World Health Organisation (WHO) recommended that glycated haemoglobin 
(HbA1c) be used as a diagnostic test for diabetes. This test indicates the level of 
average circulating blood glucose, and the expert advisory group recommended a 
level of 6.5% and above (>48mmol/mol) indicates a positive result for the condition. 
A reading of 6-6.4% indicates a patient with a very high risk of developing diabetes 
without lifestyle adjustments and warrants retesting a minimum of every three years 
(World Health Organization 2011; National Institute for Health and Care Excellence 
2012). An oral glucose tolerance test (OGTT) is also used to classify patients that have 
impaired carbohydrate tolerance and has been shown to have reasonable accuracy 
in predicting insulin sensitivity and insulin release. After a 10 hour overnight fast, 
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subjects ingest a high glucose liquid with blood glucose measured at 30 minute 
intervals for 2 hours. A healthy individual will have a starting glucose concentration 
lower than 6mMol/L and less than 7.8mMol/L two hours after the test. A diabetic 
patient will have a starting concentration of more than 7mMol/L and more than 
11mMol/L two hours after. 
1.2.3. Type 2 Diabetes 
Type 2 diabetes is characterised by the dysregulation of glucose homeostasis as a 
result of insulin resistance and impaired β-cell function. There are numerous risk 
factors to developing type 2 diabetes. Obesity is the largest risk factor, yet other 
lifestyle factors such as physical activity, smoking and alcohol as well as genetic 
predispositions all play a role in its development (Wu, et al. 2014). 
Typically, insulin resistance in primarily muscle tissue in response to years of chronic 
exposure to high sugar and fat is the first sign of type 2 diabetes development 
(Petersen, et al. 2007). In response to the onset of insulin resistance, the pancreatic 
β-cells will initially adapt to combat the decrease in insulin sensitivity by increasing 
insulin gene expression and β-cell mass, resulting in a compensatory increase in 
insulin secretion to maintain normal glycaemic levels.  Research suggests that β-cell 
mass is mainly increased in response to increased circulating nutrients. Increased 
circulating glucose can activate mTOR signalling directly and indirectly via AMP kinase. 
The mTOR pathway is known as an important regulatory process for β-cell 
proliferation and mass (Chang-Chen, Mullur and Bernal-Mizrachi 2008)  
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Stimulation of the IRS-2 with insulin-like growth factors causes PKB phosphorylation 
which in turn inactivates the forkhead-O transcription factor-1 increasing expression 
of transcription factor PDX-1, which increases insulin gene transcription and 
promotes proliferation and growth. Increased GLP-1 production from intestinal L-
cells can also activate PKB and IRS-2 via CREB (cAMP response element-binding 
protein). Increased FFAs and signalling via GPCRs may also have a proliferative effect 
(Prentki and Nolan 2006). As a result, insulin secretion has been demonstrated to be 
more than double in non-diabetic morbidly obese patients compared to control 
patients (Camastra, et al. 2005). 
The increase in cell mass and gene expression increases insulin secretion enough to 
overcome the initial insulin resistance, however in response to chronic exposure to 
high sugar and high fat for an undetermined number of years, β-cells begin to fail. 
The mechanism behind this are discussed in more detail in glucolipotoxicity section 
(section 1.3). Consequentially, prolonged exposure to hyperglycaemia and constant 
high demand for insulin, eventually results in decreases in insulin mRNA transcription, 
insulin content and insulin secretion (Olson, et al. 1993). Pancreatic β-cell mass was 
reported to be >40% reduced in type 2 diabetic patients with a 10-fold increase in β-
cell apoptosis compared to healthy controls (Butler, et al. 2003). Diabetes is thought 
to clinically develop at 65% β-cell mass reduction (Meier, et al. 2012), resulting in 
complete dysregulation of glycaemic and fatty acid control which can be detrimental 
to all tissues types, including further compounded toxicity to β-cells. The action of β-
cell adaptation and failure is represented in Figure 1.7. 
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Figure 1. 7; β-cell adaptation and failure in type 2 diabetes in response to chronic 
exposure to glucose and free fatty acids.  
In response to insulin resistance, insulin gene expression, β-cell mass and insulin 
secretion increases. After an undetermined period of time, β-cells begin to fail and 
can no longer compensate for the higher demand and insulin. The loss of β-cell mass 
and function results in complete loss of glycaemic control, with levels remaining 
constantly within the hyperglycaemic range. Figure from (Poitout, et al. 2010) 
 
Downstream complications of type 2 diabetes arising from poor glycaemic control in 
the face of β-cell failure are very serious and can be life threatening. Diabetic 
nephropathy is the largest cause of end stage renal failure characterised by 
proteinuria and diminished glomerular filtration and if untreated it can be fatal 
(Chaturvedi 2007). Diabetic retinopathy caused by hyperglycaemic dependent 
microvascular damage is the leading cause of preventative blindness in adults ages 
20-74 years (Fong, et al. 2004). Diabetic neuropathy is the leading diabetic cause of 
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patient hospitalisation and is the most common cause of non-traumatic lower limb 
amputation. It kills 25-50% of patients with diabetic neuropathy within 10 years due 
to myocardial infarction (Bansal, Kalita and Misra 2006). Diabetes is a main risk factor 
for developing cardiovascular disease and  is the primary cause of diabetes related 
mortality as a result of  oxidative stress inhibited atherogenesis, myocardial damage 
after ischemic events and diminished low-density lipoprotein oxidation  (Leon and 
Maddox 2015; Wu, et al. 2014). 
1.3. Glucolipotoxicity in β-cells 
As type 2 diabetes is characterised by both high sugar (hyperglycaemia) and high fat 
(hyperlipidaemia), it is important to understand the synergistic destructive 
mechanistic pathways of both toxic levels of sugar and fat termed ‘glucolipotoxicity’ 
and is demonstrated in Figure 1.8. 
1.3.1. Glucotoxicity 
Glucose is required for energy production and is stored primarily in the liver as 
glycogen which can be mobilised and converted back to glucose via gluconeogenesis 
when blood glucose concentrations are low. Glucotoxicity refers to the chronic 
exposure of tissues to high levels of circulating blood glucose concentrations from 
the diet. One central mechanism by which high glucose concentrations cause damage 
to pancreatic β-cells causing the onset of diabetes is through the generation of 
oxidative and ER stress (Hasnain, Prins and McGuckin 2016).  
High levels of reactive species such as reactive oxygen and nitrogen species, ROS and 
RNS respectively, can be generated by hyperglycaemia in numerous key pathways. 
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Glyceraldehyde autoxidation occurs from enolization of the product of aerobic 
glycolysis; glyceraldehyde-6-phosphate, to produce α-ketoaldehydes. These can in 
turn be auto-oxidised to produce hydrogen peroxide (H2O2) and hydroxyl radicals 
(OH∙) (Wolff and Dean 1987). Glycerol-3-phosphate can be acylated to diacylglycerol 
which can activate protein kinase C (PKC). PKC activation has numerous biochemical 
actions including nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
activation. NAPDH oxidase is thought to be an integral activator of receptor 
stimulated ROS production (Lee, et al. 2003). H2O2 is also produced by glucosamine 
production via the hexosamine pathway (Kaneto, et al. 2001). Elevated glucose also 
increases the mitochondrial protein gradient via electron overproduction in the TCA 
cycle inhibiting complexes I and III, promoting superoxide (O2∙) species production 
(Du, et al. 2000). Superoxide produced in the mitochondria is not able to freely move 
across the membrane due to its charge, so is converted to the less reactive hydrogen 
peroxide by superoxide dismutase. Hydrogen peroxide can freely diffuse into the 
cytosol where it is converted back to the more reactive hydroxyl species. Increased 
glucose can also induct the NOS2 gene which encodes for iNOS resulting in elevated 
nitric oxide (NO) production. Numerous reactive species can then react together to 
form new species such as peroxynitrite formed from superoxide and NO (Hasnain, et 
al. 2016; Gerber and Rutter 2017). 
As β-cells have very low intracellular antioxidant systems compared to other tissues 
they are considered more susceptible to oxidative stress. In fact, compared to the 
liver, β-cells express only 1% catalase, 2% glutathione peroxidase (GPX) and 29% 
superoxide dismutase (Lei and Vatamaniuk 2011). As a result, increases in reactive 
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species concentrations primarily damage the mitochondria. Reactive species can 
damage mitochondrial DNA and intrinsic mitochondrial proteins, which in turn 
affects a β-cells ability to generate ATP. As ATP is a main instigator in the insulin 
secretory pathway, exposure to chronically elevated glucose concentrations inhibits 
glucose stimulated insulin secretion (N. Li, et al. 2009).  
Reactive species can also activate uncoupling protein-2 which can uncouple 
mitochondrial mediated oxidative phosphorylation decreasing reactive species 
generation, but also further diminishing ATP generation (Prentki and Nolan 2006). 
Furthermore, increased reactive species generation also decreases the expression of 
insulin gene transcription factors PDX-1 via c-Jun N-terminal kinase pathway 
activation and nuclear uptake of forkhead box protein O1 and MafA via p38 MAPK 
dysregulation further decreasing β-cell ability to synthesise and secrete insulin 
(Andrali, et al. 2008; Gerber and Rutter 2017).  
1.3.2. Lipotoxicity 
Long chain non-esterified fatty acids, also referred to as free fatty acids (FFAs) are an 
important energy source for most tissue types particularly in periods of intense 
prolonged exercise or starvation. FFAs are not only substrates for oxidative 
metabolism but also play a role in cell signalling, gene expression and enzymatic 
activity. In obesity conditions, circulating FFAs are increased and accumulate as long 
chain fatty acyl-CoA’s which have toxic effects at a cellular level; this is termed 
lipotoxicity.  
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FFAs converted to fatty acyl-CoA’s are primarily transported into the mitochondria 
or peroxisomes via carnitine-palmitoyl transferase-1 (CPT-1) where they undergo β-
oxidation. Acyl-CoA dehydrogenases enzymatically remove two carbons from the FFA 
acyl-chain to produce acyl-CoA which enters as a substrate into the TCA cycle to 
produce ATP (Rui 2014). In obesity with increased circulating FFAs, fatty acid 
oxidation is increased, forcing the mitochondria electron transport chain to increase 
electron production, inhibiting mitochondria complex I and III driving increased 
production of superoxide species (Fisher-Wellman and Neufer 2012). FFA 
intermediate diacylglycerol can similarly induct reactive species (hydrogen peroxide 
and superoxide) generation through PKC activation mediated activation of NADPH 
oxidase (Schönfeld and Wojtczak 2008; Jaishy and Abel 2016).  
Increased FFA also have the ability to uncouple mitochondrial carriers particularly via 
the activation of the high FFA affinity uncoupling protein-1 which in turn diminishes 
ATP production, inhibiting β-cell insulin secretion. This alongside FFA driven increases 
in pro-apoptotic gene expression (Bax and Bcl2), synthesis of ceramide and increases 
in reactive species production, can generate large holes in the mitochondrial 
membrane known as permeability transition pores. The opening of these pores 
releases proapoptotic factors into the cytosol initiating the lipoapoptosis cascade 
(Rial, et al. 2010). 
It is important to note that increased circulating FFAs in the presences of high levels 
of glucose are blocked from fatty acid β-oxidation due to the inhibition of CPT-1 from 
increased malonyl-CoA production, leading to the accumulation of more harmful fat 
intermediates such as long chain acyl-CoA esters. Glucose resultantly exacerbates 
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lipotoxicity, and this combinative destructive action is what is meant by the term 
glucolipotoxicity (Poitout, et al. 2010). 
1.3.4. Glucolipotoxic Driven ALEs and AGEs 
Membrane phospholipids and triglycerides are main targets for glucolipotoxic 
upregulated radical hydroxyl species attack, which form lipid radicals. These radicals 
are subsequently oxidised allowing lipid peroxidation of their acyl chains. After bond 
reconfiguration, more hydroxyl radicals are captured in this process and propagate 
the acyl chain length. Upon nonezymatic hock cleavage, phospholipids and 
triglycerides with shortened acyl chains and the reactive carbonyl species (RCS) α,β-
polyunsaturated lipid aldehydes are produced. The shortened acyl chain in structure, 
of membrane phospholipids and triglycerides disrupt membrane architecture (Hauck 
and Bernlohr 2016). α, β-polyunsaturated lipid aldehydes, of which 4-
hydroxynonenal (4-HNE) is the most well-researched can have serious damaging 
effects acting as advanced lipid end product (ALE) precursors.  
4-HNE can react with amino acid residues cysteine, histidine and lysine of proteins. 
There are two possible reactions, either with the primary amine to form a reversible 
Schiff base which forms more complex compounds, or it can covalently bond with 
the β-carbon forming a C=C bond. These reactions are known as Michael’s addition, 
and produce ALEs as a result. ALE production can induce protein crosslinking, protein 
aggregation and structural reconfirmations resulting in diminishing protein function 
(Esterbauer, Schaur and Zollner 1991; Negre-Salvayre, et al. 2008).  
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Advanced glycation end products (AGEs) are produced from reducing sugars 
nonenzymatically reacting with amino acids in protein and lipids. Glucose is a 
reducing sugar and its concentrations is directly proportionate to glycation product 
formation. Reactive carbonyl species such as 3-deoxyglucosone formed from 
increased reactive oxygen species also react with amino acid residues to form AGEs 
via a different polyol pathway. The formation of AGE is known as the Maillard 
reaction consisting of a series of reactions forming Schiff bases and Amadori products. 
As glycation takes several weeks, long serving proteins such as structural tissue 
components are primary targets.  
N-carboxymethyl-lysine (CML) like 4-HNE, is the most characterised AGE, produced 
via the glycation oxidative pathway, and is therefore sometimes referred to as a 
glycoxidation product.  Oxidation of polyunsaturated fats can also result in CML 
production suggesting a synergistic role of lipid metabolism in AGE formation (Singh, 
et al. 2001). AGE formation and protein cross linking can cause permanent protein 
function dysregulation but can also directly bind to specific AGE receptors (RAGE). 
Binding of the tyrosine kinase RAGE receptor can stimulate reactive oxygen species 
production via NADPH oxidase activation and inflammatory cytokine production via 
nuclear factor kappa B (NF-κB) activation (Ramasamy, et al. 2005). AGE can also cause 
phosphorylation and activation of p38/MAPK which can inhibit glucose stimulated 
insulin secretion and cause apoptosis in β-cells (You, et al. 2016). 
1.3.5. Glucolipotoxic Driven Endoplasmic Reticulum Stress 
As β-cells primary function is to secrete insulin, the ER have a heavy biosynthetic load 
to cope with in response to fluctuations in glucose. Typically, in a normal healthy β-
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cell, the ER will misfold roughly 20% of proinsulin (Sun, et al. 2015). The term ER 
stress is used when ER protein misfolding is above the normal threshold for healthy 
cells, which triggers transcription and signalling events known as the UPR response. 
There are three outcomes for UPR activation; decreased protein translation, 
decreased misfolded proteins and restoration of protein folding and ER associated 
degradation (ERAD) with the overall aim to restore normal ER protein biosynthesis 
(Walter and Ron 2011).  
The UPR activation is initiated by three signalling arms. RNA-like endoplasmic 
reticulum kinase (PERK), serine/threonine protein kinase/endoribonuclease (IRE1) 
and transcription factor activating transcription factor 6 (ATF6) which sit on the ER 
membrane and detect rises in protein misfolding. In response to increases misfolded 
protein, BiP which was previously bound to PERK and ATF6 dissociate activating them. 
PERK autophosphorylates, in turn phosphorylating the translational initiation factor-
2 (eIF2) transiently blocking further protein translation by inhibiting the assembly of 
the 80s ribosome. ATF6 activation causes translocation to the Golgi apparatus where 
it is cleaved and the ATF6 p50 fragment is translocated further to the nucleus to 
activate transcription of protein folding chaperones (Biden, et al. 2014; K. Zhang and 
Kaufman 2008).  IRE1 is activated directly by increase in misfolded proteins and 
dimerises then oligomerises to promote X-box binding protein-1 (XBP-1) 
translocation to the nucleus where it activates the transcription of genes associated 
with ER expansion, protein folding and misfolded proteins. ERAD activation labels 
and retrotranslocates misfolded proteins out of the ER to proteasomes where they 
are degraded out of circulation (Walter and Ron 2011; Hasnain, et al. 2016). 
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ER stress is primarily lipotoxic (Cunha, et al. 2008), however chronic glucose 
concentrations can induce ER stress and the UPR response due to the increased 
demand for proinsulin biosynthesis and insulin secretion (Lipson, et al. 2006). 
Elevated FFA production of oxidative stress metabolites such as superoxide, 
peroxynitrite and nitric oxide can induce ER stress. As can FFAs effect on saturating 
ER lipid content and perturbing ER calcium handling resulting in protein misfolding 
and UPR signalling (Cnop, et al. 2010; Borradaile, et al. 2006). 
In β-cells, if glucolipotoxic driven ER stress cannot be overcome by UPR adaption 
signalling, induction of the transcription factor CCAAt/-enhancer-binding protein 
homologous protein (CHOP) triggers apoptosis as part of the UPR termination 
pathway. Apoptosis instigation has also been linked directly to IRE1 signalling via the 
caspase-12 pathway and activation of the JNK protein kinase pathway (Biden, et al. 
2014). β-cell death and decrease in overall insulin secretion capabilities further 
diminishes the ability to overcome hyperglycaemia and hyperlipidaemia 
compounding the onset of type 2 diabetes. 
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Figure 1. 8; Glucolipotoxic driven stress in pancreatic β-cells.  
Increased circulation of glucose and free fatty acids increases reactive stress and ER 
stress causing loss of insulin secretion and apoptosis. This results in a constant state 
of hyperglycaemia which causes downstream diabetic complications and further 
glucolipotoxic driven stresses. 
1.4. Current Treatments for Type 2 Diabetes 
After type 2 diabetes diagnosis, achieving glycaemic control is the main target for the 
management of the condition. HbA1c is the main test to monitor glucose 
homeostasis and is used as a predictive indicator for diabetes progression and 
management. Anything below 5.7% HbA1c level is considered normal with anything 
above warranting intervention. Lifestyle changes are the initial port of call to reduce 
or delay the onset of diabetes. This typically includes losing weight via controlled 
dieting and exercising, as well as reducing alcohol and sodium intake.  
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If HbA1c percentages and therefore glycaemic control cannot be achieved via 
lifestyle changes alone, antidiabetic medication may be required. The major classes 
or therapeutic medications for type 2 diabetes are biguanides, sulphonylureas, 
meglitinides, thiazolidinediones (TZD), dipeptidyl peptidase 4 (DPP4) inhibitors, 
incretin mimetics and sodium-glucose cotransporter (SGLT) inhibitors. These work 
through three main mechanisms; to increase insulin secretion, to increase insulin 
sensitivity or to stop gluconeogenesis. Medications are prescribed singly, until HbA1c 
levels rise above 7.5% whilst medicated, then a combination of two agents or insulin 
may be prescribed to combat this (Chamberlain, et al. 2016). Numerous medications 
that operate via different mechanical pathways are required for different stages of 
diabetes onset and can be tailored to the individual. However, as treatments often 
loose effectiveness over time, it is vital to constantly develop new strategies separate 
to mechanisms already proposed. 
1.4.1. Biguanides 
Metformin (1,1-dimethylbiguanide) is a biguanide derivative that is the first-line oral 
agent of choice to treat type 2 diabetes across all patient groups. It was discovered 
in the 1940s as an antimalarial agent, before first being used to treat diabetes in 1957. 
After intensive scrutiny the compound was approved to treat diabetes in the US in 
1995, before being adopted in the UK in 1998 as the primary agent to manage 
hyperglycaemia, where it is now prescribed to at least 120 million people worldwide 
(Viollet, et al. 2012; Bailey 2017). 
The organic cation transporter 1 (OCT1) is responsible for hepatic uptake of 
metformin (Shu, et al. 2007) where it accumulates (more than 1000-fold higher than 
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anywhere else) in the mitochondria because of its positive charge. Metformin in the 
mitochondria inhibits Complex I of the respiratory chain, suppressing overall ATP 
production. The resultant change in ATP:ADP ratio and NAD+: NADH ratio contributes 
to the reduction of ATP reliant gluconeogenesis. Inhibition of the respiratory chain 
also activates AMP-activated protein Kinase (AMPK) which increases insulin 
sensitivity by the phosphorylation of Acetyl-CoA carboxylase (ACC)1 and ACC2. 
Metformin also stimulates the up-regulation of the glucose transporters GLUT1 and 
GLUT4 membrane expression in skeletal muscle and adipocytes. The resultant 
reduction in gluconeogenesis and increase in insulin sensitivity and glucose uptake 
improves the control over high blood glucose levels (Klip and Leiter 1990; Rena, 
Hardie and Pearson 2017).  
Metformin, which has a half-life of 5 hours, has minimal side effects with low risk of 
weight gain and hypoglycaemia, the most common side effect being nausea and 
vomiting, affecting ~20-30% of all patients (Diabetes Prevention Program Research 
Group 2012).  Lactic acidosis caused by dehydration is the most dangerous adverse 
complication of long-term metformin medicating, affecting roughly 1-5/100,000 
patients (Fitzgerald, Mathieu and Ball 2009). Metformin is highly effective during the 
early stages of type 2 diabetes when insulin is still being secreted by the pancreas, 
however, as the condition develops, and complete β-cell failure ensues, it loses its 
efficacy rapidly and other treatments are required.  
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1.4.2. Sulphonylureas and Meglitinides 
Sulphonylureas increase insulin exocytosis from β-cells increasing plasma insulin 
concentrations, improving glucose uptake. This therefore requires some pancreatic 
β-cell functionality and is therefore less effective with increasing β-cell failure. 
Sulphonylureas function by binding to sulphonylurea receptors SUR1 and SUR2 on 
the cellular membrane. These receptors are members of the ATP-binding cassette 
superfamily, and upon sulphonylurea binding cause KATP channels to close resulting 
in membrane depolarisation. The consequential opening of opening of Lc-type 
voltage-dependent Ca2+ channels increases the cytosolic Ca2+ concentration 
augmenting insulin exocytosis (Sola, et al. 2015). 
There are two classes of sulphonylureas. Class I included the compounds tolbutamide, 
nateglinide and gliclazide which bind to specifically to the A domain of SUR1. These 
compounds typically have a slow onset of effect and pose a higher risk of 
hypoglycaemia. The second class, containing compounds such as glibenclamide and 
glimepiride, bind non-specifically to the A and B domain of both SUR1 and SUR2 and 
are thought to be more potent and safer compared to the other classes of 
sulphonylurea compounds. Hypoglycaemia is the main risk of sulphonylurea dosing, 
as well as common side effect of headaches, nausea, dizziness and weight gain (Sola, 
et al. 2015; Chaudhury, et al. 2017). 
Meglitinides such as repaglinide and nateglinide similarly bind to SUR1 and produce 
a rapid increase in insulin secretion via KATP channel closure. However due to their 
short half-life (less than one hour), they can only augment the first phase of glucose-
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stimulated insulin secretion and have no bearing to affect the second phase insulin 
secretion response (Fuhlendorff, et al. 1998). 
1.4.3. Thiazolidinediones (TZD) 
Thiazolidinediones, sometimes referred to as glitazones, improve insulin sensitivity 
increasing metabolic control of type 2 diabetic patients. The exact function of TZDs 
remains unclear, however it is believed to be associated with the consequential high 
expression of peroxisome-proliferator activated receptor gamma (PPARγ) upon TZD 
administration. PPARγ upon TZD induction undergoes a conformational change from 
its usual heterodimer conformation with a retinoid X receptor, encouraging binding 
of this complex with the PPARγ response element (PPRE). This alters the transcription 
and translation of genes containing bound PPRE and include genes responsible for 
lipid metabolism (Hauner 2002). TZDs have common associated side effects such as 
edema, weight gain and in rare cases heart failure (Rizos, et al. 2009). 
1.4.4. Incretin Mimetics; Dipeptidyl Peptidase 4 Inhibitors and GLP-1 Receptor 
Agonists 
Incretin mimetics is the class of drugs that target the incretin system and include both 
DPP4 inhibitors and GLP-1 receptor agonists. The incretin effect accounts for ~50% 
of the insulin secretion response to oral glucose intake (Nauck, et al. 1993). They are 
becoming increasingly popular for type 2 diabetic prescription as they promote 
weight loss and decrease gastric emptying whilst increasing glucose-stimulated 
insulin secretion through the activation of G-proteins associated to adenylyl cyclases 
(Holz 2004).  
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The currently available GLP-1 receptor agonist medications are exenatide and 
liraglutide. These compounds are less susceptible to DPP4 hydrolysis allowing them 
to have a more sustained effect and have minimal gastrointestinal side effects of 
vomiting and nausea (Chaudhury, et al. 2017). 
DPP4 inhibitors, sometimes referred to as gliptins, block the degradation of 
endogenous GLP-1 and GIP allowing increased endogenous function to increase 
glucose stimulated insulin secretion via the method discussed previously. Inhibitors 
include the compounds sitagliptin, saxagliptin, vidagliptin and others.  The most 
common side effects are respiratory tract infections, headaches and nasopharyngitis 
with no apparent increased risk of hypoglycaemia (Thornberry and Gallwitz 2009; 
Chaudhury, et al. 2017). 
1.4.5. Sodium-Glucose Cotransporter Inhibitors (SGLT) 
SGLT2 inhibitors act independently of insulin, offering another strategy separate to 
other medications that require some β-cell functionality. SGLT2 inhibitors such as 
canagliflozin, dapagliflozin and empagliflozin block glucose reabsorption by sodium-
glucose cotransporters in the kidneys lowering blood glucose levels, encouraging 
decreases in weight and blood pressure even in patients where β-cells are irreversibly 
damaged beyond the point of effectiveness (Riser-Taylor and Harris 2013). 
1.4.6. α-Glucosidase Inhibitors  
The α-glucosidase inhibitors (acarbose, voglibose and miglitol) competitively inhibit 
the enzymes activity in the brush border of enterocytes. The inhibition stops the 
hydrolysation of non-hydrolysable carbohydrates reducing blood glucose 
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concentrations that occur immediately after dietary consumption (Derosa and 
Maffioli 2012). Acarbose was also shown to reduce blood glucose concentrations by 
down-regulating proinflammatory cytokines associated with diabetic inflammation 
by activating miR-10a-5p and miR-664 in the ileum (Zhang, et al. 2013). 
1.4.7. Insulin Therapy 
If monotherapy of usually metformin cannot control HbA1c levels for three months, 
a second therapy will be administered alongside. Insulin therapy is only used when 
pharmacotherapy intervention strategies can no longer regulate HbA1c to within the 
guideline limits. Neutral protamine Hagedorn and human insulin is injected 
subcutaneously at alternating injection sites and has a low risk profile of 
hypoglycaemia and is relatively low in cost. Other insulin analogs that have a delayed 
onset and longer lasting effects are also available but are more expensive. Blood 
glucose levels are measured before meals and after insulin injections to characterise 
the administration profile to determine correct dosages for future reference 
(Chaudhury, et al. 2017). 
1.5. Carnosine 
1.5.1. Carnosine Physiology 
Carnosine was first identified or at least mentioned in the year 1900 when 
acknowledged in a search for nitrogen containing non-proteins in meat extracts 
(Gulewitsch and Amiradžibi 1900). It is a dipeptide constituting of the two amino 
acids, L-histidine and β-alanine, bound by an amide bond (Figure 1.9). In mammals, 
only the skeletal muscle and olfactory bulb contains carnosine in the millimolar range 
with skeletal muscle accounting for over 99% of an organisms total carnosine content, 
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but has also been discovered in numerous regions of the brain, kidney, spleen, 
cerebrospinal fluid and plasma (Boldyrev, Aldini and Derave 2013).  
Figure 1. 9; Carnosine synthesis and degradation.  
Carnosine is synthesised by carnosine synthase from l-histidine and β-alanine and 
degraded by carnosinases 1 and 2. 
 
Carnosine is primarily present, and ingested, via red meat but is also endogenously 
synthesised from its constituent parts by the ATP and Mg2+ dependent reaction by 
carnosine synthase which produces carnosine, an inorganic pyrophosphate 
(currently unidentified) and either AMP or ADP (Drozak, et al. 2010). Carnosine 
synthase has previously been identified in the brain, olfactory bulb, heart and skeletal 
muscle consistent with these tissues high carnosine expression (Bulygina and 
Kramarenko 1995; Horinishi, Grillo and Margolis 1978; Skaper, Das and Marshall 
1973a; Stenesh and Winnick 1960). The homotetramer enzyme has a molecular mass 
of ~430kDa whilst its 950 amino acid gene sequence is located on chromosome 
11q13 in humans, spanning 9 coding exons.  It is thought that carnosine synthase has 
a broad range of substrate specificities and is responsible for various similar peptides 
to carnosine, formed from subtle replacements or modifications to either β-alanine 
or l-histidine (Kalyankar and Meister 1959). The most common of which being 
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anserine, (l-histidine methylated at the nitrogen in the imidazole ring closest to the 
side chain) and ophidine (l-histidine methylated at the nitrogen in the imidazole ring 
furthest from side chain) which were identified in 1929 and 1939 respectively 
(Boldyrev 2012). 
Carnosine is hydrolysed by an enzyme named carnosinase, which was originally 
identified in the kidney of a hog in 1951 (Smith 1951). However, in 1982, a human 
serum carnosinase was identified as separate and more highly expressed compared 
to the previous discovered tissue carnosinase (Lenney, et al. 1982).  These two 
members of the M20/M28 metalloprotease family are now conventionally named: 
carnosinase 1 (CN1) or serum carnosinase and carnosinase 2 (CN2) a tissue cytosolic 
non-specific dipeptidase (Teufel, et al. 2003). A crystallography study determined 
that CN2 is a homodimer, where each subunit contains two domains, one for metal 
binding (domain A) and another for its dimer formation interface (domain B). The 
several residue interactions between the two domains forms the active site structure 
and is therefore thought to be crucial for its enzyme capabilities and substrate 
specificity (Unno, et al. 2008).  
The human genes that encode for these enzymes are found head to tail on 
chromosome 18 and are named CNDP1 and CNDP2 for CN1 and CN2 respectively. 
CN1 has a stricter substrate specificity compared to CN2. CN1 favours binding and 
hydrolysis of carnosine, anserine, ophidine and homocarnosine in that order, whilst 
CN2 has a broader specificity and can be inhibited by a nonhydrolyzable substrate 
analog called bestatin (Boldyrev, et al. 2013; Unno, et al. 2008). CN1 is also reported 
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to have a much higher catalytic rate compared to its tissue counterpart, however 
both maintain the ability to degrade carnosine (Pandya, et al. 2011). 
Ingested carnosine can be transported across the cell membrane through numerous 
proton-coupled oligopeptide transporters. PEPT1, PEPT2 (oligopeptide transporter 1 
and 2) PHT1 and PHT2 (peptide/histidine transporter 1 and 2) have a broad specificity 
and can all transport carnosine and its various analogs (Yamashita, et al. 1997).  
Dietary ingested carnosine is thought to enter the intestine enterocyte cells through 
PEPT1, a high-capacity low-affinity transporter. Intracellularly, carnosine is in part 
hydrolysed by tissue carnosine-2 into β-alanine and L-histidine or transported further 
across the basolateral membrane by other peptide transporters into the blood, 
where circulation or further hydrolysis by carnosine-1 occurs (Boldyrev, et al. 2013). 
PHT1 is primarily expressed in skeletal muscle and the spleen suggesting that this 
transporter is responsible for carnosine entry into these tissues where the highest 
carnosine content in humans is observed (Botka, et al. 2000).  
1.5.2. Carnosine Biochemistry 
1.5.2.1. Metal Ion Chelating 
Carnosine has been reported to form complexes with various metal ions such as 
copper, zinc, cobalt, nickel and cadmium. The carnosine complex formations of 
former two have been investigated in large detail due to their biological importance 
in metal toxification.  
Carnosine can chelate copper using its carboxylate, amide and amino donor atoms, 
achieving a molar ratio of 1:1, carnosine: Cu2+. This complex has been shown to form 
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in both a monomeric structure in solution and a dimeric structure in equilibrium, with 
the complex encouraged towards dimerization with increasing pHs (Baran 2000). This 
dimer model achieved in solution is an exact representation of binding properties 
and doesn’t consider physiological environments. This was therefore considered 
improbable endogenously, due to the low concentration of intracellular copper and 
alterations caused from other circulating compounds. It was in fact shown via NMR 
spectroscopy that the copper-carnosine dimer complex was insignificant in human 
calf muscle samples and should therefore be carefully considered when discussing 
carnosine’s chelating action (Schröder, Schmitz and Bachert 2008). The Zinc-
carnosine complexes similarly forms most commonly in a dimer structure at neutral 
pH and monomerically in more acidic concentrations (Torreggiani, Bonora and Fini 
2000). Little is still known about carnosine as an effective metal chelator in 
physiological conditions and requires further investigation to elucidate the 
mechanism and functional impact of its chelating capabilities. 
1.5.2.2. pH Buffering 
It is thought that the nitrogen atom of the imidazole ring of the L-histidine amino acid 
regulates the pH buffering capacity of carnosine due to its pKa value of 6.72 (Vistoli, 
et al. 2012). Since the overall pKa of carnosine is 6.83 (Smith 1938), the high proton 
sequestering capacity therefore enables the rapid reduction of pH gradients in 
various tissue types. Carnosine is therefore highly researched in muscle performance, 
to combat decreases in muscular pH caused by lactic acid production during high 
intensity exercise. Supplementation with β-alanine increases intracellular muscle 
carnosine concentrations which in turn increases high-intensity exercise capacity due 
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to an increase in buffering capacity (Sale, Saunders and Harris 2010). One example of 
this is increases in intracellular carnosine concentrations have been shown to 
increase sprint training performance in humans (Suzuki, et al. 2004). 
1.5.2.3. Radical Species Scavenger 
Carnosine is known to directly scavenge reactive species like superoxide dismutase 
and has a reaction rate similar to another known antioxidant ascorbic acid with 
carnosine measuring at 105 M-1∙s-1 (Klebanov, et al. 1997). Carnosine can sequester 
reactive oxygen species as it can form a charge-transfer complex at the nitrogen ion 
of the imidazole ring, resulting in the formation of less reactive intermediates via a 
base-catalysed water elimination reaction (figure 1.10) (Torreggiani 1998).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 10; Carnosine scavenging of hydroxyl radical.  
Carnosine reacts with hydroxyl radical via a base-catalysed water elimination 
reaction to form a less reactive stable intermediate (Boldyrev, et al. 2013). 
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Carnosine has also been shown to scavenge peroxyl radicals. Decker et al (2000) 
demonstrated that purified carnosine within the millimolar range has the same 
peroxyl-scavenging capabilities as l-histidine, whilst β-alanine alone had no impact 
on peroxyl concentrations. This largely supports the mechanistic model suggested, 
attributing the functional scavenging ability of carnosine to the imidazole ring 
component of the l-histidine residue of carnosine. They also demonstrated that 
carnosine’s scavenging potential largely increases when free radicals are generated 
via metal ion induction. This is thought to be due to its ability to chelate metal ions 
in a manner that doesn’t interfere with its anti-oxidant activity (Decker, Livisay and 
Zhou 2000; Decker, Crum and Calvert 1992).  
It is not just reactive oxygen species that carnosine can scavenge, but reactive 
nitrogen species also. Carnosine was shown to inhibit NO-dependent activation of 
guanylate cyclase whilst also being shown to decrease total NO concentrations, and 
increase formation of carnosine/NO adducts in astroglia, demonstrating the 
compounds ability to react directly with this radical nitrogen species (Severina, 
Bussygina and Pyatakova 2000; Nicoletti, et al. 2007). Carnosine is also demonstrated 
to protect against radical species formed from both reactive oxygen and nitrogen 
species. Supplementation of carnosine within the endogenous range elicited a 
protective effect against tyrosine nitration adduction from peroxynitrite, which is 
formed from the combination of superoxide and nitric oxide radicals (Fontana, et al. 
2002a). 
Carnosine is also reported to prevent and directly react with products of reactive 
carbonyl species, ALEs and AGEs which can form harmful adducts to both lipids and 
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proteins altering their function. The most commonly studied ALE is 4-HNE, and 
carnosine has been reported to directly react with it forming carnosine-HNE 
adducted compounds. This reaction involves the synergistic action of both amino acid 
constituents of carnosine and starts with the formation of a Schiff base at the 
aldehyde group. This is followed by a Michaels addition reaction forming a 
macrocyclic adduct before hydrolysing to form a stable non-reactive hemiacetal 
product (figure 1.11) (Aldini, et al. 2002; Boldyrev, et al. 2013). Carnosine can also 
inhibit AGE species adduction via transglycation, effectively reversing the Schiff base 
reaction in the first step of protein glycation via nucleophilic reaction on the pre-
formed aldosamine. Carnosine can resultantly react directly with AGEs to form  stable 
glucosyl proteins that are less reactive (Szwergold 2005; Seidler, Yeargans and 
Morgan 2004). 
Figure 1. 11; Carnosine reaction mechanism with 4-HNE.  
Carnosine forms Schiff base at aldehyde group before undergoing Michaels addition 
and hydrolysis to form stable derivative. Adapted from (Boldyrev, et al. 2013) 
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1.5.3. Carnosine in Disease 
Carnosine was first investigated for its anti-neoplastic effects in 1986 when 
intravenous subcutaneous administration of carnosine and β-alanine in mice 
implanted with sarcoma-180 tumour cells saw a reduction in tumour growth (Nagai 
and Suda 1986). This work was further supported later when carnosine was 
demonstrated to reduce growth in various cancer types such as glioblastoma (Renner, 
et al. 2010), gut (Shen, et al. 2014), colon (Iovine, et al. 2014) and more. The 
somewhat contradictory anti-proliferative qualities of carnosine have been 
suggested to be a result of carnosine’s effect on glycolytic enzyme activity, metabolic 
regulation, redox biology, reactive species and their products, redox biology and 
gene expression and apoptosis. Carnosine’s effect is also thought to be specific to 
cancer cells due to metabolic differences between highly anaerobic cancer cells and 
other ‘normal’ cell types (Artioli, Sale and Jones 2018). 
Neurodegenerative diseases such as Alzheimer’s and Parkinson’s present with 
pathophysiology’s defined by neuronal mitochondrial dysfunction causing oxidative 
stress, loss of cellular function and eventually cell death. Alzheimer’s disease is 
characterised by amyloid plaques and neurofibrillary triangles formed from 
accumulation of amyloid-β and Tau respectively (Bloom 2014). Carnosine 
supplementation has been reported to decrease amyloid-β accumulation in amyloid-
β and Tau presenting transgenic mice and was attributed to suppressing cognitive 
decline (Corona, et al. 2011; Herculano, et al. 2013). Parkinson’s disease is 
characterised by dopaminergic neuronal cell death in the substantia nigra, causing 
progressive disorder of movement (Moore, et al. 2005). Carnosine was recently 
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presented to protect against salsolinol-induced parkinsonian rat brain and 
endothelial cells reducing/normalising cell apoptosis, mitochondria derived reactive 
species and lipid peroxidation (Zhao, Shi and Zhang 2017). Oral supplementation of 
carnosine was also shown to increase L-dopamine therapy effectiveness at improving 
patient unified Parkinson disease rating scale score (Boldyrev, et al. 2008). 
Acute kidney injury is a clinical syndrome defined by a sudden decrease in kidney 
function as a result of ATP depletion caused by ischaemic structural loss blocking 
blood flow. ATP depletion inhibits essential cellular processes causing oxidative 
stress and apoptosis or necrosis (Makris and Spanou 2016). Oral dosing of carnosine 
was reported to prevent renal dysfunction in rats after renal artery obstruction as a 
model of ischaemia (Fujii, et al. 2003), as well as reducing acute kidney injury due to 
septic shock (Sahin and Burukoglu Donmez 2018). Carnosine also decreased lipid 
peroxidation and reactive nitrogen species in a rat nephrectomised model of chronic 
kidney failure characterised by oxidative stress (Yapislar and Taskin 2014). 
Type 2 diabetes as mentioned is characterised by chronic exposure to 
hyperglycaemic oxidative stress resulting in harmful protein and lipid adduction (AGE 
and ALE formation) and low grade chronic inflammation culminating in β-cell failure 
and death, and insulin resistance. Interestingly, carnosine muscle concentrations are 
reported to be significantly decreased by ~45% in type 2 diabetic patient muscle 
biopsies compared to non-diabetics. This carnosine reduction was not observed in 
type 1 diabetic tissue muscles supporting the theory that carnosine’s lowered 
concentration in type 2 diabetic muscle samples is attributed to carnosine’s sacrificial 
action to scavenge reactive metabolites and their glycation/lipidation end-products 
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witnessed specifically in type 2 diabetes (Gualano, et al. 2012). Similarly, a five to 
seven leucine repeat polymorphism to the carnosinase-1 gene is highly associated 
with diabetic complications such as nephropathy. Patients with lower numbers of 
leucine repeats had lower incidences of nephropathy and was associated with lower 
serum carnosinase activity. Decreased carnosinase activity would increase 
endogenous carnosine action, suggesting carnosine plays some protective role to 
offset downstream diabetic complications (Janssen, et al. 2005).   
Oral carnosine supplementation has also been shown to improve glucose 
metabolism by decreasing plasma glucose and glycated haemoglobin concentration 
in an ob/ob diabetic mouse model (Albrecht, et al. 2017), whilst increasing serum 
fasting insulin concentrations in db/db diabetic mice (Sauerhofer, et al. 2007). Human 
clinical trials also suggest a potential use for carnosine as a treatment for type 2 
diabetes as a four month supplementation of cinnamon, chromium and carnosine 
resulted in a decrease in fasting plasma glucose whilst increasing fat free mass (Liu, 
et al. 2015). Another trial also reported that carnosine improved diabetic patient 
responses to a glucose tolerance test in a subset of individuals with previously 
impaired glucose tolerance, however overall saw no increase in fasting insulin 
concentrations or witnessed any change to insulin resistance (de Courten, et al. 2016).  
1.5.4. β-Alanine Supplementation 
As mentioned, carnosine is endogenously synthesised from L-histidine and β-alanine. 
Supplementation with β-alanine for 4 weeks has shown to increase carnosine 
concentrations in vastus lateralis skeletal muscle by as much as 60% (Harris, et al. 
2006). A similar study reported that 4 and 10 week β-alanine supplementation not 
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only increased muscle carnosine by ~60 and ~80% respectively, it also correlated to 
an increase in total work done in a cycling capacity test by 13% and 16% respectively 
over the two dose lengths (Hill, et al. 2007).  β-alanine is an amino acid synthesised 
solely in the liver through the breakdown of uracil before being primarily stored in 
the skeletal muscle and is therefore thought to be the rate limiting step of carnosine 
synthesis (Bakardjiev and Bauer 1994). β-alanine supplementation is therefore 
currently being extensively investigated as an ergogenic tool to increase muscle 
carnosine concentrations and enhance skeletal muscle output particularly in an 
athletic performance context. Surprisingly, little to no published literature has 
investigated β-alanine supplementation as a means to increase carnosine content 
and its effects in a disease context. 
1.6. Aim and Objectives of Thesis 
The aim of this body of work was to identify novel treatments that can preserve or 
recover β-cell insulin secretory function in response to chronic exposure to high sugar 
and high fat; the main risk component of developing type 2 diabetes.  
The initial part of this thesis details mechanistic experiments to characterise the 
scavenging effect of the dipeptide carnosine on glucolipotoxic driven reactive species, 
and to determine whether this action offers a protective effect against glucolipotoxic 
driven loss of insulin secretion. Secondly, this work investigated whether β-alanine 
or l-histidine (constituent amino acids of carnosine) supplementation, might have a 
similar protective action to that of carnosine through similar mechanistic studies. 
Subsequently, utilising in silico docking analysis strategies, carnosine analogs 
selected to fit the active site of carnosinase-2 and therefore function as carnosinase 
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inhibitors, were identified and investigated as a therapeutic strategy to improve 
endogenous carnosine function using techniques described previously.  
The latter part of this thesis utilises transcriptomic gene expression analysis in order 
to identify individual genes, families, and pathway networks, whose expression is 
most perturbed when exposed to glucolipotoxicity, with the purpose of identifying 
new therapeutic targets that play a significant role in glucolipotoxic driven 
diminished insulin secretion capacity in β-cells.  
Through the strategies mentioned here, the overall aim is to identify new potential 
targets for pharmacotherapy intervention that can augment and more importantly 
reverse the glucolipotoxic loss of insulin secretion in endocrine β-cells. 
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2. Materials and 
Methodology 
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2.1. Reagents and Solutions 
2.1.1. Reagents and Materials 
Unless otherwise stated, all reagents were purchased from Sigma Aldrich (Dorset, 
UK) and all plasticware from VWR International Ltd (Lutterworth, UK). Insulin 
secretion ELISA kits purchased from Mercodia (Sweden). Antibodies were purchases 
from Abcam (Cambridge, UK) unless otherwise stated. 
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2.1.2. Solutions and Buffers 
SOLUTION COMPOSITION 
Krebs-Ringer 
Bolution (KREBS) 
125 mM NaCl, 1.2 mM KH2PO4, 5 mM KCl, 2 mM Mg SO4, 
1.67 mM glucose, 0.1% Bovine Serum Albumin (BSA), 25 
mM HEPES, pH7.4 
PBS (Phosphate 
buffered saline) 10X 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4  
pH7.4 
RIPA Buffer 
150mM NaCl, 0.5% Deoxycholate, 0.1% SDS, 50mM Tris 
Base, 1% Triton 100, 1x protease inhibitor tablet  pH7-8 
Sample Buffer 
40% glycerol, 240 mM Tris HCl, 8% SDS, 0.04% Blue 
Bromophenol, 5% β-mercaptoethanol, pH 6.8 
Lower Buffer 1.5 M Tris HCl, 0.4% SDS, pH 8.8 
Upper buffer 1.5 M Tris HCl, 0.4% SDS, pH 6.8 
Running Buffer 0.25 M Tris HCl, 2.5 M glycine, 1% SDS, pH 8.3 
Transfer buffer 
20% 5 X Trans Blot Transfer buffer (BioRad), 60% H2O, 20% 
100% Ethanol 
TBS (Tris Buffered 
Saline) 
50mM Tris-Cl, 150mM NaCl pH7.6 
TBST TBS + 0.1% TWEEN20 
Glutamine Stock 
buffer 
2.5mM L-glutamine in lithium loading buffer 
Table 2. 1; Composition list of solutions and buffers used. 
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2.2. Cell Culture 
2.2.1. Cell Line 
Cell Line and 
Species 
Characteristic 
INS-1 - Rat 
INS-1 cells are 2-mercaptoethanol-dependent immortal insulin 
secreting cells that were established from cells isolated from x-
ray induced rat transplantable insulinoma. INS-1 cells secrete 
insulin in response to glucose within the physiological range 
whilst remaining stable with a high degree of differentiation. 
This makes them a suitable β-cell model (Asfari, et al. 1992). The 
passage number of these cells were unknown.  
C2C12 - Mouse 
C2C12 is an immortalised mouse myoblast cell line that readily 
proliferates and differentiates in high and low serum conditions 
respectively. C2C12 cells express GLUT 4 transporters that 
translocate and activate in response to insulin stimulation 
resulting in glucose uptake (Yaffe and Saxel 1977; Nedachi and 
Kanzaki 2006). 
Table 2. 2; Table of cells lines used and their characteristics 
2.2.2. Media Preparation and Cell Culture/Differentiation 
INS-1 rat β-cells were cultured in Roswell Park Memorial Institute (RPMI)-1640 media 
where 1 litre of distilled water was supplemented with pre-prepared 10.3g of RPMI 
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powder (ThermoFisher, UK), 2g of Sodium Bicarbonate (26mM), 2.3g of HEPES 
(10mM) and 3.5µl of β-mercaptoethanol (50µM). RPMI 1640 Media was 
supplemented with 10% v/v foetal bovine serum (FBS) (Life Technologies, UK), 1% 
v/v sodium pyruvate (Life Technologies, UK), 1% v/v Penicillin/Streptomycin (Life 
Technologies) and 5µl β-mercaptoethanol. C2C12 mouse skeletal myoblasts were 
cultured in high glucose DMEM supplemented with 10% (v/v) fetal bovine serum, 
10% (v/v) heat inactivated new-born calf serum and 1% (v/v) penicillin-streptomycin 
(Life Technologies, UK). C2C12 cells were then switched to DMEM supplemented 
with 2% (v/v) heat-inactivated horse serum (Life Technologies, UK) to expedite 
myocytic differentiation. Cells were seeded in T75 tissue culture treated flasks and 
incubated at 37°C in a 95% air/5% CO2 atmosphere. 
2.2.3. Cell Passage and Amplification 
Cells were passaged when 80-90% confluent before loss of cell monolayer. Growth 
media was aspirated and then cells were incubated in 4ml Trypsin-EDTA (Life 
Technologies, UK) for 5 minutes at 37°C until complete cell detachment. Detached 
cells were collected in 4ml of complete growth media and centrifuged at 400 x G for 
5 minutes at room temperature. Cell pellets were resuspended in appropriate 
volume of complete growth media before cell counting and seeding at specifically 
required densities in new tissue culture treated flasks of plates. 
 
2.2.4. Cell Counting and Plate Seeding 
Cells were seeded in 6 or 12 well plates and incubated for 3 or 5 days (72h or 120h) 
(refer to table 2.3). In all experiments described here out, cells growing in T75 culture 
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flasks had their spent media aspirated and were detached by incubating in 4ml of 
Trypsin EDTA (Life Technologies). Trypsin was neutralised with equal volume of 
complete growth media and the cell suspension collected and centrifuged at 400 x G 
for 5 minutes in a centrifuge tube. The supernatant was aspirated, and cell pellet was 
resuspended in ~8ml of complete growth media. Cells were counted manually using 
haemocytometer. 10µl of cell suspension was loaded into a Neubauer chamber 
before cell number was determined from four big squares (counting clockwise and 
North-West) highlighted in figure 2.1 and a cell concentration calculated using the 
following formula: 
 
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 =  
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐶𝑒𝑙𝑙𝑠 × 10000
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑞𝑢𝑎𝑟𝑒𝑠 × 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛
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Figure 2. 1; Counting cells using haemocytometer.  
 
Cells were seeded at the various densities specified in table 2.2.3 depending on size 
of plate. 
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Tissue Culture 
Plate (number 
of wells) 
 
Total Volume      
(mls) 
Experimental 
Incubation Period 
(days) 
 
Number of Cells 
6 2 3 (4 total) ~70,000 
6 
2 (media 
changed on day 
2 or 3 of 
treatment) 
5 (6 total) ~100,000 
12 1 3 (4 total) ~35,000 
12 
1 (media 
changed on day 
2 or 3 of 
treatment) 
5 (4 total) ~50,000 
Table 2. 3; Seeding density for various treatment lengths and plate type. 
 
2.2.5. Cryo-conservation and Recovery of Frozen Cells 
T75 flasks of cells were grown to ~80-85% confluency before aspiration of growth 
media and incubation in 4ml Trypsin-EDTA (LifeTechnologies, UK) for ~5minutes at 
37°C to detach cells. Cells were collected in 4ml of complete growth media and 
centrifuged at 400 x G for 5 minutes at room temperature. Cell pellets were 
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resuspended in 4ml of Synth-a-freeze (liquid cryopreservation medium containing 10% 
dimethylsulfoxide (DMSO)) (Life Technologies, UK) and transferred into 4 cryovials 
(1ml each). Cells were stored in -80°C freezer in a freezing container designed to 
achieve a rate of cooling close to -1°C/minute for 24h - 2 months before being 
transferred to liquid nitrogen for long term storage. 
Cells recovered from long term storage were defrosted rapidly before 4ml of 
complete growth media was added drop by drop. Cells were centrifuged at 400 x G 
for 5mins before pellet was washed in growth media, resuspended gently in 4ml of 
growth media and seeded in a T75 tissue culture flask and incubated at 37°C in a 95% 
air/5% CO2 atmosphere. 
2.2.6. Mycoplasma Screening 
All cells were biannually screened for mycoplasma infection using a highly sensitive 
polymerase chain reaction (PCR) mycoplasma detection kit (Geneflow Ltd., 
Staffordshire). The primer sets used amplify a highly conserved region within the 16S 
rRNA gene region of mycoplasma and produces a PCR reaction product of 270bp 
band when run on an agarose gel.  
0.5-1ml of cell culture supernatant was collected and centrifuged at 250 X g for 30 
seconds to pellet any cell debris. Supernatant was transferred to a new tube before 
centrifugation at 20,000 X g for 10 minutes to sediment mycoplasma. The resulting 
supernatant was aspirated gently, and the pellet resuspended thoroughly with 50µl 
of buffer solution. Samples were heated at 95°C for 3 minutes. 
The PCR reaction reagents were mixed as shown in table 2.4. 
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Reagents Volume (µl) 
H2O 35 
Pre-Prepared PCR Reaction 
Mix 
10 
Test Sample / positive control 
/ negative control 
5 / 1 / 5 
Table 2. 4; Composition of PCR reaction mixture 
 
Tubes were placed in a DNA thermal cycler with the cycling parameters for PCR 
shown in table 2.5. 
 
Temperature 
(°C) 
Time (seconds) Cycles 
94 30 1 
94 30  
60 120 35 
72 60  
94 30  
60 120 1 
72 300  
4 ∞  
Table 2. 5; PCR reaction cycling parameters 
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20µl of PCR product was separated by gel electrophoresis using a 2% agarose gel. A 
positive sample and positive control will have amplified 270bp DNA fragment. An 
example of a contaminated sample is shown in figure 2.2.  
Figure 2. 2; Mycoplasma Screening. 
Positive mycoplasma detection example – positive band at ~270bp 
 
Mycoplasma PCR reaction was performed on the supernatant of cultured cells that 
were growing for a minimum of 24 hours.  
2.2.7. Mycoplasma Decontamination and Future Prevention 
To decontaminate positively infected cells, an antibiotic proven effective in the 
elimination of 90% of mycoplasma infections found in cell cultures was used. BIOMYC 
- 3 (Geneflow Ltd. Staffordshire) based upon a member of the fluoroquinolone group 
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was used at the recommended concentration and didn’t demonstrate any cytotoxic 
effects to the cells. Cells were grown in media containing 1 X BIOMYC – 3 for 2 weeks 
and were resultantly free from mycoplasma infections. A non-toxic pharmacidal 
disinfectant spray (Geneflow Ltd. Staffordshire) containing n-octyl-dimethyl-
benzylammonium-acetate, benzelthoniumacetate and 
methylbenzenethoniumacetate was sprayed in the incubator and tissue culture 
hoods once a week to prevent mycoplasma recontaminations. 
2.3. Mice 
2.3.1. Mice Strain 
The mice used were CD-1 mice (Charles River, UK) maintained in a 12 hour light/ 12 
hour dark cycle and fed a standard rodent diet. After 10 weeks, mice were sacrificed 
whilst fed (between 08:00 hours and 10:00 hours) by overdose of anaesthetic to 
facilitate pancreatic islet isolation. 
2.3.2. Islet Isolation 
CD-1 male mouse pancreata were digested by injection of ice-cold 1mg/ml 
collagenase P (Roche Applied Science, Switzerland) and 0.15mg/ml DNAse 1 (Roche 
Applied Science, Switzerland) diluted in RPMI1640 was injected directly into the 
pancreas duct. Upon pancreas inflation, it was excised and cut into small pieces by 
surgical scissors and placed in ice cold RPMI. Samples were sealed with parafilm and 
incubated at 37°C for 7 minutes under static conditions followed by forceful shaking 
every minute post incubation until suitable pancreatic tissue digestion. Digested 
tissue was allowed to settle before supernatant removal and transfer to black 
bottomed container. Islets were picked by hand using microscope and p200 pipette 
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and cultured in flask containing RPMI 1640 and incubated at 37°C in a 95% air/5% 
CO2 atmosphere. 
All animal procedures were undertaken by collaborators at King’s College London (Dr. 
Sophie Sayers) and approved by King’s College London Ethics Committee and carried 
out in accordance with the UK Home Office Animals (Scientific Procedures) Act 1986 
2.4. BSA Conjugated Fatty Acids and Experimental Media 
Preparation  
To imitate diabetic extracellular glucolipotoxic conditions in vitro, cells were 
incubated for the stated period in complete growth medium containing to 28mM 
glucose, 200µM palmitic acid and 200µM oleic acid either alone (high glucose or high 
fatty acid) or in combination (glucolipotoxic). Stock solution of palmitic acid and oleic 
acid were prepared. 100mM solutions of palmitic acid dissolved in 100% ethanol and 
sodium oleate dissolved in 50% ethanol were heated to 100°C to ensure full 
dispersion were used to supplement the complete growth media prior to 
experimental incubation to a final concentration of 200µM respectively. The media 
was supplemented with 2% fatty acid free BSA and allowed to incubate at 37°C for a 
minimum of one hour to allow fatty acid conjugation to BSA. Media was filtered with 
0.2µM Millipore PES membrane filters. Individual experimental conditions of high 
glucose and fatty acids alone or combination are stated in text and figure legends. 
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2.5. Gene and Protein Expression Analysis 
2.5.1. RNA Analysis 
2.5.1.1. RNA Extraction 
Total RNA was extracted from cells grown in stated conditions using RNeasy Microkit 
and RNAse free DNAse I kit (Qiagen, UK). Spent media was discarded and cells 
detached with trypsin before centrifugation at 400 x G for 5 minutes. Appropriate 
amount of RLT buffer was used to homogenise cell pellet before addition of equal 
volume of 70% ethanol. Samples were transferred to RNeasy MinElute spin column 
and centrifuged at 8000g for 15 seconds. Flow through was discarded and 10µl of 
DNAse I stock solution and 70µl buffer RDD placed in column and allowed to incubate 
for 15 minutes at room temperature. 350µl of RWI buffer was added and column 
centrifuged at 8000g for 15 seconds. 500µl of RPE buffer was added before 
centrifuging again at 8000g for 15 seconds. Flow through was discarded and 500µl of 
ethanol added to column before centrifugation at 8000g for 2 minutes. Flow through 
again was discarded and column spun for 5 minutes without lid to dry membrane. 
20µl of DNAse free water was added to centre of membrane and sample collected 
by centrifugation at maximum speed for 1 minute. Samples were stored at -80°C 
when not in use. 
2.5.1.2. RNA Quantification 
Extracted total RNA was quantified and quality checked using NanoDropTM 8000 
spectrophotometer (ThermoFisher, UK). The absorbance of samples was measured 
after blanking with H2O at 260nm. Absorbance increased linearly with concentration 
of RNA allowing quantification. RNA absorbs at 260nm whilst sample impurities such 
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as protein, and ethanol content absorbs at 280nm. The resultant ratio of absorbance 
at 260nm to 280nm indicates RNA purity with a value of 2 considered pure. 
2.5.1.3. cDNA Synthesis via Reverse Transcription 
The reaction setup for cDNA was as follows using cDNA synthesis kit (ThermoFisher, 
UK): 
Reagents Volume (µl) for 1 X reaction 
RT buffer 2 
dNTPs 0.8 
Random Primers 2 
Reverse Transcription 
enzyme 
1 
RNA 1.5µg 
dH2O Make up to 20 
Table 2. 6; Reverse transcription reaction for cDNA synthesis 
 
1.5µg of RNA was reverse transcribed with a total reaction volume made up to 20µl 
with deionised water for each RNA sample. The samples were placed in thermocycler 
set to 25°C for 10 mins, prior to two hours at 37°C then 5 minutes at 85°C. Samples 
were left at 4°C until collection and analysis. 
2.5.1.4. Quantitative PCR 
Real time qPCR allows the measurement of amplified PCR product per round of 
amplification through the use of a fluorescent label. During amplification, a 
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fluorescent tag (SYBR GREEN – BioRad, UK) binds either directly or indirectly to a 
labelled hybridising probe. The accumulating fluorescent double stranded DNA 
molecules are recorded after each cycle of amplification and quantified. The 
fluorescent signal is proportionate to increasing DNA concentration and therefore 
allows comparison between RNA samples. The threshold cycle (Ct) value is the point 
at which fluorescence is first detected to be statistically significant above the 
background and determines the amplification cycle number of detectable DNA 
sample. The lower the cycle number that the amplified product takes to be detected, 
the lower the Ct value. This is inverse to specific RNA expression. Briefly, the sooner 
a sample is detected, the more RNA for the specific targeted gene is expressed in the 
sample and vice versa.   
2.5.1.4.1. Primer Design 
Primers were designed using idt primer design tool and purchased from Sigma (UK). 
Specific qPCR primers 18-25 base pairs long were designed with a GC content 
between 30 and 80%, melting temperature of 61.5°C, desalted purification and a 
concentration of 0.05µM. Primer specificity was then determined using NCBI primer 
blast search and returned corresponding amplicons between 100 and 150 base pairs 
allowing the procurement of high level fluorescence without compromising 
efficiency. Primers are listed in Appendix A. 
2.5.1.4.2. Primer Denaturing and Specificity Analysis 
A Taq polymerase master mix was prepared containing cDNA and both forward and 
reverse primers. Samples were placed into the thermocycler with denaturing 
temperatures ranging from 58-62.5°C. Products were then ran on a 1.5% agarose gel 
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dissolved in TAE buffer that was heated until agarose was fully dissolved and poured 
to set in a gel cassette. Samples were loaded with a loading dye alongside a SYBR safe 
DNA gel stain ladder. The gel was run at 90volts for 50 minutes before visualisation 
using GeneSnap software. Primer specificity was determined by presence of product 
bands (figure 2.3).  
Figure 2. 3; Primer denaturing and specificity analysis.  
Example of primer testing using TAAR 2 forward and reverse primer pair 
2.5.1.4.3. qPCR Reaction Set up 
qPCR reactions were performed using SYBR GREEN (BioRad, UK), specifically 
designed forward and reverse primers for target gene and cDNA reverse transcribed 
from extracted total RNA. The reactions were set up as follows: 
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Reagents Volume (µl) for 1 X reaction 
SYBR GREEN 10 
Forward Primer 0.8 
Reverse Primer 0.8 
cDNA 0.5 
dH2O 7.9 
Table 2. 7; qPCR reaction set up quantities 
Reactions were performed in triplicate using Corbett Rotor GeneTM 6000 (Qiagen, UK) 
with the following thermal profile:  
Number of Cycles Temperature (°C) Time 
1 95 5 mins 
35 
95 5 seconds 
61.5 10 seconds 
72 12 seconds 
1 72 3 minutes 
∞ 10 ∞ 
Table 2. 8; qPCR reaction programme.  
2.5.1.4.4. qPCR Data Analysis 
Data was analysed using comparative delta delta Ct (ΔΔCT) method. This method 
quantifies the ratio between the amount of the target gene and reference control 
gene in a sample. The advantage of this is that using an internal reference standard 
or ‘housekeeping’ gene target that does not change expression between samples 
with minimise potential variation by normalising for slight deviations in sample RNA 
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concentration. GAPDH was used throughout as housekeeping gene for gene 
expression normalisation. 
Having obtained a Ct value for each sample, the ΔΔCT can be used to calculate fold 
change in gene expression relative to control samples using equation 2^ ΔΔCT 
2.5.2. RNA Sequencing 
2.5.2.1. DNAse Treatment 
Contaminant genomic DNA was removed from extracted total RNA samples by 
treating with DNA-free DNA removal kit (Life Technologies, UK). 0.1 volumes of 10X 
DNAse buffer was added to each RNA sample before incubating for 10 minutes at 
37°C with gentle agitation. 0.1 volumes of DNAse activation agent was subsequently 
added to each sample and incubated for a further 2 minutes at room temperature 
mixing regularly. Samples were centrifuged at 1000 X g for 1.5 minutes and RNA 
transferred to fresh tubes. 
2.5.2.2. RNA Quality Assessment 
Before performing genome wide RNA sequencing analysis, it is vital to check the 
quality of extracted RNA. Whilst the aforementioned NanodropTM 8000 can 
determine RNA concentration and RNA purity, it cannot assess other parameters of 
RNA quality, primarily RNA degradation. RNA integrity was therefore determined 
using an Agilent Bioanalyser (Santa Clara, CA). This machine assesses the integrity of 
RNA through the detection of ribosomal RNA (rRNA) which accounts for ~80% of total 
RNA as opposed to messenger RNA (mRNA), which accounts for only 1-3% that would 
reduce detection and therefore overall sensitivity. Ribosomal RNA is primarily 
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comprised of 18S and 28S rRNA species which using a micro fabricated chip, can be 
separated by mass-to-charge ratio via capillary electrophoresis. An included 
fluorescent dye intercalates between RNA strands and is quantified where data is 
translated as an image with bands at different weights and presented as 
electropherograms. This method assumes that rRNA quality is a true reflection of the 
mRNA population with an approximate ratio of 2:1 of 28S and 18S respectively, set 
as the benchmark for intact RNA. Degraded RNA will therefore typically peak before 
18S and indicate poor RNA quality. An RNA Integrity number (RIN) value is calculated 
using an algorithm built-in to the software and given a value from 0-10. A RIN value 
of 8 and above is considered adequate quality. 
Figure 2. 4; RNA Integrity number (RIN).  
RIN scores are calculated from the ratio of 18S to 28S rRNA and used as a 
measurement of RNA quality and integrity. Scores range from 1-10 with a score of 8 
and above considered as a good quality RNA sample. (Figure adapted from Agilent 
technologies protocol and resultant data). 
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RNA samples were analysed using a RNA 6000 Nanochip (Agilent, Santa Clara, US) 
following manufacturers standard protocol. Nanochip wells were preloaded with 
included gel and fluorescent dye before setting and addition of 1µl of each RNA 
sample and molecular weight ladder. Nanochip was vortexed for 10 minutes and 
analysed on Agilent Bioanalyser software. Only samples with a RIN score of 8 and 
above were used for further analysis. 
2.5.2.3. Library Preparation 
Known high quality RNA (RIN score >8) was sent to the Sarah Lamble laboratory in 
Oxford for subsequent library preparation and sequencing using Illumina mRNA seq 
sample preparation kit (Illumina, San Diego, US). 
Initially, samples were ribo-depleted, removing the majority of rRNA allowing 
increased sensitivity and analysis power of transcriptomes and less abundant 
sequences. 
The library was then generated with the fragmentation of small pieces of mRNA using 
cations under increased temperatures, before reverse transcription with random 
primers and resultant cDNA strand synthesis. Double strand cDNA was synthesised 
by removing the RNA template and synthesising a replacement cDNA strand. The 
fragments were then ‘end-repaired’ by blunting the overhanging sequence ends 
using T4 DNA polymerase and Klenow DNA polymerase. The 3’ to 5’ exonuclease 
activity of the added enzymes removes the 3’ end overhand, whilst the polymerase 
activity fills in the 5’ overhang. The fragments were then prepared for ligation to 
 78 
 
adapters that have a T base overhang at their 3’ end by adenylation at the 3’ end (A 
base added to 3’ end) through the Klenow antibody polymerase activity. 
Adapters were subsequently ligated to the DNA fragments. Fragments were size 
selected (~200bp) and purified on a gel for downstream enrichment before 
amplification via PCR with primers that target the adapters. The resultant library was 
validated, and quality control assured using Agilent Bioanalyser method described 
previously, before sequencing. 
Figure 2. 5; RNAseq library preparation.  
RNA is purified by removing rRNA and fragmented into small pieces. Double stranded 
cDNA is synthesised via reverse transcription before the ends are repaired and 
adenylated. Adapters are ligated, and samples are size selected and purified before 
quality check, amplification and resultant library sequencing (Figure adapted from 
EpiGentek and Agilent Websites). 
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2.5.2.4. Sequencing  
The aforementioned library was used to perform paired end sequencing over one 
lane of a flow cell on Illumina-HiSeq 2000 instrument in Oxford. This technology 
depends on random fragmented genomic DNA attachment to an optically 
transparent planar surface. The attached DNA is extended and amplified to produce 
and ultra-high-density sequencing flow cell, containing hundreds of millions of DNA 
clusters, each consisting of roughly 1000 copies of each template. The templates 
were sequenced using a four-colour DNA sequencing by synthesis technology used 
reversible terminators with removable fluorescent dyes.  
2.5.2.5. Data Analysis 
The raw RNAseq data was analysed by Dr. Rob Lowe (Blizard Institute). The output 
sequencing data (compressed FASTQ files) from the Illumina machine run were 
aligned to an annotated reference genome using Top Hat v 2.0.9: 
http://tophat.cbcb.umd.edu. Reads that were aligned to exons, genes and splice 
junctions were counted using a reference genome ‘rn4’ extracted from UCSC 
(http://genome.ucsc.edu/goldenPath/credits.html#rat_credits).  
Using the HTseq-count programme (http://www-
huber.embl.de/users/anders/HTSeq/doc/count.html), data was visualised and 
interpreted, calculating gene and transcript expression, and then citing variations in 
expression between samples and conditions.  
Using the programme DEseq 
(http://www.bioconductor.org/packages/devel/bioc/html/DESeq.html) samples 
were normalised to correct in-sample distributional differences. Statistical 
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significance of gene expression fold changes was then calculated by comparing read 
counts from experimental samples to that of corresponding control samples with p 
values adjusted using the Bonferroni formula. 
2.5.2.6. Network Analysis 
To identify enriched pathways and functions between differently expressed genes, 
data was sent to Dr. Tania Jones (Blizard Institute). Data was loaded into pathway 
analysis programmes: PANTHER (http://www.pantherdb.org/) and Metacore, 
version 6.34 from Thomson Reuters (http://thomsonreuters.com/metacore/) which 
identify enriched networks, pathways, molecular functions, biological processes, 
cellular components, protein classes and diseases associated with the resultant list 
of differentially expressed genes. Enrichment is calculated with statistical values for 
genes within a specific pathway and considered significant if more genes of a given 
pathway are listed than would be expected by chance, based on the complete 
number of genes associated with that pathway. Bespoke enriched networks were 
created indicating directionality and expression change of genes within that pathway. 
2.5.3. Protein Analysis 
2.5.3.1. Protein Extraction 
Cells were cultured for stated period in control or experimental conditions before 
supernatant was removed and cells were washed in PBS three times. Cells were then 
scraped in RIPA buffer containing protease inhibitors (1ml/35cm2 growth area) to 
destroy cellular integrity and collected in microcentrifuge tubes. Samples were 
stored on ice for at least 30mins with regular vortexing to disaggregate protein from 
cell debris. Samples were centrifuged at 400 x G for 10minutes to remove any cell 
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debris before supernatant was transferred to new microcentrifuge tubes ready for 
analysis. For short-term storage, protein extracts were stored at 80°C.  
2.5.3.2. Protein Quantification - Bicinchoninic acid (BCA) Assay 
BCA protein assay (PierceTM BCA Protein Assay Kit – ThermoFisher Scientific, UK) 
allows the quantification of protein by chelating copper to protein in an alkaline 
environment whereby peptides of three amino acids or more form a coloured chelate 
complex with cupric ions. BCA then reacts with the reduced cuprous ions to produce 
a quantifiable purple coloured precipitate of one cuprous ion to two BCA molecules 
with an absorbance at 562nm. The absorbance is concentration dependent with a 
linear trend within the working range of 20-2000µg/ml. BSA included in the kit was 
diluted to concentrations ranging from 0-2000µg/ml to establish a calibration curve. 
10µl of extracted protein sample or BSA calibrator standard was added to each well 
of a 96 well plate with 200µl working solution which was prepared following 
manufacturer’s instructions diluting 1 part of BCA reagent B in 50 parts reagent A. 
Subsequently the plate was incubated for 30 minutes at 37°C before absorbance was 
read at 595nm (closest absorbance possible using iMarkTM microplate absorbance 
reader – BioRad, UK). The standard curve was set plotting BSA concentration (X-axis) 
and absorbance (Y-axis) with unknown sample concentration values deduced from 
this. 
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2.5.3.3. Western Blotting  
2.5.3.3.1. SDS Gel Preparation 
Gels were handcast using BioRad Mini-Protean tetra handcast system. A 12.5% 
polyacrylamide running gel mix was prepared as shown in table 2.5.3.3.1. and was 
poured between one short and one spacer plate assembled in a casting clamp. This 
mixture was topped with 100% ethanol to ensure a linear set. Subsequently, once 
the gel had set, the ethanol was removed and replaced with prepared stacking gel 
(table 2.9) and a ten 30µl teeth comb and allowed to set. 
Ingredients for one gel Running Gel (µl) Stacking Gel (µl) 
Water 1875 1560 
30 Acrylamide Bis-Acrylamide 2475 600 
Lower buffer 1560 0 
Upper Buffer 0 780 
10% SDS 60 30 
Temed 
(Tetramethylethylenediamine) 
6 3 
10% APS 
(Ammonium Persulfate) 
60 30 
Table 2. 9; Recipe for one 12.5% polyacrylamide gel 
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2.5.3.3.2 Sample preparation, loading, separation and transfer 
Known concentration samples were normalised and diluted in RIPA buffer to a final 
protein content of 20µg and volume of 20µl. 5µl of 4X denaturing sample buffer 
(950µl denaturing buffer with 50µl β-mercaptoethanol) (BioRad, UK) was added to 
each sample before incubation at 95°C for 5 minutes. Gels were placed in an 
electrophoretic tank containing an adequate volume of running buffer and the comb 
removed. Samples were loaded in a known order alongside a molecular weight 
marker. Gels were run at 80V for ~20 minutes to ensure no sample overflow. Voltage 
was then increased to 120V and run until sample front approached the bottom of the 
gel. 
Subsequently, protein were transferred from gel to a nitrocellulose membrane using 
Trans-Blot TurboTM Transfer system (BioRad, UK) with the gel placed on top of the 
membrane and sandwiched between filter paper soaked in transfer buffer. A roller 
was used to remove air bubbles and excess transfer buffer. Transfer was carried out 
using manufactures preprogramed protocol for mixed molecular weights (5-150 kDA) 
1.3A; up to 25V for 7 minutes. An example of a transferred membrane is shown in 
figure 2.6. 
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Figure 2. 6; Western Blot Transfer Example.  
Separated protein samples were transferred to nitrocellulose membrane using 
Trans-Blot TurboTM with preprogramed setting for mixed molecular weights; 25 volts 
constant for 7 minutes. Tranfer was of good quality as shown by the weight markers. 
2.5.3.3.3. Immunoblotting 
Membrane was soaked in panceau solution (Sigma, UK) to check for adequate 
transfer from gel to membrane. Panceau was removed by numerous washes in TBST. 
Membrane was blocked in 5% (w/v) milk (marvel original dried skimmed milk 
powder) in TBST for 2 hours. Subsequently membrane was incubated overnight with 
desired primary antibody (see appendix 2) diluted in 5% (w/v) milk in TBST at 4°C. 
Membrane was washed three times in TBST for 10 minutes before incubation in 
appropriate peroxidase-conjugated (HRP) secondary antibody (anti-rabbit or mouse 
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IgG) diluted in 5% milk in TBST for ~1 hour at room temperature. Membrane was 
washed three times in TBST for 10 minutes each before being developed in ECL plus 
mix solution (GE Healthcare, UK) for 5 minutes in darkness and imaged by 
chemiluminescence sensitive Image reader LAS4000 (GE Healthcare, UK). 
Protein band densitometry was performed using programme Image J where intensity 
of protein of interest band was divided by corresponding housekeeping protein band 
and data represented as fold change between conditions in comparison to control. 
2.6. Cell Function Analysis 
2.6.1. Cell Viability 
Calcein AM cell viability dye (ThermoFisher, Loughborough) was used to assess cell 
viability. Calcein AM is a non-fluorescent cell permeable dye that is converted to a 
green-fluorescent calcein after acetoxymethyl ester hydrolysis by intracellular 
esterases that viable eukaryotic cells possess. Cells were cultured in standard or 
experimental conditioned growth media for the stated time period before cell 
viability assay was performed as follows: Spent media was aspirated and cells were 
washed 3 times in KREBS. A final concentration of 5µM Calcein AM cell viability dye 
resuspended in KREBS was loaded for 1 hour before washing again 3 times with 
KREBS. Cell viability was measured via fluorescence, with excitation and emission at 
490nm and 520nm respectively with viability represented as percentage change 
compared to standard control conditions. 
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2.6.2. Radical Species Quantification 
Reactive species quantification was determined using 2’,7’-Dichlorofluorescin 
diacetate (DCFDA), a non-fluorescent cell-permeable probe that is de-esterified 
intracellularly and highly fluoresces upon oxidation by intracellular reactive species 
and conversion to 2’,7’-dichlorofluorescein. Within literature, DCFDA is commonly 
referred to a measurement of reactive oxygen species, however, DCFDA can be 
oxidised by some reactive nitrogen species as well. The use of DCFDA in this body of 
work will therefore refer to the presence of all reactive species, not just reactive 
oxygen (Kalyanaraman, et al. 2012).  
Cells were cultured in standard or experimental conditioned growth media for the 
stated period of time before radical species was quantified as follows: Spent media 
was aspirated and cells were washed 3 times in KREBS before a final concentration 
of 20µM DCFDA in KREBS was loaded for 1 hour before washing again 3 times in 
KREBS. Radical species measured via fluorescence, with excitation and emission at 
495nm and 530nm respectively with quantification presented as percentage change 
compared to control conditions 
2.6.3. 3-Nitrotyrosine (3-NT) Quantification 
3-Nitrotyrosine (3-NT) residue formation is a product of reactive nitrogen species 
such as peroxynitrite caused by oxidative stress. Cells were cultured in standard or 
experimental conditioned growth media for the stated period before 3-NT was 
quantified as follows: cells were lysed in extraction buffer containing protease 
inhibitor at a concentration ~ 2 million cells/ml and incubated on ice for 20 minutes. 
Samples were centrifuged at 16,000 x g for 20mins at 4°C to remove cell debris before 
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the supernatant was transferred to clean tubes for testing. Samples were diluted to 
appropriate concentration (8-1000ng/ml) before 3-NT residue formation was 
determined following 3-NT ELISA kit protocols (Abcam, Cambridge). Cellular protein 
content was assayed using BCA protein assay (PierceTM BCA Protein Assay Kit – 
ThermoFisher Scientific, UK) and used to normalise 3-NT data to protein content. 
2.6.4. 4-Hydroxynonenal (4-HNE) Quantification 
The α,β-unsaturated hydroxyalkenal  4-Hydroxynonenal (4-HNE) is the primary 
product of lipid peroxidation caused by oxidative stress. Cells were cultured in 
standard or experimental condition growth media for the stated period before 4-HNE 
was quantified as follows. Cells were lysed in RIPA buffer at a concentration of 
~2million cells/ml and stored on ice for one hour with regular vortexing, before 
centrifugation at 400 x G for 10 minutes to remove cell debris and supernatant was 
transferred to clean tubes for testing. Samples were diluted in RIPA to the 
appropriate concentration (0.63-40ng/ml) before 4-HNE formation was determined 
following 4-HNE ELISA kit protocol (Abbexa, UK). Cellular protein content was 
assayed using BCA protein assay (PierceTM BCA Protein Assay Kit – ThermoFisher 
Scientific, UK) and used to normalise 4-HNE data to protein content. 
2.6.5. Insulin Secretion 
2.6.5.1. INS-1 Insulin Secretion 
Cells were grown in standard or experimental conditioned growth media for stated 
period of time before cells were washed in KREBS 3 times and subsequently 
incubated for 2 hours in KREBS with or without insulin secretagogue cocktail 
containing 1mM Tolbutamide, 10mM Leucine, 10mM Glutamine, 1mM 3-isobutyl-1-
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methylxanthine (IBMX), 1µM phorbol 12-myristate 13-acetate (PMA) and 10mM 
glucose. Supernatant was collected and centrifuged at 300 x G for 2 minutes to 
remove any cell debris before insulin secretion was determined following standard 
ELISA kit protocols (Mercodia, Sweden). Cellular protein content was assayed using 
BCA kit protocol (ThermoFisher, Loughborough) and used to normalise insulin 
secretion data to protein content. 
2.6.5.2. Islet Insulin Secretion 
In collaboration with King’s college; sized match islets were pre-incubated in buffer 
containing 2mM glucose, 2mM CaCl2 and 0.5mg/ml BSA (pH7.4) for 1 hour at 37°C 
before incubation in buffer containing 2mM or 20mM glucose for one hour at 37°C 
with gentle shaking. Islet insulin secretion was determined using radioimmunoassay 
with an in-house Bovine 125I-insulin raised in guinea pig by repeated subcutaneous 
injection of insulin coupled to albumin. Diluted 1:60,000, antiserum allowed a 
detection limit of 8pg. Purified mouse insulin was used as standard.  
2.6.6. Cyclic Adenosine Monophosphate (cAMP) Accumulation Quantification 
cAMP is an important second messenger in many biological systems and is a known 
insulin secretion enhancer in β-cells. Cells were cultured in standard or experimental 
conditioned growth media for stated period of time before cells were washed in 
KREBS 3 times. Cells were stimulated with KREBS containing 0.5mM IBMX (3-isobutyl-
1-methylxanthine) and various trace amine associated receptor ligands at stated 
concentrations for 30 minutes. Supernatant was removed, and cells were incubated 
in 0.1M Hydrochloric acid (1ml/35cm2 culture area) and left at room temperature for 
20 minutes. Cells were scraped, collected and centrifuged at 1000 X g for 10 minutes 
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to remove cell debris before supernatant was transferred to clean tubes for testing. 
cAMP accumulation was determined following standard Select ELISA kit protocols 
(Cayman Chemical, US).  
2.7. High Performance Liquid Chromatography (HPLC) – Amino 
Acid Analysis (AAA) 
HPLC is a type of column chromatography that allows the identification and 
quantification of different analytes depending on their polarities and interactions. 
Analytes in a solvent are pushed through a chromatographic packing material filled 
column at high pressure. The sample is then carried by a gas stream of either helium 
or nitrogen where its retention times of the separated sample is measured. This 
retention time corresponds to known samples allowing the identification of 
unknowns. This technology can separate and identify concentrations of analytes as 
low as one parts per trillion making it incredibly accurate and sensitive even at 
miniscule concentrations. HPLC analysis was carried out in collaboration with Dr 
James from the NTU sports science department as follows. 
2.7.1. Sample Preparation 
Cells were detached with Trypsin-EDTA (Life Technologies, UK) by incubating for 5 
minutes at 37°C. Cells were pelleted by centrifuging at 300 X G for 5 minutes before 
washing twice with DPBS (Life Technologies, UK). 15µl of 8M Urea was added to the 
pellet followed by 20µl of 0.05% ProteaseMAXTM surfactant (Promega, UK) and 
vortexed to ensure full cell lysis. To the cell mix, 58.5µl of 50mM TEAB (Triethyl 
ammonium bicarbonate) was added and incubated at 4°C (on ice) for a minimum of 
15 minutes. The debris was pelleted by centrifugation at 14000 X G for 10 minutes 
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and supernatant transferred to fresh tubes. To boost cell lysis, the supernatants were 
alternated three times being placed in a water bath sonicator at full power for 5 
minutes and then ice for 5 minutes. Cell debris was pelleted again by centrifugation 
at 13000 X G for 5 minutes and supernatant transferred ready for analysis. 
100µl of lysed sample was added to 100µl of sulphosalicyclic acid deproteiniser with 
internal standard or norleucine (500µMol/L). Samples were vortexed thoroughly to 
ensure complete mixing and left on ice or in 4°C fridge for 30 minutes. A white 
precipitate formed. Samples were then centrifuged at 10,000 X G for 5 minutes 
before the supernatant was collected and transferred into correspondingly labelled 
filter tubes. Samples were centrifuged through the filter for ~1 minute. Filters were 
discarded and the ultrafiltrate solute was transferred into corresponding amino acid 
analysis tube for analysis. 
2.7.2. Standard Preparation 
Firstly, the stock solution was made by mixing 100µl of the acidic and neutral amino 
acids, 100µl of the basic amino acids, 100µl of glutamine stock buffer and 200µl of 
the lithium loading buffer. 
The first three standards were made as shown in table 2.10. 
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Standard 
Concentration 
(µMol) 
Stock solution 
(µl) 
Lithium Buffer 
(µl) 
Sulphosalicyclic acid 
deproteiniser with 
500µMol/L Norleucine 
(µl) 
250 100 0 100 
200 80 20 100 
150 60 40 100 
Table 2. 10; Recipe for higher concentration three AAA standards. 
The remaining three standards require diluted stock buffer. This was made by mixing 
200µl of the original stock buffer with 500µl of lithium buffer. The remaining 
standards were made as shown in table 2.11.  
Standard 
Concentration 
(µMol) 
Diluted Stock 
solution (µl) 
Lithium Buffer 
(µl) 
Sulphosalicyclic acid 
deproteiniser with 
500µMol/L Norleucine 
(µl) 
100 100 0 100 
50 100 100 100 
25 100 300 100 
Table 2. 11; Recipe for lower concentration three AAA standards. 
All standards were aspirated to mix thoroughly and labelled ready for analysis. 
2.7.3. HPLC Sample Analysis 
In collaboration with Dr Ruth James (NTU), 40µl of sample or standards ranging from 
250-25µMol/L were injected onto analytical column for analysis. Amino acid 
concentrations were determined using a Biochrom 30+ high-performance liquid 
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chromatography ion exchange system with OPA derivatisation. Analytes were 
normalised to the internal standard of norleucine and presented as µM/L 
concentrations. 
2.8. Computation Aided Carnosinase Inhibitor Drug Design 
In collaboration with the NTU chemistry department (Dr Garner, Suniya Khatun and 
Daniel Cotton), the MayBridge library (https://www.maybridge.com) which contains 
over 53,000 diverse compounds was prepared in OMEGA 
(https://www.eyesopen.com/omega) for virtual screening in ROCS 
(https://www.eyesopen.com/rocs). The ROCS system uses an algorithm to identify 
potentially similarly active compounds to that of a known active compound (in this 
case carnosine), by virtual 3D shape and chemistry compound comparison, with the 
theory that molecules with similar shapes and chemistry may have similar function. 
The top 50 hits, using the Tanimoto combo scoring function in ROCS from the 
MayBridge library, using carnosine as the reference molecule were selected for 
further analysis.  
The resulting top 50 hits from the library were then tested for their docking ability 
into the A1 active site of carnosinase-2 using the crystalline structure of this 
compound pocket and a programme named GOLD 
https://www.ccdc.cam.ac.uk/solutions/csd-discovery/components/gold/. The 
analysis provides a binding interaction score which was set to a threshold of 50 to 
identify compounds with the stronger binding interactions, whilst remaining much 
lower than that of carnosine to resist enzymatic hydrolysis. Bestatin, the known non-
specific competitive inhibitor of human carnosinase-2 (PEPPERS and LENNEY 1988) 
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was run alongside all compounds as an internal control, as any changes in bestatin 
docking scores are indicative of internal software errors.  
 Of the 50 compounds initially screened, 14 scored above the threshold. Of these, 9 
were purchased and screened for their capacity as carnosinase inhibitors and were 
coded M4, M8, M14, M21, M28, M38, M44, M48 and M49. Compounds were 
disaggregated and dissolved in 1ml of 100% ethanol before dilution in sterilised 
KREBS and used at a final concentration of 100µM. 
2.10. Statistical Analysis 
All data were expressed as mean ± standard error of the mean (SEM) (n = 3 or more 
independent experiments) and calculated as follows: 
=
𝑆𝑡𝑑𝑒𝑣(𝑚𝑒𝑎𝑛 𝑣𝑎𝑙𝑢𝑒𝑠)
𝑆𝑄𝑅𝑇(𝐶𝑜𝑢𝑛𝑡(𝑚𝑒𝑎𝑛 𝑣𝑎𝑙𝑢𝑒𝑠))
 
Parameters were compared using one-tailed student t-test assuming equal variance, 
with statistical significance determined using an alpha value of 5%. A p value below 
0.05 was therefore considered statistically significant. 
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3. Carnosine Scavenging 
of Glucolipotoxic Free 
Radicals Enhances 
Insulin Secretion and 
Glucose Uptake 
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3.1. Introduction 
Type 2 diabetes is a metabolic disorder characterised by pancreatic β-cell dysfunction 
and cell death, as well as insulin resistance in peripheral tissues. The highest risk 
factor and leading cause of developing type 2 diabetes is obesity (Cerf 2013). 
Molecular mechanisms leading to cell failure result from the associated chronic 
exposure to high circulating sugar and free fatty acid concentrations that are typically 
ingested from the diet. These conditions typically induce a compensatory increase in 
cell mass, insulin production and insulin secretion, in order to maintain glucose 
homeostasis. This is thought to occur primarily in response to the increased free fatty 
acid concentration rather than glucose, however many of the mechanisms of β-cell 
adaptation are still largely unknown (Cusi, et al. 2007; Poitout 2008).  
After an unspecified period of time depending on the individual pre-dispositions to 
diabetes, the first specific β-cell specific loss is that of glucose stimulated insulin 
secretion. This is followed by a decrease is insulin mRNA, thereby resulting in loss of 
insulin synthesis. Consequently -cells can no longer adapt as part of a compensatory 
response and begin to fail from the detrimental effects of circulating sugar and fat 
levels in the blood. Unless effectively treated, from this point systemic blood glucose 
concentrations permanently fall within the hyperglycaemic range (Poitout, et al. 
2010).  
Reactive species generation is a hallmark of type 2 diabetes. In the presence of 
toxically high glucose and fat concentrations, unwarranted reactive species are 
generated, including production of O2- by mitochondrial processes such as fatty acid 
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oxidation, as well as NOS2 gene induction encoding iNOS and resulting in increased 
NO production.  These elevated radical species perturb insulin synthesis and the 
secretory capacity of β-cells by inhibiting PDX1 and MAFA transcription factor 
expression and activity (Rosca, et al. 2012; Hasnain, et al. 2016). These, along with 
downstream products resulting from lipid peroxidation and glycation reactions, can 
interfere with cellular function by disrupting molecular conformation and altering 
activity and degradation processes (Baynes 2002). It is this, alongside the continual 
pressure on β-cells to synthesise and secrete more and more insulin in sub-optimal 
‘stress’ conditions that causes a constant feedback cycle, eventual loss of cell 
function and therefore loss of glycaemic control. 
As type 2 diabetes is characterised by multiple defects across several cell and tissue 
types, numerous different pharmaco-intervention strategies that work through 
different methods of actions are required. The two main targets for this are drugs 
that increase insulin secretion from failing β-cells, and medicines that increase insulin 
sensitivity at target tissues or decrease gluconeogenesis in the liver. Currently, there 
are a limited amount of options to treat the disease, with metformin and the 
thiazolidinedione; pioglitazone  currently prescribed to increase insulin sensitivity, 
and sulphonylureas, GLP-1 agonist analogs and DPP-4 inhibitors prescribed to 
enhance impaired insulin secretion  (DeFronzo 2010; Consoli and Formoso 2013). The 
issue with these either oral or injectable medications is that they often loose 
effectiveness over time. Thus, there is an urgent need to not only better characterise 
the underlying causes of the onset of diabetes, and particularly relating to 
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glucolipotoxicity, but to then identify and develop new targets and treatments that 
can be used either alone or in combination with existing pharmacotherapies. 
Carnosine, a dipeptide synthesised from β-alanine and L-histidine has recently 
emerged as a promising molecule as a recent study studying the effect of a dietary 
supplement containing cinnamon, carnosine and chromium was shown to lower 
fasting plasma glucose and increase lean mass in overweight or obese patients (Liu, 
et al. 2015). It was also shown to increase fasting insulin and disrupt insulin resistance, 
resulting in a significant reduction in circulating glucose concentrations in response 
to a glucose tolerance test (de Courten, et al. 2016). Despite these beneficial findings, 
there is however a significant absence of literature detailing molecular mechanisms 
of carnosine action on the pancreas itself. 
This project focuses on the dysregulation of insulin secretion in response to a 
glucolipotoxic model of type 2 diabetes. The aim of this chapter of work was to 
characterise the scavenging effects of carnosine supplementation in INS-1 β-cells 
exposed to chronic high glucose and free fatty acid concentrations utilising various 
ELISA and fluorescent dye techniques. Subsequent experiments were initiated to 
identify the resultant effect on stimulated insulin secretion in both INS-1 β-cells and 
primary ex vivo mouse islets. Following this, similar supplementation procedures 
were used in skeletal muscle myotubes to characterise the potential for carnosine as 
a treatment for both insulin augmentation and insulin sensitivity. 
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3.2. Results 
3.2.1. β-Cell Self Recovery from Glucolipotoxic Exposure 
It is well established that chronic exposure to both high sugar and high fat diminishes 
β-cells ability to secrete insulin secretion in response to a stimuli (Marshak, et al. 
1999; Ling, et al. 1996; Marshall, et al. 2007). In-vitro studies in the cell line HIT-T15 
suggest that diminished insulin content, secretion and gene expression in response 
to gluocotoxic media incubation can be fully reversed if moved to standard control 
media. The likelihood of full β-cell functional recovery is however decreased with 
increasing periods of antecedent glucotoxicity (Gleason, et al. 2000). 
 In order to investigate whether β-cells have the ability to self-recover from damaging 
combinative glucolipotoxic (GLT) exposure, INS-1 cells were incubated in the 
presence of GLT growth media (control growth media supplemented to 28mM 
glucose and 200µM palmitic acid and 200µM oleic acid) for 3 days, before being 
removed and replaced with control media for a further 2 days prior to analysis. Cells 
were then incubated in KREBS buffer or a secretagogue cocktail for 2h and insulin 
secretion determined. As can be seen in Figure 3.1, cells that were incubated for a 
full 5 days in GLT media had significantly diminished stimulated insulin secretion, 
reduced from 5.8 ± 0.2 ng/µg protein in control to 3.8 ± 0.3 ng/µg (p=0.003). By 
contrast, when cells were initially grown in GLT media but then changed to control 
growth media after 3 days, stimulated insulin secretion was significantly increased 
compared to GLT conditions increasing to 5.0 ± 0.1 ng/µg (p=0.01). 
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Figure 3. 1; INS-1 cells can partially recover the ability to secrete stimulated insulin 
secretion in response to 3 day glucolipotoxic exposure.  
INS-1 cells were cultured in RPMI-1640 media, or GLT media for 5 days, or 3 days 
followed by 2 days in control growth media. Insulin secretion was determined by 
ELISA following incubation ± secretagogue cocktail for 2 hs [(-) blue, (+) red] with data 
normalised to cellular protein content. Data are expressed as mean ± SEM from 3 
independent experiments. *p<0.05, **p<0.005  
This result indicates that INS-1 β-cells have the ability to recover some of their lost 
functionality, if removed from the toxic growth conditions. Despite the potential for 
some recovery, it is not practical as a therapeutic strategy in terms of type 2 diabetic 
patients, as patients cannot simply remove the hyperglycaemic and hyperlipidaemid 
environment which causes the deleterious effect on β-cell function. However, as the 
** 
* * 
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harmful effects of this toxic environment is widely attributed to oxidative stress, non-
enzymatic glycation and their resultant products, pharmacotherapy interventions 
that counteract reactive species could offer a similar and potentially more 
pronounced effect at maintaining β-cell function.  
3.2.2. Effect of Carnosine on β-cells 
The data presented here reports the beneficial actions of carnosine upon insulin 
secretion and glucose uptake in β-cells and skeletal muscle myotubes respectively.  
3.2.2.1. Carnosine Scavenging of Glucolipotoxicity-Associated Reactive Species and 
their Products 
It has been shown that carnosine is an effective scavenger of reactive carbonyl 
species (RCS) generated by lipoxidation such as hydroxynonenal (Aldini, et al. 2002) 
in a rodent model of diabetic nephropathy (Albrecht, et al. 2017). Carnosine was 
therefore investigated as a potential scavenger of reactive oxygen and nitrogen 
species (RONS) the building blocks of downstream RCS generation and cause for 
ablated β-cell function and viability.  
INS-1 cells were incubated in control or GLT media for 5 days, before a final 
incubation for 1h with or without 10mM carnosine supplemented to fresh 
experimental condition media. To determine the amount of reactive species present 
in each condition, 20 µM 2’7’-dichlorofluorescein diacetate (DCFDA), a cell permeant 
fluorogenic dye that detects and quantifies peroxyl, hydroxyl and other reactive 
species, was added for 1h and results shown in Figure 3.2. GLT increased reactive 
species significantly to 180.4 ± 8.2% (p=0.0006) normalised to control, whilst a 1h 
10mM carnosine treatment reversed the upregulation back to within control limits 
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(77.5 ± 19.7%, p=0.003 v GLT). A 1h treatment of carnosine in control conditions 
caused a non-statistically significant yet modest reduction in reactive species 
compared to control, reducing detection to 69.1 ± 20.9%. 
Figure 3. 2; Carnosine is an effective scavenger of glucolipotoxic reactive species in 
β-cells.  
INS-1 cells were cultured in RPMI-1640 media or GLT media for 5 days before 
incubation with media supplemented ± 10mM carnosine for 1h. 20µM DCFDA was 
loaded in KREBS buffer for 1h and reactive species detected via fluorescence with 
excitation and emission of 495nm and 530nm respectively. Reactive species is 
expressed as percentage change in comparison to control from 4 independent 
experiments ± SEM. **p<0.005 
 
0
20
40
60
80
100
120
140
160
180
200
Control Carnosine GLT GLT +
Carnosine
P
e
rc
e
n
ta
ge
 C
h
an
ge
 in
 R
ad
ic
al
 S
p
e
ci
e
s 
D
et
e
ct
io
n
 in
 C
o
m
p
ar
is
o
n
 t
o
 C
o
n
tr
o
l  
(%
)
****
 102 
 
As radical species detection with DCFDA was not normalised to cell number or 
protein content it was important to investigate the effect of GLT on cell number and 
viability to ensure the witnessed effect was not an artefact of glucolipotoxic driven 
cell death, or glucose driven cell proliferation. Using calcein AM, a cell permeable dye 
that fluoresces upon acetoxymethyl ester hydrolysis by eukaryotic intracellular 
esterases is indicative of cell viability and can be quantified. All viable eukaryotic cells 
will have the esterases required for the dye esterification and is therefore an 
accepted model of cell viability/number. The increase in reactive species in chronic 
GLT exposure conditions shown in Figure 3.2 were not caused by glucolipotoxic 
changes in β-cell viability. As shown in Figure 3.3, INS-1 cells treated for 5 days in GLT 
media showed only a small and non-statistically significant increase in viability to 
112.2 ± 7.0% compared to control (p>0.05).  
 103 
 
Figure 3. 3; GLT doesn’t alter cell viability over 5 days.  
INS-1 cells were cultured in control or GLT media for 5 days prior to addition of 5µM 
calcein AM for 1h before detection via fluorescence with excitation and emission of 
490nm and 520nm respectively and expressed as percentage change compared to 
control from 3 independent experiments ± SEM. 
 
To determine whether carnosine can influence reactive nitrogen species 
concentrations in response to glucolipotoxic exposure, INS-1 cells were incubated in 
control or GLT media ± 10mM carnosine for 5 days before cells were lysed and 
proteins separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE). Protein were subsequently transferred to nitrocellulose membrane and 
immunoblotted with an anti-inducible nitric oxide synthase (iNOS) antibody. iNOS is 
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the enzyme responsible for nitric oxide (NO) production from oxidisation of L-
arginine using oxygen NADPH electrons (Lowenstein and Padalko 2004). Increased 
iNOS expression would infer that nitrogen reactive species were equally upregulated. 
 Figure 3.4 demonstrates an example of protein band intensity, supportive of data 
published (Cripps, et al. 2017), that determined a 5 day GLT incubation caused 
significant fold change upregulation of iNOS expression by 3.7 ± 0.6 (p=0.0075), 
whilst a combined treatment of GLT and 10mM carnosine repressed the GLT driven 
upregulation of iNOS by 79.1 ± 4.7% (p=0.017). This data demonstrates that 
carnosine offers another protective method of action in β-cells, as a long term 
exposure to it can alter protein expression of key enzymes involved in harmful 
species formation. 
Figure 3. 4; Carnosine inhibits GLT driven upregulation of iNOS.  
INS-1 cells were cultured in control or GLT media supplemented with or without 
10mM carnosine for 5 days before cells were lysed, protein extracted and separated 
via SDS-PAGE, transferred to nitrocellulose and immunoblotted using anti-iNOS or 
anti-actin antibody. 
 
As both nitrous oxide (NO) and superoxide (O2∙-) species have been revealed to be 
significantly elevated by glucolipotoxicity, peroxynitrite, another harmful reactive 
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species formed from the combination of these species is also likely to be elevated. 
Peroxynitrite (ONO2-) itself is hard to detect, but the downstream residue adduction 
product of peroxynitrite, 3-nitrotyrosine (3-NT) can be quantified by ELISA. 3-
nitrotyrosine is an indicative biomarker for peroxynitrite and therefore reactive 
nitrogen species. It is produced from peroxynitrite targeting and reacting with L-
tyrosine and protein bound tyrosine to produce free circulating or protein bound 3-
NT respectively. The resultant alteration or adduction of key regulatory proteins is 
then likely to interfere with their cellular processes (Ahsan 2013). 
In order to investigate the presence of peroxynitrite, INS-1 cells were again cultured 
in control or GLT media supplemented with or without 10mM carnosine for 5 days 
prior to cells being lysed in suppled extraction buffer and extracts analysed. A 5 day 
GLT incubation significantly increased 3-NT modification of proteins by 32.9 ± 7.4% 
(p=0.005) compared to control. A 10mM carnosine dose combined with GLT, again 
significantly reversed the GLT upregulation (p=0.007) causing 3-NT detected 
adductions to fall to 94.3 ± 6.0% compared to control. 
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Figure 3. 5; Carnosine reverses glucolipotoxic driven 3-NitroTyrosine production.  
INS-1 cells were cultured in control or GLT media supplemented ± 10mM carnosine 
for 5 days. Cells were lysed and extracts 3-NT determined by ELISA with absorbance 
measured at 450nm and normalised to protein content. Results are expressed as 
percentage change compared to control from 3 independent experiments ± SEM. 
*p<0.05 **p<0.005 
 
Next, 4-HNE an α,β-unsaturated hydroxyalkenal produced from lipid peroxidation, 
and hence a hallmark of oxidative stress, was similarly determined via ELISA. Again 
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INS-1 cells were cultured in control or GLT media with or without 10mM carnosine 
for 5 days before cells were lysed in RIPA buffer and samples analysed for 4-HNE 
formation shown in Figure 3.6. As anticipated, GLT drove up 4-HNE formation by 43.5 
± 3.4% compared to control. Importantly, a 10mM carnosine dose was able to 
completely prevent GLT induced 4-HNE species production (p=0.026) to a 12.6 ± 8.5% 
compared to control samples. 
Figure 3. 6; Carnosine reverses glucolipotoxic driven 4-HNE production.  
INS-1 cells were cultured in control or GLT media supplemented ± 10mM carnosine 
for 5 days. Cells were lysed and extracts 4-HNE determined by ELISA and normalised 
to protein content. Results are expressed as percentage change compared to control 
from 3 independent experiments ± SEM. *p<0.05 **p<0.005 
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3.2.2.2. Carnosine Increases Stimulated Insulin Secretion in in vitro and ex vivo β-
cells 
As carnosine has been shown to be effective at scavenging reactive species and 
inhibiting harmful residue formations, it was important to determine if chronic 
treatment with carnosine can improve β-cell function, and in particular its main role, 
insulin secretion. INS-1 cells were incubated in standard growth media in the absence 
or presence of 1mM and 10mM carnosine for 5 days. This is well within the 
physiological range that has been shown to range from 2-20mM in wet human 
skeletal muscle (Artioli, et al. 2010; Guiotto, et al. 2005), and more specifically 12-
60mmol/kg dm in the human vastus lateralis muscle and ~2.25mmol/kg dm for the 
male rat soleus and rectus femoris muscles (Sale, et al. 2013; Naderi, et al. 2017). No 
data however exists for clonal or primary pancreatic β-cell carnosine concentrations. 
After a 5 day incubation, cells were washed and incubated in either KREBS or a 
secretagogue cocktail for 2h. Insulin secretion was quantified between conditions 
using an ELISA and normalised to protein content. As shown in Figure 3.7, 
secretagogue stimulated insulin secretion was moderately increased by 34.6 ± 8.1% 
when treated with 1mM carnosine increasing from 3.11 ± 0.48 ng/µg cellular protein 
to 4.13 ± 0.2 ng/µg. A 10mM treatment of carnosine however, significantly increased 
insulin secretion per cellular protein by 77.2 ± 18.7% rising to 5.14 ± 0.46 ng/µg 
(p=0.018).  
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Figure 3. 7; Carnosine increases secretagogue stimulated insulin secretion dose 
dependently in INS-1 cells.  
INS-1 cells were cultured in RPMI-1640 media in the presence of 1mM or 10mM 
carnosine for 5 days. Insulin secretion was determined by ELISA following incubation 
± secretagogue cocktail for 2h [(-) blue, (+) red] with data normalised to cellular 
protein content. Data are expressed as mean ± SEM from 3 independent experiments. 
*p<0.05, compared to control stimulated samples (+). 
 
As previously detailed, INS-1 cells are a well characterised, stable and wholly 
accepted β-cell clonal line that secretes insulin in response to stimuli within the 
physiological range. However, as transformed cell lines are not a completely true 
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representative of full animal physiology, it is essential to support any findings where 
possible with in vitro studies. Therefore, through collaboration with King’s College 
London (Dr Sophie Sayers and Dr Paul Caton), islets from CD-1 male mice were 
isolated and cultured in standard growth media, or media supplemented again with 
either 1mM or 10mM carnosine for 2 days (48h). After incubation, islets were spun 
down and incubated in KREBS supplemented to 2mM or 20mM glucose for 1h, before 
insulin secretion was determined using an iodine labelled insulin tracer and 
quantified by radioimmunoassay. Primary mice islets glucose-stimulated insulin 
secretion displayed in figure 3.8, increased modestly from 1.23 ± 0.25 to 1.87 ± 0.33 
an increase of 51.9 ± 26.8% when incubated in 1mM carnosine for 2 days. A 
significant rise to 2.37 ± 0.34 indicative of a 93.1 ± 27.5% increase in glucose-
stimulated insulin secretion occurred when incubated in 10mM carnosine for 2 days 
compared to control conditions (p=0.013). At a concentration of 10mM, carnosine 
treatment therefore offered moderate enhancement of both an immortal tissue 
culture β-cell line and primary tissues innate ability to secrete insulin in response to 
stimuli. 
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Figure 3. 8; Carnosine increases glucose-stimulated insulin secretion dose 
dependently in ex-vivo mouse islets.  
Islets were isolated from CD-1 mice and cultured in RPMI-1640 media supplemented 
with 1mM or 10mM carnosine for 2 days. Islets were subsequently incubated in 2mM 
[(-) blue] or 20mM [(+) red] glucose for 1h and insulin secretion determined by 
radioimmunoassay. Data is presented as the mean ± SEM from a minimum of 6 
independent experiments. *p<0.05 compared to control stimulated samples 
 
3.2.2.3. N-Acetylcysteine Supports Carnosine’s Method of Action 
To support the view that carnosine can enhance stimulated insulin secretion through 
its ability to scavenge reactive species and inhibit harmful adduct formation, another 
known anti-oxidant, N-acetylcysteine (NAC), was investigated. NAC was investigated 
at 10mM; the same concentration previously used by Al-Nahdi, John and Raza (2018) 
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investigating the cytoprotective effects of NAC in the β-cell clonal line RIN-5F (Al-
Nahdi, John and Raza 2018). This concentration was also consistent with the 
concentration of carnosine used in previous experiments. NAC is an aminothiol and 
synthetic precursor of intracellular glutathione and cysteine (Sun 2010) which has 
been shown to mimic the effects of naturally occurring antioxidants by inhibiting 
ROS-dependent apoptosis and inhibited hydrogen peroxide induced ROS detection 
(Curtin, Donovan and Cotter 2002; Halasi, et al. 2013). INS-1 cells were therefore 
cultured in control or GLT media for 5 days prior to supplementation with or without 
10mM NAC for 1h. After 1h cells were washed and incubated in 20µM DCFDA for 1h 
before radical species quantification via fluorescence. GLT as shown before, 
increased reactive species significantly over the 5 days by 62.3 ± 20.1% compared to 
control (p=0.003). Similarly, to a 1h 10mM carnosine dose, a 10mM treatment of NAC 
with GLT decreased reactive species detected to 79.4 ± 2.0% compared to control. 
This therefore represented a significant reduction from GLT conditions (p=0.001).  
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Figure 3. 9; NAC scavenges glucolipotoxic driven reactive species.  
INS-1 cells were cultured in RPMI-1640 media or GLT media for 5 days before 
incubation with media supplemented ± 10mM NAC for 1h. 20µM DCFDA was loaded 
in KREBS buffer for 1h and reactive species detected via fluorescence with excitation 
and emission of 495nm and 530nm respectively. Reactive species is expressed as 
percentage change in comparison to control from 4 independent experiments ± SEM. 
**p<0.005 
 
As expected, the known anti-oxidant NAC and therefore viable internal control for 
reactive species related function, can scavenge glucolipotoxic driven reactive species 
in INS-1 β-cells. However, the downstream effects of carnosine on insulin secretion 
which was attributed to its ability to scavenge radical species depends on a similar 
response when treated with NAC. If they share similar effects, it can be established 
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that the increase in stimulated secretion can be attributed to the reduction in free 
circulating radicals which are upregulated in the physiology of type 2 diabetes.  
Therefore INS-1 cells were cultured for 5 days in the presence or absence of 10mM 
carnosine or 10mM NAC in standard growth media. As shown in Figure 3.10, 2h 
secretagogue stimulation significantly increased by 54.8 ± 17.0% when treated with 
carnosine for 5 days (p=0.013), consistent with previously presented and published 
data. Similarly, a 5 day treatment of NAC increased secretagogue stimulated insulin 
secretion significantly by 50.5 ± 20.8% (p=0.025) 
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Figure 3. 10; NAC increases secretagogue stimulated insulin secretion similarly to 
carnosine.  
INS-1 cells were cultured in RPMI-1640 media in the presence of 10mM carnosine or 
10mM NAC for 5 days. Insulin secretion was determined by ELISA following 
incubation ± secretagogue cocktail for 2h [(-) blue, (+) red] with data normalised to 
cellular protein content. Data are expressed as mean ± SEM from 3 independent 
experiments. *p<0.05, compared to control stimulated samples (+). 
 
This data is therefore supportively indicative that carnosine’s ability to enhance 
stimulated insulin secretion is dependent upon its capacity as a scavenger of harmful 
reactive species.  
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3.2.2.4. Carnosine Reversal of Glucolipotoxic Inhibited Insulin Secretion 
As mentioned, it has previously been published by this research group that a 72h 
incubation of INS-1 cells in glucolipotoxicity inhibits stimulated insulin secretion 
(Marshall, et al. 2007). To determine whether carnosine could reverse this GLT 
associated inhibition, these experiments were repeated but with an extended 
incubation time of 5 days to maximise not only harmful effects of GLT without 
triggering apoptosis (identified in previous research carried out by Turner Research 
team), but to maximise any potential beneficial protective actions that carnosine 
could have.  
INS-1 cells were initially cultured in control or GLT media for 5 days before the 
addition of 10mM carnosine 2h prior to secretagogue stimulation (Figure 3.11). 
Consistent with previous data, GLT significantly diminished secretagogue stimulated 
insulin secretion from 4.7 ± 0.2 ng/µg cellular protein in control to 2.4 ± 0.08 ng/µg 
representing a decrease of 48.1 ± 1.9% (p=1.5 X 10-6). A 2h acute dose of 10mM 
carnosine partially reversed this diminished insulin release to 3.3 ± 0.04 ng/µg. This 
still represents a significant decrease from control conditions by 28.0 ± 0.9% (p=4.5 
X 10-5), yet also a statistically significant increase from GLT treatment alone (p=3.1 X 
10-6). Interestingly, 2h carnosine treatment in control conditions had no apparent 
effect on stimulated insulin secretion. This data therefore indicates that carnosine, 
even over a short period can start to reverse the damage caused by GLT. This is likely 
due to its rapid quenching of free radicals which cause an adverse effect on the 
insulin secretory pathway. 
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Figure 3. 11; An Acute 2h treatment of carnosine starts to reverse GLT inhibited 
insulin secretion.  
INS-1 cells were cultured in RPMI-1640 media in control or GLT RPMI-1640 media for 
5 days. 2h prior to stimulation, cells were incubated with or without experimental 
condition media supplemented with 10mM carnosine. Subsequently Insulin 
secretion was determined by ELISA following incubation ± secretagogue cocktail for 
2h [(-) blue, (+) red] with data normalised to cellular protein content. Data is 
expressed as mean ± SEM from 5 independent experiments. ***p<0.0005 
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If an acute 2h dose of carnosine could cause a significant change to insulin secretion 
it was warranted to investigate if a longer exposure of carnosine would be able to 
reverse the damage entirely. For this reason, INS-1 cells were similarly incubated in 
control or GLT media for 5 days, but carnosine was supplemented 2 days as opposed 
to 2h prior to stimulation and insulin secretion quantification (Figure 3.12). 
Consistently GLT reduced stimulated insulin secretion significantly by 63.1 ± 0.4% as 
expected (p=7.5 X 10-11). In agreement with previously offered data, 48h treatment 
of 10mM carnosine in control conditions increased secretagogue stimulated insulin 
secretion by 29.9 ± 2.0% (p=1.1 X 10-6). This increase is consistent with earlier data 
as it is a smaller increase than witnessed in Figure 3.8 with a 5 day carnosine 
incubation period, yet higher than when acutely incubated for 2h. One possible 
explanation for these findings could be that in β-cells already exposed to chronic GLT 
carnosine may require a longer period of time to exert full benefit, suggesting that 
GLT-adducted proteins may first need to turn over in order for non-adducted fully 
functional proteins to replace them. 
Importantly, 2 day treatment of carnosine was able to fully reverse GLT-associated 
loss of insulin secretion. In fact, it enhanced secretion above control by 42.4 ± 0.4%. 
This is a statistically significant change from both control and GLT conditions with p 
values of 1.7 X 10-9 and 2.5 X 10-16 respectively.  This data therefore indicates that 
carnosine is not only able to enhance insulin secretion, but it can reverse and inhibit 
the damaging effects that would have already accrued from the initial 3 days and 
succeeding 2 days co-exposure to a high sugar and high fatty acid environment.  
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Figure 3. 12; A 5 day carnosine treatment fully reverses GLT inhibited insulin 
secretion.  
INS-1 cells were cultured in control or GLT media for 5 days. 2 days prior to 
stimulation, cells were incubated with or without experimental conditioned media 
supplemented with 10mM carnosine. Insulin secretion was determined by ELISA 
following incubation ± secretagogue cocktail for 2h [(-) blue, (+) red] with data 
normalised to protein content. Data is expressed as mean ± SEM from 5 independent 
experiments. ***p<0.0005 
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3.2.3. Effect of Carnosine on Skeletal Muscle Myotubes 
As carnosine was shown to have protective qualities in clonal β-cells through reactive 
species scavenging, it was sought to determine whether the same scavenging effect 
could be elicited in C2C12 skeletal muscle myotube cells and resultantly increase 
diminished glucose uptake. Therefore, working in collaboration with a colleague 
(Charlie Lavilla) myocytic differentiation was induced in C2C12 cells, before cells were 
cultured in DMEM media or DMEM supplemented to 28mM glucose and 200µM oleic 
acid and 200µM palmitic acid for 5 days. Cells were then cultured in the presence or 
absence of 10mM carnosine for 1h, before further incubation in 20µM DCFDA for 1h. 
Total reactive species were then measured and quantified via fluorescence and 
presented in Figure 3.13. 
A 5 day incubation of skeletal muscle cells in GLT media caused a significant increase 
in reactive species by 169.6 ± 23.9% compared to control (p=0.001). A 1h dose of 
10mM carnosine significantly reduced reactive species in control conditions (p=0.03) 
but importantly significantly reduced the GLT driven upregulation of reactive species 
back to within control conditions (122.1 ± 37.1% compared to control p=0.014).  This 
data again suggests that carnosine can directly scavenge reactive species in 
numerous tissue types, due to the nature of the acutely timed treatment. 
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Figure 3. 13; Carnosine is an effective scavenger of glucolipotoxic reactive species 
in skeletal muscle.  
C2C12 cells were differentiated and cultured in DMEM media or GLT media for 5 days 
before incubation with media supplemented ± 10mM carnosine for 1h. 20µM DCFDA 
was loaded in KREBS buffer for 1h and reactive species detected via fluorescence 
with excitation and emission of 495nm and 530nm respectively. Reactive species is 
expressed as percentage change in comparison to control from 3 independent 
experiments ± SEM. *p<0.05 **p<0.005 
 
C2C12 cells were subsequently incubated in media ± GLT, ± 10mM carnosine for 5 
days to investigate insulin stimulated glucose uptake via 2DG6P detection. Carnosine 
addition resulted in a statistically significant increase in glucose uptake in comparison 
to the diminished amount of glucose uptake observed in GLT treated cells (p=0.04). 
This was not the result of altered cell viability (p>0.05) (data not shown) (Cripps, et 
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exert dual beneficial actions on glucose homeostasis through the enhancement of 
both clonal INS-1 and primary mouse β-cell insulin secretion and also target tissue 
skeletal muscle glucose uptake. 
3.3. Discussion 
The damaging effects of glucolipotoxicity have been attributed to many molecular 
mechanisms, including but not limited to oxidative stress, activation of protein kinase 
C, increased production of mitochondrial superoxide and the generation reactive 
carbonyl species (Ahmad, He and King 2005; Brownlee 2001). Reactive carbonyls can 
be produced both via lipid-peroxidation and glycoxidation resulting in ALE and AGE 
respectively. The former is derived through a series of intracellular oxidation and 
cleavage reactions on membrane-derived polyunsaturated fatty acids (Esterbauer, et 
al. 1982) to produce most commonly aldehydes. Malondialdehyde (MDA) is the most 
common lipid peroxidation product produced, accounting for roughly 70% of the 
total products, hexanal roughly 15% and hydroxynonenal (HNE) 5% (Benedetti, 
Comporti and Esterbauer 1980; Esterbauer, et al. 1991). 4-HNE is the most 
extensively researched lipid-peroxidation end-product as it is incredibly more 
reactive and therefore more damaging in comparison to more abundant products  
(Ayala, Munoz and Arguelles 2014). 
AGEs (advanced glycation end products) are heterogenous compounds formed from 
carbonyls produced via glycoxidation through covalent bonding of either aldehyde or 
ketone groups of reducing sugars to free amino groups on proteins. This is known as 
the Maillard reaction. This creates a Schiff’s base, which can spontaneously rearrange 
to form a more stable reactive carbonyl intermediate keto-amine. These species can 
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then complete a series of structural and reactive reconfirmations yielding an 
irreversible and damaging AGE structure (Basta, Schmidt and De Caterina 2004; Sato, 
et al. 2006; Ellis 2007). Increased AGE production as seen in diabetes, gradually 
accumulates both in sera and tissues and contributes to retinopathy, cataract, 
neuropathy, nephropathy and many other downstream complications associated 
with diabetes (Ahmed 2005; Goh and Cooper 2008).  
Many of the resultant carbonyl species produced from these two methods are 
extremely reactive. Alkenals containing a C=C α,β-unsaturated double bond are the 
most reactive of the subset of species. HNE’s are extremely reactive because of this 
and is one of the most cytotoxic aldehydes that can cause significant damage at 
micromolar concentrations (Brambilla, et al. 1986). Reactive carbonyl species can 
interact and interfere directly with proteins responsible for cellular function, trigger 
apoptosis as well as damage, delete or mutate DNA (Ellis 2007). Reactive aldehydes 
can also disrupt and significantly lower intracellular glutathione levels (White and 
Rees 1984). Glutathione enzymes are specifically suited to HNE detoxification as they 
have low Km values for HNE catalysis making them very efficient controllers 
intracellularly (Tiedge, et al. 1997). This observed reactive aldehyde driven 
downregulation of glutathione is particularly important in pancreatic islets, as they 
are already regarded as one of the least protected in terms of an anti-oxidant defence 
system and hence particularly susceptible to oxidative stress related damage 
(Robertson and Harmon 2007).  
Taken together, these modifications exert a negative impact on cellular function, and 
in the case of β-cells can perturb insulin secretion. This may also shed some light on 
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why β-cells, if removed from toxic stress, have the ability to partially recover 
functional capacity lost from glucolipotoxicity. However, perhaps it is because the 
defence system needed to mop up the remaining reactive compounds simply isn’t 
strong enough to exhibit a full recovery over a short period of time that explains why 
we only see a partial recovery. Nevertheless, administration of an anti-oxidant 
compound such as carnosine to patients with T2D as a daily therapy might prove 
more effective. Moreover, even if only partially effective this is still likely to enhance 
insulin secretion and reduce the loss of -cell mass seen in patients with longstanding 
T2D, thereby delaying the onset of diabetic complications and improving patient 
prognosis. 
Consistent with our aim and hypothesis, the data presented here shows that 
glucolipotoxic media generates reactive oxygen and nitrogen species, which in turn 
generated 3-NT protein adduct formation. The presence of 3-NT indicates that 
peroxynitrite is just one of the reactive species present, formed from the 
combination of superoxide with nitric oxide which were also shown to be significantly 
upregulated by GLT. Similarly, the harmful reactive carbonyl species of α,β-
unsaturated hydroxyalkenal,  4-HNE was also upregulated in GLT, most likely 
produced from the aforementioned peroxidation of membrane derived lipids. 
In order to offset the damaging effects of reactive oxygen, nitrogen and carbonyl 
species that result in AGE and ALE production that are known to have a devastating 
effect on β-cells, and the self-defence anti-oxidant system being weak and potentially 
reduced even further by reactive stress, other molecules are also likely required to 
protect cell function and viability. As significantly diminished reactive species were 
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detected after a 1h acute treatment of carnosine, it indicates that carnosine is a 
potent scavenger of reactive species in INS-1 β-cells. This can be deduced as reactive 
species scavenging reaction happens very quickly, whereas protein turnover or gene 
perturbation that could alter reactive species generation would take a longer 
exposure of at least 48-72h to witness any changes. This work demonstrated that the 
dipeptide carnosine is not only an effective scavenger of reactive metabolites but can 
also inhibit harmful adduct formation on potentially key protein targets resulting in 
an increase in insulin secretion demonstrated both in vitro and vivo. 
4-HNE as mentioned is one of the most abundant and most reactive carbonyl species. 
Carnosine’s wide biological functions are still largely unknown, but it is accepted that 
it can sequester 4-HNE and other reactive carbonyl species alike, through a reaction 
called Michael’s addition (figure 3.14). 
Figure 3. 14; Carnosine sequestering of 4-HNE reaction.  
Carnosine reacts with 4-HNE on the imidazole ring of the histidine amino acid. 
Adapted from (Song, et al. 2014) 
It is the histidine component (particularly the imidazole ring) of the carnosine 
compound that reacts with nucleophilic residue within the HNE protein, forming a 
stable and ‘sacrificial’ non-reactive adduct (Aldini, et al. 2003; Aldini, et al. 2002). This 
inhibits any future potential damage that molecule of HNE can cause to other 
intracellular proteins. 
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Histidine containing dipeptides such as carnosine are therefore thought to act at two 
key points within oxidative stress biology; by scavenging reactive oxygen species 
directly before any of their toxic downstream products (reactive carbonyls) are 
produced, and by directly reacting and forfeiting itself by forming non-reversible 
adducts with any carbonyl species that are produced from prolonged stress exposure 
(Song, et al. 2014). This is most likely why this work also presented carnosine’s ability 
to be able to reverse the damage caused by 5 day glucolipotoxic exposure from just 
a 2 day carnosine incubation. This demonstrated carnosine’s potential use as not only 
a preventative medication for patients in a pre-diabetic state, but also for fully 
diagnosed diabetic patients that still have some β-cell function remaining that could 
be enhanced. Furthermore, in addition to having a protective role in clonal β-cells in 
terms of preserving insulin secretion in the face of glucolipotoxicity, carnosine also 
demonstrated a positive effect on glucose uptake in skeletal muscle through what 
we believe the same scavenging and adduction preventative action. Further 
characterisation of this in vivo is required. 
In conclusion, the data presented here demonstrates that β-cells may have some 
capacity for self-recovery if removed from toxic conditions. This illustrates the need 
for tight glycaemic control in patients with existing T2D, and the need for strict 
dietary control and aggressive therapy with existing therapeutic agents such as 
sulphonylureas to help manage and control blood sugar levels. Alongside this, the 
data presented indicates that taking the nutritional supplement of carnosine might 
further improve patient prognosis, as carnosine is a potent scavenger of reactive 
species in β-cells, inhibiting the harmful adduction of proteins by reactive carbonyls 
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and reactive nitrogen species resulting in an increase in insulin secretion. Importantly, 
it was also shown that carnosine can inhibit and reverse the damaging effects of GLT 
on both insulin secretion and glucose uptake, implicating a potential use for 
carnosine as a treatment for type 2 diabetes to stabilise glucose homeostasis on two 
fronts. 
3.4. Future Directions 
Controversial findings have reported diminished endogenous carnosine 
concentration in type 2 diabetic mouse and human tissues (Gualano, et al. 2012; 
Peters, et al. 2015; Liu, et al. 2016). Future studies could address this through the 
generation of carnosine synthase (CARNS1-/-), carnosinase-1 (CNDP1-/-), and 
carnosinase-2 (CND2-/-) knockout animals - which would provide depleted tissue 
carnosine, full plasma carnosine, and full tissue carnosine models respectively. The 
resultant tissues from these animals would then provide fresh insight to the debate 
of carnosine metabolism and altered carnosine contents in various pathologies, 
whilst also providing a plethora of full physiological samples for further analysis. 
There are also a number of additional avenues for investigation surrounding 
carnosine’s role in influencing glucose homeostasis in type 2 diabetes. The body of 
work presented in this thesis and elsewhere has already indicated the ability of 
carnosine to inhibit protein adduction by advanced lipidation and glycation end 
products. Whilst the beneficial action upon glucose homeostasis in both β-cell and 
skeletal muscles has now been shown, it is currently unreported in the literature 
which specific proteins are adducted by these glucolipotoxic driven species, and 
equally importantly, which proteins carnosine protects.  
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Utilising immunoprecipitation techniques in conjunction with mass spectrometry, 
ongoing work within the Turner research group aims to identify key regulators that 
are adducted by either 4-HNE and 3-NT in both β-cells and skeletal muscle in 
response to chronic glucolipotoxic exposure. Subsequently, samples will also identify 
proteins protected by carnosine to develop a deeper understanding of carnosine’s 
potential therapeutic use in this disease. Preliminary data has been generated in 
tissue culture cells and has identified specific functional classes of target proteins 
prone to adduction by these separate reactive species. Future studies will replicate 
this work using both animal models of diabetes and human patient samples in order 
to both validate existing data and indicate likely patient benefit.  
Also if β-cells express the protein carnosine synthase, supplementation through the 
dietary intake of β-alanine should also allow β-cells to synthesise their own carnosine 
to increase the intracellular pool. This endogenously synthesised carnosine would 
potentially have the same capacity to influence glucose metabolism as demonstrated 
in this chapter. However, one issue with either carnosine or -alanine strategies are 
that carnosine is rapidly hydrolysed by carnosinase enzymes, both in serum and 
tissue, so the development of non-hydrolysable carnosinase inhibitors and carnosine 
mimetics may represent a more effective treatment strategy that provides greater 
sustained efficacy. This strategy forms the basis for work presented in Chapter 4. 
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4.1. Introduction 
Previous work from the Turner group (Cripps et al, 2017) showed that carnosine 
regulates glucose homeostasis by increasing glucose uptake and insulin secretion. 
This occurs as a consequence of scavenging glucolipotoxicity-mediated reactive 
species. Nevertheless, one problem arising from using carnosine supplementation as 
a treatment for any pathophysiology is the rapid hydrolysis by serum and tissue 
carnosinases (Teufel, et al. 2003). Dietary carnosine, once ingested, can cross the 
intestinal enterocyte cellular membrane through PEPT1 transporters, whereupon it 
is either broken down by carnosinase-2, or else further transported out into the 
blood stream. There carnosinase-1 can also hydrolyses the dipeptide before it 
reaches any peripheral tissues, where its potential for beneficial action is highest 
(Boldyrev, et al. 2013). One solution to this could be regular administration of high 
doses of carnosine that would offset rapid hydrolysis, thereby potentially increasing 
the circulating pool of carnosine to high enough levels to elicit a biological effect. 
However constant oral dosing isn’t very practical in terms of medicating or 
monitoring purposes, and other more suitable options working around the same 
strategy may exist. 
In addition to being present in food such as red meat, carnosine is also synthesised 
endogenously by carnosine synthase from the amino acids β-alanine and L-histidine. 
-alanine is a non-proteogenic amino acid that is synthesised from the breakdown of 
uracil in the liver, yet has a very slow production rate resulting in an almost 
untraceable concentration in the serum, and as low as 40µmol/l in skeletal muscle 
where it is primarily stored and utilised (Bakardjiev and Bauer 1994; Harris, et al. 
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2006). This is much lower than the reported 3.24mol/l concentration of the standard 
α-alanine amino acid in skeletal muscle and ~350-450µmol/l in plasma and whole 
blood samples of normal individuals (Lewis, Waterhouse and Jacobs 1980; Roth, et 
al. 1985). For this reason, the rate limiting step of carnosine synthesis is thought to 
be β-alanine concentration, as whilst endogenous concentrations may be low, the 
affinity for carnosine synthase is high with a Km of roughly 1.0-2.3mM, meaning any 
possible synthesis is rapid (Ng and Marshall 1978; Skaper, Das and Marshall 1973b).  
It has previously been reported that β-alanine supplementation could increase 
intramuscular carnosine content in humans where it was shown to have a positive 
effect on cellular performance (Harris, et al. 2006; Hill, et al. 2007). If carnosine 
synthase is present in our INS-1 β-cells (currently unreported), it is therefore possible 
that supplementation with β-alanine might increase the intracellular pool of 
carnosine, thereby resulting in similar downstream positive effects on insulin 
secretion as discussed previously. 
The other constituent part of carnosine, L-histidine is also a topic of current research 
for its potential use as an amino acid supplementation, as it is the imidazole ring that 
is thought to be functional element of carnosine (Boldyrev, et al. 2013). Lower than 
typical L-histidine concentrations have been shown to occur in patients with chronic 
kidney disease (Watanabe, et al. 2008), obese women compared to non-obese 
women (Niu, et al. 2012), and young obese patients and patients with type 2 diabetes 
(Mihalik, et al. 2012). Decreased L-histidine concentrations therefore correlate with 
reactive species related diseases. L-histidine will therefore also be investigated as a 
potential tool to decrease reactive species and improve insulin secretion from β-cells. 
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As previously mentioned, whilst carnosine synthesis may be possible, the other half 
to the carnosine challenge is rapid high affinity hydrolysis of carnosine to its 
constituent amino acids by carnosinases both in the blood and in tissue.  This could 
simply negate any synthesis that may be possible through amino acid 
supplementation. Therefore a second treatment strategy, working alongside 
colleagues with expertise in medicinal chemistry at NTU, is to screen chemical 
libraries for potential compounds that can serve as carnosinase inhibitors. A recent 
study reported that reduced serum carnosinase activity as a result of treating with 
cysteine compounds, protected type 2 diabetic patients from diabetic nephropathy 
(Peters, et al. 2017).  Using the crystalline structure of carnosinase-2 (CN2), chemical 
library databases have been screened in-silico for compounds that closely fit the 
catalytic cleft of CN2, whilst not being hydrolysed themselves, thereby potentially 
acting as carnosinase inhibitors. 
The aim of this chapter is to identify if β-alanine or l-histidine supplementation can 
have a similar scavenging effect to that of carnosine in a type 2 diabetic model of 
glucolipotoxicity, and like carnosine, augment but importantly reverse glucolipotoxic 
driven loss of insulin secretion in β-cells. Secondly the aim was to identify carnosinase 
inhibitors using in silico docking techniques and screen the compounds for their 
ability to influence endogenous carnosine action, resulting in reversal of 
glucolipotoxic driven reactive species and loss of stimulated insulin secretion capacity 
in INS-1 β-cells. 
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4.2. Results 
4.2.1. Carnosine Synthase is Expressed in β-cells 
To determine if INS-1 β-cells express the protein capable of synthesising carnosine 
intracellularly, INS-1 cells were cultured in control media until confluent. Cells were 
lysed using RIPA buffer, and the resulting protein samples separated via SDS-PAGE. 
Protein was then transferred to nitrocellulose membrane and immunoblotted using 
anti-ATPGD1 (carnosine synthase) (Santa Cruz, USA) goat polyclonal antibody that 
reacts with rat species antigens.  
Figure 4.1 shows that carnosine synthase is expressed in clonal INS-1 β-cells but is at 
the very edge of detection even when loading high levels of protein (30µg). This is 
likely either a result of low carnosine synthase expression in β-cells, or due to ageing, 
or low efficacy of the antibody. Either way, its presence in β-cells, which has never 
been previously reported, is suggestive that carnosine synthesis occurs in these cells. 
Furthermore, if β-alanine can enter these cells, then carnosine synthesis, and 
therefore the readily active pool of carnosine, should increase. As such, this therefore 
warranted investigation into the supplementation of β-alanine in INS-1 β-cells.  
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Figure 4. 1; Carnosine synthase is expressed in INS-1 β-cells.  
INS-1 cells were cultured in control RPMI-1640 media, then lysed and protein 
separated by SDS-PAGE. Samples were transferred to a nitrocellulose membrane and 
immunoblotted using anti-ATPGD1 antibody (Santa Cruz) n=1.  
4.2.2. Effect of -alanine Supplementation on Glucolipotoxicity-Mediated Reactive 
Species 
As carnosine was shown to scavenge reactive species generated by incubation of INS-
1 β-cells in a glucolipotoxic environment, it was first sought to determine whether β-
alanine supplementation could offer similar protection. INS-1 were therefore 
cultured in control or GLT media for 5 days. 1h prior to reactive species detection 
cells were then incubated in experimental media conditions ± 10mM β-alanine for 
1h. Reactive species were detected using DCFDA dye and fluorescence quantified.  
Consistent with previously presented data, 5 day incubation of INS-1 cells in GLT 
media (Figure 4.2) increased reactive species by 68.8 ± 27.7% compared to control 
(p=0.024). However, 1h incubation with β-alanine in control conditions had no 
significant effect upon reactive species level. Similarly, a 1h dose of β-alanine in cells 
incubated in GLT for 5 days also had no effect on reversing GLT driven reactive species, 
with reactive species increased 67.1 ± 25.5% compared to control (p=0.019). As 
shown in chapter 3, carnosine was able to reverse GLT driven reactive species back 
to within control level in the space of 1h, as the reaction for free radical quenching is 
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rapid upon addition of a scavenger. This data therefore implies that β-alanine has no 
scavenging potential per se in itself, yet may still provide a protective action if dosed 
for long enough to allow carnosine synthesis to occur. 
Figure 4. 2; 1h treatment of β-alanine has no effect on glucolipotoxicity-mediated 
reactive species.  
INS-1 cells were cultured in control or GLT media for 5 days before the addition of 
10mM β-alanine for 1h. Cells were washed and incubated in 20µM DCFDA for 1h 
prior to measurement, with reactive species measured via fluorescence at excitation 
495nm and emission 530nm. Reactive species is expressed as percentage change in 
comparison to control from 4 independent experiments. *p<0.05 compared to 
control. 
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INS-1 cells were next cultured in control or GLT media ± 10mM β-alanine for 5 days 
prior to reactive species detection via DCFDA (Figure 4.3). This resulted in a 
statistically significant increase in GLT condition by 57.4 ± 15.6 compared to control 
(p=0.006). Importantly, whereas a 1h treatment of β-alanine had no effect on 
reactive species, 5 day treatment caused a significant reduction compared to that of 
GLT, reducing reactive species level to 118.6 ± 12.1% (p=0.039) relative to control. 
This indicates that long-term treatment with β-alanine can potentially reverse 
glucolipotoxic driven reactive species generation. 
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Figure 4. 3; 5 day treatment of β-alanine reverses glucolipotoxic driven reactive 
species.   
INS-1 cells were cultured in control or GLT media ± 10mM β-alanine for 5 days prior 
to the addition of 20µM DCFDA for 1h. Reactive species were measured via 
fluorescence with an excitation and emission of 495nm and 530nm respectively. 
Reactive species is expressed as percentage change in comparison to control from 6 
independent experiments. *p<0.05  
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4.2.3. β-Alanine Supplementation Increases Stimulated Insulin Secretion 
As damaging glucolipotoxic driven reactive species were substantially reduced 
following 5 day treatment of β-alanine, the logical next step was to determine 
whether this resulted in increased insulin secretion. INS-1 cells were cultured in the 
presence of ± 10mM β-alanine for 5 days prior to secretagogue stimulation, and 
insulin secretion determined by ELISA (Mercodia, Sweden).  Incubation of INS-1 cells 
with 10mM β-alanine for 5 days increased secretagogue-stimulated insulin secretion 
from 4.5 ± 0.4 ng/µg cellular protein to 6.0 ± 0.6 ng/µg cellular protein. This 
corresponds to a significant increase of 31 ± 14.0% (p=0.045) (Figure 4.4). Whilst not 
as big an increase as dosing with carnosine directly (chapter 3), this nevertheless 
offers a promising alternative for use as a dietary supplement. 
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Figure 4. 4; β-alanine increases stimulated insulin secretion.  
INS-1 cells were cultured in RPMI-1640 media in the presence of 10mM β-alanine for 
5 days. Insulin secretion was determined by ELISA following incubation ± 
secretagogue cocktail for 2h [(-) blue, (+) red] with data normalised to cellular protein 
content. Data are expressed as mean ± SEM from 6 independent experiments. 
*p<0.05 compared to control stimulated samples (+). 
4.2.4. β-alanine Reversal of Glucolipotoxic Inhibition of Insulin Secretion 
As β-alanine was shown to increase the secretory output from β-cells as a 
consequence of reducing glucolipotoxic driven reactive species, it was important to 
investigate whether, like carnosine, it could also reverse the associated inhibition of 
0
1
2
3
4
5
6
7
- + - +
Control Alanine
In
su
lin
 S
ec
re
ti
o
n
 (
n
g
/µ
g 
ce
llu
la
r 
p
ro
te
in
) * 
 140 
 
insulin secretion that results from chronic exposure to a glucotoxic environment. INS-
1 cells were resultantly cultured in control or GLT media ± 10mM carnosine for 5 days 
and stimulated with a secretagogue cocktail and insulin secreted determined (Figure 
4.5). Consistent with previously reported data, both in this thesis and the literature, 
incubation in GLT media for 5 days resulted in a significant reduction in secretagogue-
stimulated insulin secretion. Specifically, secretion was reduced from 5.3 ± 0.5 ng/µg 
cellular protein in control stimulated conditions to 3.8 ± 0.2 ng/µg cellular protein in 
GLT (p=0.016). Similar to the data presented in Figure 4.4, a 5 day 10mM dose of β-
alanine again increased stimulated insulin secretion to 7.0 ± 0.6 ng/µg cellular protein, 
representative of significant increase by 31.3 ± 12.0% compared to control (p=0.04). 
Importantly, when β-alanine was added to GLT media insulin secretion rose, to 4.7 ± 
0.5 ng/µg cellular protein (p=0.22 v control), indicating a significant reversal of 
glucolipotoxic inhibition (p=0.049). 
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Figure 4. 5; β-alanine reverses GLT inhibited insulin secretion.  
INS-1 cells were cultured in control or GLT media ± 10mM β-alanine for 5 days. Insulin 
secretion was determined by ELISA following incubation ± secretagogue cocktail for 
2h [(-) blue, (+) red] with data normalised to protein content. Data is expressed as 
mean ± SEM from 4 independent experiments. *p<0.05 
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4.2.4. β-alanine Supplementation Increases Intracellular β-alanine, But Not 
Carnosine 
Whilst this work theorises that β-alanine’s positive effect scavenging reactive species 
and decreasing GLT driven inhibition of insulin secretion is the result of increased 
carnosine synthesis by carnosine synthase (which was shown earlier to be expressed 
in INS-1 β-cells), it is important to support this with quantifiable data. Therefore, in 
collaboration with Dr Ruth James and Dr Katie Hanna at NTU, INS-1 cells were 
prepared for high performance liquid chromatography (HPLC) analysis. HPLC is a 
column chromatography technique that pumps analytes through a high-pressured 
column. The sample is carried by a moving gas stream which separates and 
resultantly identifies compounds in a sample by measuring its retention time in the 
column.  
INS-1 cells were therefore cultured in standard media and supplemented with 10mM 
β-alanine for 5 days prior to sample lysis. The samples were then added to an equal 
volume of sulphosalicyclic acid deproteiniser with an internal standard of norleucine 
at a concentration of 500µM. Samples alongside known standards were injected onto 
the analytical HPLC column and amino acid concentrations determined using a 
Biochrom 30+ HPLC ion exchange system with OPA derivatisation. Amino acid 
concentrations were normalised using the internal norleucine control allowing direct 
comparison between different samples. 
Preliminary HPLC data (n=2) indicates that INS-1 cells supplemented with 10mM β-
alanine for 5 days had an increased intracellular β-alanine concentration rising from 
7.6 ± 3.2 µM to 527.8 ± 12.2µM. Unfortunately, there was an issue with quality 
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control on the third repeat of β-alanine supplementation, so this particular data point 
must for the moment be considered as preliminary data only. The data is however 
consistent with the idea that INS-1 β-cells express transporters responsible for amino 
acid transport across the cell membrane, and that β-alanine can utilise these to 
increase intracellular β-alanine concentration. However intracellular concentrations 
are still much lower than the dose of 10mM, suggesting that either transport across 
the membrane is slow, or else that transported β-alanine is rapidly utilised for cellular 
processes. 
Figure 4. 6; Supplemented β-alanine is transported into INS-1 β-cells.  
INS-1 cells were cultured for 5 days in standard growth media ± 10mM β-alanine 
before protein extraction. Samples were mixed with sulphosalicyclic acid 
deproteiniser with internal standard or norleucine (500µM) before ultrafiltrate 
sample was collected and analysed using Biochrom 30+ high-performance liquid 
chromatography ion exchange system with OPA derivatisation. Analytes were 
normalised to the internal standard of norleucine and presented as β-alanine µM 
concentrations. Control n=3, β-alanine n=2.  
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Surprisingly, when the same samples were used to determine intracellular carnosine 
concentrations following β-alanine supplementation, the carnosine concentration 
did not significantly change (Figure 4.7). The working hypothesis had been that it was 
β-alanine driven carnosine synthesis that caused the downstream effect on both 
reactive species scavenging and insulin secretion, yet in the current experiment 
carnosine concentrations remain effectively unchanged. However, the hypothesis 
may still be valid. If endogenous carnosine produced by carnosine synthase is rapidly 
utilised to quench high levels of circulating reactive species in the face of low anti-
oxidant defence systems in β-cells then consequently, the intracellular carnosine 
pool would show little change in the HPLC analysis shown here. Unfortunately, the 
answer to this question lies outside the scope of current experiments, but more in-
depth enzymatic analysis in future studies will hopefully answer this dilemma. 
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Figure 4. 7; β-alanine supplementation does not significantly increase carnosine 
concentration in INS-1 cells.  
INS-1 cells were cultured for 5 days in standard growth media ± 10mM β-alanine 
before protein extraction. Samples were mixed with sulphosalicyclic acid 
deproteiniser with internal standard or norleucine (500µM) before ultrafiltrate 
sample was collected and analysed using Biochrom 30+ high-performance liquid 
chromatography ion exchange system with OPA derivatisation. Analytes were 
normalised to the internal standard of norleucine and presented as carnosine µM/L 
concentrations. Control n=3, β-alanine n=2. 
4.2.5. L-histidine Supplementation is Toxic to β-cells 
Whilst β-alanine is defined as the rate limiting step in carnosine synthesis, it is 
actually the imidazole ring of the L-histidine amino acid that is credited for its 
protective action in reactive species biology (Fontana, et al. 2002b). It was therefore 
investigated whether L-histidine supplementation would cause a decrease in reactive 
species, and thereby consequently result in enhanced insulin secretion from β-cells. 
INS-1 were cultured in control or GLT media ± 10mM l-histidine for 5 days prior to 
radical species detection using DCFDA (Figure 4.8). In line with previous experiments, 
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GLT resulted in a rise of reactive species by 46.0 ± 7.0% relative to control (p=0.001). 
Unexpectedly however, incubation with L-histidine in either control or GLT 
conditions caused a rise in reactive species by 53.6 ± 8.3% (p=0.001) and 79.5 ± 21.4% 
(p=0.01) respectively. This effect was mirrored by a decrease in secretagogue-
stimulated insulin secretion of 20.0 ± 10.3% (p=0.11) relative to control (Figure 4.9).  
 
Figure 4. 8; L-histidine increase in reactive species.  
INS-1 cells were cultured in control or GLT media for 5 days ± 10mM L-histidine prior 
to the addition of 20µM DCFDA for 1h. Reactive species were measured via 
fluorescence with an excitation and emission of 495nm and 530nm respectively. 
Reactive species is expressed as percentage change in comparison to control from 3 
independent experiments. *p<0.05 **p<0.005 
** 
** 
* 
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Figure 4. 9; L-histidine decreases secretagogue stimulated insulin secretion. 
 INS-1 cells were cultured in control or GLT media ± 10mM l-histidine for 5 days. 
Insulin secretion was determined by ELISA following incubation ± secretagogue 
cocktail for 2h [(-) blue, (+) red] with data normalised to protein content. Data is 
expressed as mean ± SEM from 3 independent experiments. 
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4.2.6. Carnosinase-2 is Expressed in β-cells 
Carnosinase-2 is the physiological intracellular tissue carnosinase. As it degrades 
carnosine back down to its constituent parts once carnosine either enters into cells, 
or upon endogenous synthesis, carnosinase-2 is a potential major barrier to 
supplementation strategies. It is therefore important to determine whether 
carnosinease-2 is expressed in β-cells. INS-1 cells were cultured in control media, 
then cells lysed and protein separated by SDS-PAGE. Resultant proteins were 
transferred to nitrocellulose and immunoblotted using an anti-CNDP2 antibody 
(Abcam, UK). Membranes were developed and demonstrated that carnosinase 2 is 
indeed expressed in INS-1 β-cells (figure 4.10). 
Figure 4. 10; INS-1 β-cells express carnosinase-2.  
INS-1 cells were cultured in RPMI-1640 media until 70% confluent, cells lysed, and 
proteins separated by SDS-PAGE. Samples were transferred to a nitrocellulose 
membrane and immunoblotted using anti-CNDP2 or anti-actin antibody (Abcam, UK).  
4.2.7. Compounds Designed as Carnosine-2 Inhibitors have Varied Effect on β-cell 
Viability 
Given the challenge of carnosine supplementation as a practical solution to enhance 
insulin secretion in the face of -cell carnosinase-2, alternative solutions could be to 
either enhance endogenous carnosine action through delivery of carnosine inhibitors 
Carnosinase 2 
(CNDP2) 
Actin 
Control 
55kDa 
42kDa 
Control Control Control 
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into the -cell, or else adopt a supplementation strategy that instead utilises weakly 
hydrolysable carnosine mimetic molecules.  
In order to develop the first of these strategies, computational docking analysis was 
undertaken. As detailed in chapter 2.8, the top 50 MayBridge compounds identified 
from ROCS virtual screenings as having similar chemistry and structural shape to 
carnosine and measured using the Tanimoto combo scoring were docked in the A1 
active site of CN2 using carnosinase-2’s crystalline structure, in the programme GOLD, 
alongside bestatin. Bestatin is a competitive inhibitor of human tissue carnosinase-2 
and acted as an internal control with any variation in docking best fit percentage 
scores indicative of errors or malfunction in the software that would need retesting. 
A binding interaction score of 50 (which is lower than that of carnosine binding) was 
chosen as the benchmark score. As the aim of the in-silico screening process was to 
find carnosine-shaped molecules stable against carnosinase hydrolysis, a score of 50 
is a high enough score to theoretically fit the active site yet low enough to have only 
a relatively weak interaction with the enzyme. As such this should result in an 
insufficient interaction for carnosine 2 to adopt the active conformation around the 
compound required for hydrolysis.  
Of the 50 compounds screened, 14 had a score above 50. M28 had the highest score 
and M47 having the lowest (with 70 and 20 respectively). All structures with a score 
of 50 and over were relatively small in size and had an either a 6 or 5 membered 
aromatic ring joined by an alkyl chain bridge to the rest of the molecule. The 6 
membered rings were mainly benzene or pyridine, whilst the compounds with a five 
membered ring consisted of either furan, azol or imidazole. Imidazole is the same 
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aromatic character as carnosine (the L-histidine component). Unfortunately however, 
due to IP / patent considerations, the remaining structure of the chosen compounds 
must remain confidential at this time.  
The top 9 highest scoring compounds (M4, M8, M14, M21, M28, M38, M44, M48 and 
M49) were purchased from MayBridge and screened for their potential. Upon arrival, 
the newly purchased compounds were disaggregated in 1ml of 100% sterile ethanol 
and diluted in sterile KREBS to a final concentration of 10mM. These were then 
diluted 1:100 into experimental media to give a final concentration of 100µM. This 
final concentration was chosen as pharmaceutical compounds would be expected to 
have significantly greater efficacy than carnosine (Peters, et al. 2017). As carnosine is 
optimally effective at a concentration of 10mM, 100µM was selected as a starting 
concentration for throughput screening purposes. However, once an effective 
compound is identified, more comprehensive dose-response experiments will be 
carried out to determine the most suitable concentration for physiological 
application moving forward. 
In control and GLT control conditions, a vehicle of ethanol was added to act as a 
vehicle control. This vehicle control did not affect cell viability, as shown in Figure 
4.11. The effect of the 9 screened compounds upon cell viability is detailed in Table 
4.1. Of the 9 compounds, only M4, M8, M14, and M28 did not decrease cell viability 
- as determined through observation down a light-microscope over the 5 day 
incubation period. M21, M38, M44, M48 and M49 by contrast were toxic, decreasing 
cell proliferation and killing cells. Example images of a number of the treated 
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compounds are displayed in Figure 4.11. Based on this data, only compounds that 
had no visible effect on cell phenotype and viability was taken forward for trials. 
Compound Code Name 
Cells Viable after 5 day 
exposure 
M4 ✔ 
M8 ✔ 
M14 ✔ 
M21 ✘ 
M28 ✔ 
M38 ✘ 
M44 ✘ 
M48 ✘ 
M49 ✘ 
Table 4. 1; Effect of Maybridge compounds on β-cell viability. 
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Figure 4. 11; Effect of selected compounds on cell viability.  
INS-1 cells were grown in RPMI-1640 media supplemented with labelled compound 
(vehicle, M4, M8, M14, M21, M48 and M49) for five days prior to imaging at 10X 
magnification using Zeiss Primovert microscope with AxioCam ERc5s camera. 
4.2.8. Compounds Designed as Carnosine-2 Inhibitors are Ineffective at Reversing 
Glucolipotoxic Reactive Species in -cells 
Compounds that were not toxic were next taken forward to functional analysis 
screening. Reactive species quantification was chosen as an initial screening 
experiment for these compounds based on cost and the relatively high throughput 
generation of data that had previously been observed when INS-1 cells were 
incubated in GLT media incubated +/- carnosine. INS-1 cells were therefore cultured 
in vehicle control or GLT media, or control or GLT media supplemented with the 
compound of interest to a final concentration of 100µM. As the compounds were 
chosen on the ability to fit the active site of carnosinase-2, the theory is that 
Vehicle 
Control  Vehicle GLT  M4 M8 
M14 M21 M48 M49 
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carnosinase-2 activity should be diminished, and endogenous carnosine then able to 
scavenge radical species without being turned over. Consequently, should this in fact 
be the case, then this should potentially increase insulin secretion, as observed 
previously. As such, after 5 days incubation in control or GLT media supplemented 
with the compounds, cells were washed and then treated with DCFDA before their 
intracellular reactive species were quantified by fluorescence and normalised to 
control (Figure 4.12).  
Figure 4. 12; Compounds designed as carnosinase inhibitors have no significant 
effect upon glucolipotoxic driven reactive species.  
INS-1 cells were cultured in control or GLT media supplemented with a) M4, b) M8, 
c) M14 and d) M28 for 5 days. Cells were washed and incubated in 20µM DCFDA for 
1h prior to measurement, with reactive species measured via fluorescence at 
excitation 495nm and emission 530nm. Reactive species is expressed as percentage 
change in comparison to control from a minimum of 3 independent experiments. 
*p<0.05, **p<0.005, ***p<0.0005 compared to control, #p>0.05 compared to GLT. 
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Unfortunately, the compounds that were chosen for their ability to fit the active site 
of carnosinase-2 and were non-toxic (i.e. had no clear effect on cell viability) to β-
cells over a 5 day period had no significant effect on reactive species. GLT as expected 
resulted in significant increase in reactive species compared to control in all instances. 
Reactive species were still increased by 55.7 ± 13.8%, 63.9 ± 14.8%, 53.5 ± 3.3% 
respectively compared to control for a co-treatment of GLT and either M4, M8 and 
M28. These were all statistically significant increases compared to control (p<0.05). 
Compound M4, M8 and M28 did however slightly reduce GLT driven reactive species 
modestly, however the change was small and statistically non-significant with p 
values of 0.15, 0.21 and 0.16 respectively compared to GLT treatment alone. 
Conversely, GLT and M14 compound treatment increased reactive species above GLT 
conditions alone to 209.2 ± 31.8% (p=0.004 compared to control, p=0.26 compared 
to GLT), suggesting this compound is causing additional yet non-significant stress 
when INS-1 cells were cultured in GLT co-treatment and was therefore deemed toxic.  
4.2.9. Compounds Designed as Carnosine-2 Inhibitors had No Effect on Reversing 
Glucolipotoxic Inhibition of Insulin Secretion 
As a modest decrease in average reactive species for 3 of the screened compounds 
was observed, insulin secretion was therefore determined. Compounds were 
screened just once to determine the likelihood of them having any beneficial effect 
on insulin secretion (as the insulin secretion kits are very expensive) and if so, more 
insulin secretion experiments would be carried out for positive compound hits. 
INS-1 cells were therefore incubated in control media, GLT media or GLT media 
supplemented with a final concentration of 100µM of M4, M8 or M28 for 5 days. On 
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the fifth day, cells were stimulated with a secretagogue cocktail or incubated in 
KREBS for 2h and secreted insulin determined by ELISA (figure 4.13).  
Consistent with both previously presented data here and in literature, a 5 day GLT 
incubation caused a reduction in secretagogue stimulated insulin secretion 
compared to control. Co-incubation with the chemical compounds that had a limited 
and insignificant effect on reactive species, had no effect on reversing the loss of 
insulin secretion from GLT. In fact, some lowered secretion below that of GLT alone. 
For this reason, it was decided to discontinue insulin secretion analysis with these 
compounds. As no compounds were seen to illicit a direct positive effect upon insulin 
secretion from β-cells, further experimentation in other tissue types, and the 
generation of more compounds is needed. 
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Figure 4. 13; Compounds designed as carnosinase inhibitors have no significant 
effect on reversing glucolipotoxic diminished insulin secretion.  
INS-1 cells were cultured in control and GLT media or GLT media ± 100µM of 
compound M4, M8 or M28 for 5 days. Insulin secretion was determined by ELISA 
following incubation ± secretagogue cocktail for 2h [(-) blue, (+) red] with data 
normalised to cellular protein content. Data are expressed as mean from one initial 
screening experiments. 
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4.3. Discussion 
Data presented here shows for the first time that carnosine synthase is expressed in 
clonal INS-1 β-cells. Whilst the concentration of carnosine synthase is yet to be 
determined, this is at least proof of principle that carnosine can be synthesised 
intracellularly within β-cells. This suggests that β-alanine supplementation could 
therefore potentially increase endogenous carnosine concentration, and thus elicit 
the same protective effect as administration of extracellular carnosine (Cripps, et al. 
2017). 
 In terms of a full physiological model this would also have several benefits over 
carnosine supplementation. Carnosine and β-alanine from oral dosing would have to 
be transported through intestinal cells and then again into the blood for circulation 
to the pancreas. This opens carnosine up to rapid hydrolysis to its constituent parts, 
both by carnosinase-2 in the intestinal tissue cells and carnosinase-1 in the blood. 
Supplementation of the same concentration of β-alanine would therefore in theory 
result in similar circulating β-alanine concentrations as when carnosine was 
hydrolysed to its component parts. 
 The data presented indicates that β-alanine supplementation whilst having no 
scavenging potential of its own, can elicit a protective effect over glucolipotoxic 
driven reactive species if chronically dosed over 5 days. This would suggest that the 
protective action is coming from β-alanine’s utilisation to form carnosine. This is in 
keeping with previously reported data, as 5 day β-alanine supplementation resulted 
in both an increase in stimulated insulin secretion in control conditions, but 
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importantly was able to reverse the glucolipotoxic inhibition of insulin secretion seen 
in β-cells.  
 Interestingly, the HPLC data presented in this chapter indicates that β-alanine can 
be transported into these cells, yet surprisingly there was little increase observed in 
intracellular carnosine concentration. One potential explanation for this might be 
that carnosine is difficult to quantify with high sensitivity using HPLC, as due to its 
highly hydrophilic nature it is poorly retained in the reverse phase C18 HPLC columns 
as well as lacking sufficient absorbance in the UV-visible spectra (Xie, et al. 2013). 
This would however seem unlikely to account for the scale of the discrepancy 
observed.  Instead there may be a biological explanation for the findings.  
As mentioned previously, carnosine synthase has a very high affinity for β-alanine 
(Skaper, et al. 1973b; Ng and Marshall 1978), suggesting that upon entry into cells, 
synthesis to carnosine is likely to be rapid. However, given the high levels of reactive 
species found within -cells and low intracellular anti-oxidant defence systems 
(Robertson and Harmon 2007) this newly synthesised carnosine might therefore be 
utilised immediately, thereby resulting in the decrease of reactive species and 
increase in secretagogue stimulated insulin secretion presented here. This would 
explain why, despite the observed functional effects, no change was observed in 
intracellular carnosine concentration following cellular exposure to β-alanine. Future 
experiments should therefore aim to determine the rate of carnosine synthesis 
within β-cells, as well as investigate the potential functional role of β-alanine as a 
therapeutic tool to regulate glucose homeostasis in type 2 diabetes.  
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In contrast to β-alanine, L-histidine supplementation had adverse effects both on 
cellular reactive stress and function. The reason for this is unknown, as L-histidine is 
regarded as the protective component of carnosine. However, there is a noticeable 
difference between the histidine component of carnosine and that of free histidine. 
The imidazole ring of carnosine has a pKa of 6.83 and is the undisputed effecter of 
carnosine’s role as a pH buffer. However, in free histidine, the pKa of the imidazole 
ring is lower at 5.83 (Smith 1938; Hill, et al. 2007). pKa is a measure of acid strength, 
therefore the lower the value the more acidic the compound. As free histidine’s pKa 
is lower, dosing with concentrations as high as 10mM may have elicited an acidic 
toxic effect resulting in an increase in reactive stress, accompanied by a decrease in 
insulin secretion capabilities.  For this reason, as well as β-alanine concentration 
reportedly being the more likely rate limiting component of the carnosine synthesis 
pathway, L-histidine supplementation alone was not considered for further research 
as a therapeutic agent to combat type 2 diabetes. 
Carnosinase-2 was shown to be expressed in INS-1 β-cells, and could potentially 
therefore counteract either carnosine supplementation or enhanced carnosine 
synthesis as a strategy through rapid hydrolysis by this enzyme. However, 
compounds that were derived from in-silico screening for their ability to fit the active 
site of carnosinase-2, whilst not binding with high enough precision to be hydrolysed, 
were screened as potential non-hydrolysable carnosinase inhibitors. Surprisingly, 
they were shown to be ineffective in INS-1 β-cells at reversing the damage caused by 
glucolipotoxicity. This was witnessed through a non-ability to reduce reactive species 
 160 
 
that are significantly upregulated in the presence of GLT, thereby resulting in no 
change to glucolipotoxicity-associated loss of insulin secretion.  
We should not be too hasty to disregard the potential of this strategy however, as 
data from a colleague in the Turner group working with skeletal muscle myotubes 
and the very same compounds, shows them to be effective at reducing 
glucolipotoxicity-associated reactive species in these cells, thereby resulting in 
enhanced glucose uptake. What might be the reason for such differing cellular 
outcomes?  
These compounds were chosen for their ability to fit the active site of carnosinase-2 
and therefore function as carnosinase inhibitors. As such, this strategy is dependent 
upon there being a high enough existing concentration of carnosine within the cell 
to elicit an effect. In skeletal muscle, carnosine concentrations are reportedly as high 
as 5-8mmol/L in wet weight (Derave, et al. 2010), yet in β-cells this concentration is 
unknown and unpublished. Therefore, if the -cell carnosine concentration were 
substantially lower than that of skeletal muscle, this might account for their 
effectiveness in skeletal muscle, but lack of efficacy in -cells. Therefore, it is 
imperative to identify the endogenous carnosine concentration in β-cells. 
Preliminary data presented in this chapter indicates that this in fact the case, with 
intracellular carnosine concentration in INS-1 β-cells in the low M range. This might 
therefore explain why the carnosinase inhibitors were ineffective in β-cells. This data 
is therefore also consistent with islets being reported as one of the least protected 
tissues in terms of intrinsic antioxidant activity. This renders these cells particularly 
susceptible to damage from oxidative stress resulting from prolonged exposure to 
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glucolipotoxicity (Robertson and Harmon 2007). Other therapeutic strategies based 
on carnosine mimetics, rather than carnosinase inhibition, may however prove 
effective at enhancing insulin secretion. 
4.4. Future Directions 
-alanine continues to be a promising amino acid supplement that could offer a 
protective action against glucolipotoxicity driven diabetes. However, similar to 
carnosine, its method of action is still not fully understood. Future work will therefore 
aim to identify both its mechanism of action and the rate of carnosine synthesis in β-
cells. By so doing we should be able to determine whether β-alanine 
supplementation offers real promise as a therapeutic strategy. 
Whilst the drug discovery compounds investigated in this chapter were designed as 
carnosinase inhibitors, it may be more beneficial to select and screen non-
hydrolysable carnosine mimetics. These mimetics would be based more on biological 
function as opposed to structural shape and should elicit the same advantageous 
actions of carnosine but without rapid hydrolysis by carnosinase enzymes (both in 
tissue and sera). This would allow for a much lower dosing concentration, thereby 
decreasing the probability of the compounds having idiopathic toxic effects whilst 
also offering a longer lasting action on reducing reactive stress and increasing insulin 
secretion. This will be the basis for future collaborative work at Nottingham Trent 
University. 
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5.1. Introduction 
The transcriptome is a complete set of transcripts contained within a cell. The 
number of transcripts per gene varies specifically, dependent upon the physiological 
condition or developmental stage of that particular cell. Developing an 
understanding of the transcriptome will allow the interpretation of the whole 
genome, in turn identifying novel functional molecular elements within both cell and 
tissue. This depth of understanding will also make it possible to recognise clear 
changes within the transcriptome in response to disease. Novel key regulators of 
disease onset will be elucidated to allow further characterisation of their functional 
role within certain diseases, with the aim to generate new treatment strategy targets. 
There are various technologies developed to quantify the transcriptome, these 
include but are not limited to hybridisation with custom made microarray 
approaches or sequence-based approaches. The Turner research team recently 
published a transcriptomic study into the effect of glucolipotoxicity upon pro-
inflammatory β-cell gene expression utilising microarray technology (Bagnati, et al. 
2016). This identified that hyperglycaemia and hyperlipidaemia upregulation of 
tumour necrosis factor (TNF)-5 activates the transcription factors NF-κB and signal 
transducer and activator of transcription (STAT-1), and that this in turn ultimately 
triggers the onset of islet cell death. 
Whilst microarray technology has proven useful and successful for the identification 
of novel gene regulators, the development of next generation sequencing (RNAseq), 
offers numerous different advantages over microarray technology. Hybridisation 
techniques depend on pre-existing knowledge of the genome sequence to design the 
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custom microarray and can sometimes have limited detection powers owing to high 
background level readings as a result of cross-hybridisation (Okoniewski and Miller 
2006; Royce, Rozowsky and Gerstein 2007).  
RNAseq technology converts a whole population of purified RNA to cDNA fragments 
before the overhanging ends are blunted and adenylated. Amplification adapters are 
added to one or both ends of the fragments and amplified accordingly. The resulting 
sample is then sequenced in a high-throughput manner obtaining short sequence 
reads from one end of the fragments to the other, typically 30-400 base pairs long. 
The presence, but more importantly the quantity of each RNA can be calculated and 
directly compared between different biological samples. The advantage of RNAseq 
over technologies such as microarray is that RNAseq doesn’t have an upper limit for 
detection. This allows highly sensitive and highly reproducible detection of 
expression ranges of each transcriptome increasing the likelihood of accurate results 
(Wang, Gerstein and Snyder 2009).  
Building from the previous microarray dataset from the Turner research group, the 
aim of this chapter of work was to utilise Illumina-HiSeq gene expression analysis 
data to more accurately examine transcriptome changes in INS-1 β-cells that are 
driven or exacerbated by glucolipotoxicity. Upon the identification of TAARs as a 
family of receptors whose gene expression was particularly altered by 
glucolipotoxicity, the aim was to characterise the mechanistic action of TAAR 
stimulation to investigate these receptors as a potential therapeutic strategy to treat 
type 2 diabetes. 
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5.2. Results 
5.2.1. Identification of Protein Families Differentially Expressed in Glucolipotoxicity 
To characterise and better understand mechanisms in which chronic exposure to 
high glucose and/or high fatty acid concentrations affects cellular function across the 
genome, INS-1 β-cells were incubated in standard RPMI growth media, or media 
supplemented to 28mM glucose and or 200µM oleic acid and 200µM palmitic acid 
for 72h. After 3 days, total RNA was isolated and purified before quality assessment 
using an Agilent Bioanalyser (Santa Clara, CA). High quality samples (RIN score above 
8 – see section 2.5.2.2.) were then sent to the Sarah Lamble laboratory in Oxford for 
sequencing and library preparation using an Illumin HiSeqTM 2000 instrument 
(Illumina, San Diego, USA). The resultant raw RNAseq data was analysed by Dr Rob 
Lowe (Blizard Institute, Barts and The Royal London School of Medicine) who aligned 
the raw data to an annotated reference genome (rn4 extracted from UCSC 
http://genome.ucsc.edu/goldenPath/credits.html#rat_credits) using Top Hat v 2.0.9 
(http://tophat.cbcb.umd.edu.) with reads that aligned to exons, genes and splice 
junctions counted. The data was visualised using the programme HTseq-count 
(http://www-huber.embl.de/users/anders/HTSeq/doc/count.html), the data was 
visualised and interpreted citing gene and transcript expression as read counts. 
DEseq (http://www.bioconductor.org/packages/devel/bioc/html/DESeq.html) was 
then used to normalise the expression data to in-sample distributional changes. 
Genes significantly differentially expressed in a combinative treatment of both high 
sugar and high fatty acids (GLT) relative to control (p<0.05), were analysed by Dr 
Tania Jones, using PANTHER gene ontology software (http://www.pantherdb.org/). 
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This software determined genes that had the greatest differential expression when 
cultured in glucolipotoxic media for 72h and calculates the number of genes that are 
significantly enriched within a specific biochemical pathway. Enrichment was only 
considered significant when there were more differentially expressed genes listed for 
a specific pathway than would be expected randomly, determined by the total 
number of genes associated with that given pathway. 
As shown in Table 5.1, G-protein coupled receptors (GPCRs) were the highest of any 
specific protein class in terms of significance of differentially expressed genes (p=1.67 
X 10E-24). This chapter of work will therefore focus on GPCR families that are 
differentially expressed when exposed to glucolipotoxicity within the RNAseq dataset, 
to determine whether their dysregulation contributes to glucolipotoxic β-cell 
dysfunction.  
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Protein Class P Value 
Receptor 1.88 E-38 
G-protein coupled receptor 1.67 E-24 
RNA binding protein 3.54 E-20 
Ribosomal protein 1.54 E-18 
Signalling molecule 1.28 E-17 
Nucleic acid binding 2.91 E-17 
Transporter 8.91 E-16 
Immunoglobulin 1.13 E-13 
Ion Channel 2.72 E-13 
Cell adhesion molecule 4.58 E-11 
Table 5. 1; Differential expression of protein family classes when exposed to 
glucolipotoxicity.  
Comparative analysis using PANTHER of protein family gene expression when INS-1 
cells were cultured in control or GLT media for 72h compared to control. Data is 
ordered in significance and compiled from 3 independent RNAseq analyses per 
condition. 
5.2.2. Glucolipotoxic Down Regulation of Trace Amine Associated Receptor (TAAR) 
Expression in INS-1 β-cells 
G-protein coupled receptors are essential mediators of communication between 
intracellular and extracellular environments. They are characterised typically by 
having seven membrane spanning α-helical structures, divided by alternating internal 
and external loop regions. Whilst GPCR’s have a multifaceted functionality, the 
classical role is to couple the binding of its agonist, to the activation of an associated 
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heterotrimeric G-protein which modulates downstream effectors (Rosenbaum, 
Rasmussen and Kobilka 2009a).  
One GPCR family of note that were differentially expressed within the Illumina HiSeq 
data set when INS-1 cells were exposed to glucolipotoxicity for 72h was the family of 
trace amine associated receptors (TAAR).  TAARs were first identified in 2001 as 
receptors for trace amines such as p-tyramine, 2-phenyethylamine and others. 
Stimulation of receptors with these ligands resulted in an increase in cAMP 
production, implicating its potential use as a novel pharmacological intervention tool 
(Borowsky, et al. 2001; Bunzow, et al. 2001). 
The Illumina HiSeq data (Figure 5.1) indicated that TAAR3, 4, 5, 6, 7a, 7b, 7c, 7d, 7e, 
7g, 7h, 8b, 8c and 9 were all infinitely downregulated when exposed to GLT for 72h. 
This meant that there were no read counts for these genes in GLT, where there 
previously was in control conditions, and all of which corresponded to a statistically 
significant reduction (p<0.05). TAAR1, 2 and 8a, also had a significant reduction in 
read counts for GLT conditions compared to control, with p values of 0.02, 0.0001 
and 0.001 respectively.  All TAAR family member RNA expression was also 
significantly driven down (p<0.05) in solo treatments of high sugar or high fatty acid 
concentrations, bar TAAR1 in high fat (p=0.12). Importantly for this work, a 
combination treatment had the largest downregulation effect across all TAAR 
members and therefore this combinative treatment was used for all subsequent 
experiments. 
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Figure 5. 1; Illumina HiSeq expression data of TAAR family members.  
INS-1 cells were cultured for 72h  in standard growth media or media supplemented 
to 28mM glucose and or 200µM oleic acid and 200µM palmitic acid. RNA was 
extracted, and quality assessed before Illumina HiSeq sequencing and analysis was 
undertaken. Data is expressed as mean RNA read counts per condition ±SEM, from 3 
independent RNAseq analyses per condition  
 
In order to validate these RNAseq findings, independent qRT-PCR analysis was 
performed on TAAR family members TAAR1, 2, 3, 4, 5, 6, 7b and 9. INS-1 cells were 
cultured in control or GLT media for 72h before RNA isolation, cDNA synthesis was 
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carried out and qRT-PCR analysis performed (Figure 5.2). 72h incubation in GLT 
caused all TAAR family member RNA expression to significantly decrease (p<0.05). 
RNA expression decreased by 34.8 ± 8.7%, 53.0 ± 12.1%, 50.3 ± 12.1%, 30.1 ± 12.0%, 
43.8 ± 6.3%, 51.2 ± 5.5%, 60.8 ± 10.2% and 54.3 ± 8.4% for TAAR1, 2, 3, 4, 5, 6, 7b and 
9 family members respectively. 
Figure 5. 2; qRT-PCR expression data for TAAR family members in GLT.  
INS-1 cells were cultured in control or GLT media for 72h before RNA extraction and 
qRT-PCR analysis performed using primers and cycle conditions detailed in materials 
and methodology section. Data is expressed as fold change in RNA expression ± SEM 
compared to control using comparative delta delta Ct (ΔΔCT) method from 3 
independent experiments. *p<0.05, **p<0.005 v control 
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Whilst the PCR data validated the RNAseq data, RNA expression changes do not 
always correspond to protein expression. It was therefore important to quantify 
protein expression changes of TAAR’s in GLT compared to control. Therefore INS-1 β-
cells were cultured in control or GLT media for 72h prior to protein extraction using 
RIPA buffer. Protein was quantified, normalised and separated by SDS-PAGE. The 
subsequent gel was transferred to nitrocellulose membrane and immunoblotted 
using an anti-TAAR1 antibody (Figure 5.3). An anti-TAAR1 primary antibody was the 
only TAAR family member antibody that was commercially available (Abcam, UK). 
Densitometry analysis of 4 independent experiments demonstrated that a 72h GLT 
incubation decreased TAAR1 protein expression by 42.6 ± 9.1% compared to control 
(p=0.0017).  
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Figure 5. 3; TAAR1 Protein Expression in GLT.  
INS-1 cells were cultured in control or GLT media for 72h prior to protein extraction, 
separation via SDS-PAGE, transferred to nitrocellulose and immunoblotted using 
anti-TAAR1 primary antibody (Abcam, UK). Data was normalised to β-tubulin and is 
expressed as mean fold change ± SEM using densitometry analysis from 4 
independent experiments. **p<0.005 v control. 
5.2.3. TAAR-Associated Adenylyl Cyclase Signalling is Downregulated by 
Glucolipotoxicity 
To more fully understand the role of glucolipotoxic driven TAAR downregulation and 
how this impacts the functional capacity of β-cells, network analysis was performed 
using MetaCore, an integrated knowledge database of pathways from Thomson 
Reuters (https://portal.genego.com). This programme uses pre-existing literature to 
build interactome maps that can be enriched with transcriptomic data indicating 
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directionality and expression changes of genes within that pathway. Utilising the 
RNAseq expression data as an input list, the analyse network algorithm (with default 
settings – reactome version 29, http://www.reactome.org) (Matthews, et al. 2008) 
generated a bespoke network of molecules predicted to interact with TAAR1, the 
most extensively characterised member of the TAAR family. As can be seen in Figure 
5.4, a network of TAAR1 interaction was produced, with genes with a red adjacent 
circle indicating GLT-associated upregulation, and genes with a blue adjacent circle 
indicating GLT -associated down-regulation. This interactome indicates that TAAR1 
(shown as TAR1 within the interactome) is downregulated by 72h glucolipotoxic 
exposure. It also shows that TAAR1 has both a positive and negative downstream 
effector pathway on GPCR signalling through Gα proteins. Specifically, the inhibitory 
pathway through Gαi is upregulated by GLT exposure, whereas the stimulatory 
pathway through Gαs is downregulated. The consequence of these complimentary 
effects is a concerted downstream negative action upon adenylyl cyclase’s. Adenylyl 
cyclase expression was also downregulated within the interactome. Adenylyl 
cyclase’s are the enzyme responsible for cAMP formation from ATP, which once 
released intracellularly acts to regulate a vast array of cellular processes (Steer 1975). 
Of importance to this body of work, cAMP is a molecule known to augment insulin 
secretion in β-cells (Phang, et al. 1984). 
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Figure 5. 4; Glucolipotoxic MetaCore pathway and network analysis of TAAR.  
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The Illumina HiSeq data was utilised to enrich a bespoke TAAR interactome using 
MetaCore network analysis programme (Thomson Reuters - http://genego.com). 
Blue circles indicate a significant glucolipotoxic driven downregulation, whilst the red 
circles indicate a significant upregulation using Bonferroni corrected p value smaller 
than 0.05.  Green arrows indicate the direction of a positive interaction, and ted a 
negative interaction. 
 
To further validate the bespoke network analysis and Illumina HiSeq data used to 
enrich it, protein expression of adenylyl cyclase’s were carried out to confirm their 
downregulation by glucolipotoxicity. INS-1 cells were therefore cultured in control or 
GLT media for 72h prior to protein extraction. Proteins were separated via SDS-PAGE, 
then transferred to nitrocellulose and immunoblotted using anti-ADCY5/6 and anti-
ADCY9 primary antibodies (Abcam, UK). ADCY5/6 protein expression was reduced by 
11.3 ± 1.9% (p=0.0003) when cells were exposed to glucolipotoxicity for 72h. Likewise, 
ADCY9 protein expression was significantly reduced by glucolipotoxic exposure by 
40.0 ± 17.2% (p=0.04) compared to control. 
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Figure 5. 5; Adenylyl cyclase 5/6 and 9 are downregulated by GLT.  
INS-1 cells were cultured in control or GLT media for 72h prior to protein extraction 
and separation via SDS-PAGE before transfer to nitrocellulose membrane. Proteins 
were immunoblotted using anti-ADCY5/6 and anti-ADCY9 primary antibody (Abcam, 
UK). Data is expressed as the mean fold change ± SEM in densitometry from a 
minimum of three experiments between bands of control and GLT conditions and 
normalised to housekeeping protein density immunoblotting using anti-GAPDH or 
anti-β-tubulin antibodies (Abcam, UK). *p<0.05, **p<0.005 v control 
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5.2.4. Effect of TAAR Signalling on INS-1 β-cell Function 
5.2.4.1 Effect of TAAR Stimulation with Amine Ligands on Intracellular cAMP 
The TAAR1 bespoke interactome (Figure 5.4) is consistent with previous literature 
demonstrating adenylyl cyclase activation via Gαs proteins associated with TAAR1 
signalling (Bunzow, et al. 2001). It was therefore investigated to see whether TAAR 
stimulation with known amine ligands could enhance cAMP production via adenylyl 
cyclase in INS-1 β-cells resulting in augmented insulin secretion. INS-1 cells were 
therefore cultured in control growth media until ~70% confluent before being 
washed and incubated in KREBS and 0.5mM 3-Isobutyl-1-methylxanthine (IBMX) or 
KREBS, 0.5mM IBMX ± trace amine ligands isopentylamine (Iso) (TAAR3), p-tyramine 
(Tyr) (TAAR1 and TAAR4), 2-phenylethylamine (Phe) (TAAR1 and TAAR4), agmatine 
(Agm) (putative TAAR6 and TAAR8 ligand), N,N-dimethylcyclohexylamine (Cyclo) 
(TAAR7, TAAR8 and TAAR9 isoforms), and N,N- dimethyloctylamine (Ctyl) (TAAR7 
isoforms) at a final concentration of 10µM, or the TAAR1 inverse agonist EPPTB at a 
concentration of 10nM, for 30min. Cells were then lysed in 0.1M hydrochloric acid 
and cAMP determined via select cAMP ELISA (Cayman Chemical, USA) (figure 5.6).  
The presence of the adenosine (A1) receptor antagonist IBMX in both conditions 
inhibits cAMP hydrolysis via phosphodiesterase (Cherry and Pho 2002). This allows 
the quantification of differences in cAMP accumulation over the 30min incubation 
time with or without the individual amine ligands.  
Isopentylamine significantly increased cAMP accumulation fold change by 3.5 ± 0.6 
(p=0.019). The same was true for p-tyramine, 2-phenylethylamine and agmatine that 
likewise increased cAMP accumulation fold change by 3.7 ± 0.5 (p=0.01), 4.1 ± 0.74 
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(p=0.021) and 2.7 ± 0.27 (p=0.005) respectively. By contrast to this, amine ligands 
N,N-dimethyloctylamine and N,N-dimethylcyclohexylamine resulted in a very 
modest, yet significant decrease in cAMP accumulation decreasing to 0.83 ± 0.05 
(p=0.01) and 0.90 ± 0.01 (p=0.003). The inverse agonist of TAAR1, EPPTB similarly 
resulted in a decrease in cAMP accumulation to 0.78 ± 0.04 (p=0.004).  
Figure 5. 6; Trace amine supplementation increases cAMP accumulation.  
INS-1 cells were cultured in standard RPMI growth media until confluent before being 
washed and incubated in KREBS and 0.5mM IBMX, or KREBS, 0.5mM IBMX and either 
Isopentylamine (Iso), p-tyramine (Tyr), 2-phenylethylamine (Phe), Agmatine (Agm), 
N,N-dimethycyclohexylamine (Cyclo) or N,N-dimethylocytlamine (Ctyl) to a final 
concentration of 10µM or the TAAR1 inverse agonist EPPTB to a final concentration 
of 10nM for 30 minutes.  After 30 minutes cells were lysed in 0.1M hydrochloric acid 
and cAMP accumulation determined via cAMP select ELISA. Data is expressed as the 
mean fold change compared to control ± SEM from 3 independent experiments. 
*p<0.05, **p<0.005 v control 
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5.2.4.2. Effect of TAAR Stimulation with Amine Ligands on Insulin Secretion in vitro 
and vivo 
As stimulation with a number of the trace amines resulted in a significant increase in 
cAMP accumulation over a 30min period, it was sought to determine if this increase 
augmented secretagogue stimulated insulin secretion as cAMP is a known enhancer. 
INS-1 cells were therefore cultured in standard RPMI growth media to 70 % 
confluency, before being incubated in KREBS or secretagogue cocktail (KREBS 
supplemented with 13.5mM glucose, 1µM phorbol 12-myristate 13-acetate, 1mM 
isobutyl methylxanthine, 1mM tolbutamide, 10mM leucine, 10mM glutamine) with 
or without the addition of Isopentylamine (Iso), p-tyramine (Tyr), 2-
phenylethylamine (Phe), Agmatine (Agm), N,N-dimethycyclohexylamine (Cyclo) or 
N,N-dimethylocytlamine (Ctyl) to a final concentration of 10µM or the TAAR1 inverse 
agonist EPPTB to a final concentration of 10nM for 2h. After 2h insulin secretion was 
determined via ELISA (Mercodia, Sweden) and normalised to cellular protein content 
via BCA assay (figure 5.7). In accordance with the cAMP accumulation data, the trace 
amines that increased cAMP also increased stimulated insulin secretion. 
Isopentylamine, p-tyramine and 2-phenylethylamine all significantly increased 
secretagogue stimulated insulin secretion to 1.14 ± 0.03 (p=0.007), 1.23 ± 0.09 
(p=0.046), 1.26 ± 0.07 (p=0.016) fold change respectively, compared to control. 
Agmatine which also increased cAMP showed a modest increase in secretagogue 
stimulation that was just outside statistical significance (p=0.056) increasing by 16.0 
± 6.9% compared to control. Of the amine ligands that increased cAMP, agmatine 
had the lowest effect on cAMP accumulation, and was mirrored by the non-
significant modest effect on insulin secretion. Also in keeping with the cAMP 
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accumulation data, N,N-dimethycyclohexylamine had no significant change upon 
secretagogue stimulated insulin secretion demonstrating a modest decrease by 7.8 
± 5.7% (p=0.12), whereas N,N-dimethylocytlamine and EPPTB decreased stimulated 
insulin secretion by 13.2 ± 5.0% (p=0.029) and 18.2 ± 4.0% (p=0.005) compared to 
stimulated control. This data therefore supports the role of TAAR stimulation with 
cAMP accumulation and resultant cAMP mediated increases in stimulated insulin 
secretion. 
Figure 5. 7; Trace amine supplementation increases Insulin secretion.  
INS-1 cells were cultured in control growth media until 80% confluent. Subsequently 
Insulin secretion was determined by ELISA following incubation ± secretagogue 
cocktail for 2h [(-) blue, (+) red] with or without the addition of Isopentylamine (Iso), 
p-tyramine (Tyr), 2-phenylethylamine (Phe), Agmatine (Agm), N,N-
dimethycyclohexylamine (Cyclo) or N,N-dimethylocytlamine (Ctyl) to a final 
concentration of 10µM or the TAAR1 inverse agonist EPPTB to a final concentration 
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of 10nM for 2h. Data was normalised to cellular protein content and expressed as 
the mean fold change compared to control ± SEM from a minimum of 3 independent 
experiments. *p<0.05, **P<0.005 v control stimulated (+) 
 
Whilst INS-1 cells are an accepted well characterised and stable immortal β-cell line, 
it is imperative, where possible to carry out vivo studies to further validate key 
findings in primary cells. Therefore, in collaboration again with Dr Sophie Sayers and 
Dr Paul Caton of Kings College London, islets from CD1 male mice were isolated and 
cultured in standard growth media. The islets were size matched and pre-incubated 
in a buffer containing 2 mM glucose, 2 mM CaCl2 and 0.5 mg/ml BSA, pH 7.4 for 1h 
at 37°C. Islets were then incubated in this buffer containing 2mM or 20mM glucose 
± p-tyramine or 2-phenylethylamine at ranging concentrations from 0.1-100µM 
(alongside the monoamine oxidase inhibitor paragyline or deprenyl respectively) for 
1h with gentle shaking at 37°C, before insulin secretion was determined via 
radioimmunoassay with an in house 125I-labelleled insulin tracer. In keeping with the 
clonal cell line secretion data, p-tyramine increased glucose stimulated insulin 
secretion by 33.2% ± 20.3% (p=0.199), 83.2% ± 11.8% (p=0.004), 41.2% ± 23.4% 
(p=0.156) and 47.8% ± 26.8% (p=0.067) at concentrations of 0.1, 1, 10 and 100µM 
respectively (figure 5.8a). Incubation with 2-phenylethylamine likewise increased 
insulin secretion at the lower concentration of 0.1 and 1µM by 49.1 ± 23.7% (p=0.08) 
and 14.8 ± 12.2% (p=0.30) respectively (Figure 5.8b). Whilst in this latter case this is 
not a statistically significant change, it follows a similar pattern to p-tyramine and is 
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likely an issue of needing further repeats to combat the nature of inter-experimental 
variability when using primary tissues. 
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Figure 5. 8; Trace amines increase insulin secretion in CD1 mouse islets.  
Islets were isolated from male CD-1 mice and cultured in RPMI-1640 media for 2 days 
prior to analysis. Islets were subsequently incubated in 2mM [(-) blue] or 20mM [(+) 
red] ± stated concentration of (a) p-tyramine with the monoamine oxidase inhibitor 
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paragyline or (b) 2-phenylethylamine with the monoamine oxidase inhibitor deprenyl 
for 1h and insulin secretion determined by radioimmunoassay. Data is presented as 
the mean ± SEM from a minimum of 5 independent experiments. **p<0.005 
compared to control stimulated samples (+) 
5.2.4.3. Potential Ancestral Origin of Adenylyl Cyclase modulation  
From the experiments investigating both cAMP and insulin secretion, it was clear 
there was a split in cellular response to the different trace amines in standard 
conditions. As these ligands are known to stimulate different members of the TAAR 
family, it was sought to determine whether there may be an evolutionary explanation 
for this disagreement in functional capacity between receptors. The resulting 
phylogenetic tree alongside ligand responsiveness (Figure 5.9) demonstrates a clear 
divergence within the TAAR family separating TAAR members 1-4 from 5-9. This 
along with the previously shown data indicate that there is a possible conserved 
ancestral ability for receptors 1-4 to modulate cAMP production via adenylyl cyclase 
regulation and activation as ligands that had a positive effect (p-tyramine, 2-
phenylethylamine and Isopentylamine) all bind with receptors on this branch. 
Whereas the N,N-dimethylalkyamines that had no cellular response fall on the TAAR 
arm of receptors 5-9.  
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Figure 5. 9; Phylogenetic tree of TAAR with trace amine ligand responsiveness. 
 
5.2.4.4. TAAR Stimulation Cannot Reverse Glucolipotoxic Inhibition of Insulin 
Secretion 
Whilst these trace amines were shown to increase cAMP and insulin secretion in 
control conditions, to assess their potential use as suitable drug candidates to treat 
type 2 diabetes, it was important to repeat the insulin secretion experiments when 
β-cells are exposed to glucolipotoxicity to see if they elicit the same response. INS-1 
cells were cultured in control or GLT media for 3 days prior to a 2h incubation in 
KREBS or secretagogue cocktail ± 10µM of the amine ligands that previously had a 
positive effect on insulin secretion; Isopentylamine, p-tyramine, 2-phenylethylamine 
and agmatine (figure 5.10). In the absence of any trace amines, GLT decreased insulin 
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secretion by 73.3 ± 9.6% as expected, and in line with previously reported data here. 
Crucially however, all trace amines that previously had a positive effect on 
augmenting insulin secretion in control conditions no longer had any effect. 
Secretagogue stimulation was still reduced drastically from control and was not 
significantly different to GLT treatment alone (p>0.05). GLT with the addition of 
Isopentylamine, p-tyramine, 2-phenylethylamine and agmatine still saw reduction in 
secretion to 33.6 ± 13.9%, 25.5 ± 10.6%, 32.1 ± 13.3% and 28.2 ± 11.5% respectively 
compared to control. The ability for the trace amines to affect insulin secretion which 
was lost when INS-1 cells were exposed to glucolipotoxic conditions most likely stems 
from the glucolipotoxic driven diminished receptor expression also previously 
reported within this chapter.  
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Figure 5. 10; Trace amine have no effect on reversing glucolipotoxic diminished 
insulin secretion.  
INS-1 cells were cultured in control or GLT media for 72h prior to incubation ± 
secretagogue cocktail for 2h [(-) blue, (+) red] with or without the addition of 
Isopentylamine (Iso), p-tyramine (Tyr), 2-phenylethylamine (Phe), Agmatine (Agm), 
to a final concentration of 10µM. Insulin secretion was determined via ELISA and 
normalised to cellular content and expressed as the mean fold change compared to 
control ± SEM from a minimum of 3 independent experiments. 
5.2.5. Olfactory Receptor Signalling Contributes to Glucolipotoxicity  
All family members of the TAAR family, except TAAR1, have previously been shown 
to also function as olfactory receptors (Liberles and Buck 2006; Horowitz, et al. 2014; 
Maguire, et al. 2009). Unlike TAAR1 that signals via Gαs to activate adenylyl cyclase 
and therefore increase intracellular cAMP concentration (Bunzow, et al. 2001), in the 
0
0.2
0.4
0.6
0.8
1
1.2
- + - + - + - + - + - +
Control GLT GLT + Iso GLT + Tyr GLT + Phe GLT +
Agm
In
su
lin
 S
ec
re
ti
o
n
 F
o
ld
 C
h
an
ge
 R
el
at
iv
e 
to
 C
o
n
tr
o
l (
+)
 188 
 
olfactory epithelium all other TAAR members are thought to couple to Golf. Howver, 
Golf is also associated with adenylyl cyclase activation that in turn increase cAMP 
(Liberles and Buck 2006; Ferrero, et al. 2012a; J. Zhang, et al. 2013). It was therefore 
important to identify whether other olfactory receptors that have the potential to 
augment insulin secretion via cAMP production are also sensitive to glucolipotoxicity. 
Utilising the Illumina HiSeq data, all olfactory receptor RNA read counts were 
measured in control and 72h glucolipotoxic exposure. Of the 1199 olfactory 
receptors identified in the RNAseq data, 734 receptors were significantly 
downregulated by GLT (p<0.05). From those receptors 619 had a higher read count 
than the threshold for control conditions. These receptors, like TAARs, are on the 
very cusp of detection, nonetheless, read count threshold was set at 10. Figure 5.11 
demonstrated the quantity of receptors significantly downregulated by GLT and 
above the threshold, ordered by the read counts for control, highest to lowest.  
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Figure 5. 11; Glucolipotoxicity downregulates olfactory receptor RNA expression.  
INS-1 cells were cultured for 72h in standard growth media or GLT media. RNA was 
extracted, and quality assessed before Illumina HiSeq sequencing and analysis was 
undertaken. 734 Olfactory receptors (with read counts above ten) presented were 
all significantly downregulated in GLT conditions (p<0.05) and ordered from most 
read counts in control conditions to least. Data is expressed as mean RNA read counts 
per condition ±SEM, from 3 independent RNAseq analyses per condition  
 
The top 20 of these receptors ordered by significance in expression change between 
control and GLT are shown in Figure 5.12 and had p values smaller than 0.001 in all 
instances. All of the top 20 olfactory receptors RNA expression when ordered by 
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significance were infinitely downregulated when INS-1 cells were cultured in GLT for 
72h, except for Olr693 and Olr1735.  
As olfactory receptors expressed in β-cells have the ability to modulate cAMP 
production via adenylyl cyclase G-protein coupled receptor signalling, and therefore 
the potential ability to augment insulin secretion, this data therefore indicates that 
olfactory receptor signalling could also contribute to glucolipotoxic inhibitory effect 
on insulin secretion in INS-1 β-cells.  
Figure 5. 12; Top 20 olfactory receptor RNA expression by statistical significance.  
INS-1 cells were cultured for 72h in standard growth media or GLT media. RNA was 
extracted, and quality assessed before Illumina HiSeq sequencing and analysis was 
undertaken. The top 20 olfactory receptors were ordered by statistically significant 
change between control and GLT conditions are presented. Data is expressed as 
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mean RNA read counts per condition ±SEM, from 3 independent RNAseq analyses 
per condition.  
5.3. Discussion 
Utilising Illumina HiSeq RNA sequencing analysis technology, RNA that was isolated 
from INS-1 β-cells in both control conditions, and diabetic glucolipotoxic conditions 
was sequenced and counted, allowing the identification of genes dysregulated 
following chronic exposure to high concentrations of free fatty acids and glucose. Of 
the genes dysregulated by chronic glucolipotoxic exposure, receptors in general had 
the highest statistical change compared to control conditions. In conjunction with 
previous findings from the Turner group utilising microarray technology (Bagnati et 
al, 2016) this is indicative that glucolipotoxicity, in INS-1 β-cells at least, primarily 
affects molecules involved in cell signalling pathways, protein trafficking, and 
transcription factor binding regulation. The current RNAseq data however did 
identify GPCR signalling as the highest statistically significant differentially expressed, 
specific protein class.  
GPCRs comprise the largest family of proteins within the mammalian genome 
(Venter, et al. 2001; International Human Genome Sequencing Consortium 2001). 
They have two specific requirements; that their structure spans the membrane with 
seven α-helices (roughly 25-35 residues long each) to form the agonist recognition 
site, and that the receptor interacts with a G-protein enabling activation to transduce 
a signal through a downstream pathway. GPCRs have enormous variability in both 
ligand stimulation (ligands vary from ions, peptides, protein lipids, odorants and 
many more) and the signalling pathways the function within (ranging from vision to 
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olfaction and taste). GPCRs in vertebrates are commonly classified into five 
subfamilies depending on sequence, structure and activation. The largest and most 
diverse of these is the rhodopsin family that contains a further 13 sub-classes, with 
the other families being secretin, glutamate, adhesion and frizzles/taste2 
(Fredriksson, et al. 2003). The typical role of GPCRs is to activate specific 
heterotrimeric G-protein protein signalling upon agonist binding to the recognition 
site, leading to downstream modulation (either activation or inactivation) of effector 
proteins (Rosenbaum, et al. 2009a). This can be annulled directly by inverse agonist 
binding or other intracellular processes such as receptor phosphorylation or 
desensitisation by GPCR activated β-arrestin translocation and resultant promotion 
of GPCR internalisation (Ma and Pei 2007).  
One such family of the rhodopsin class of GPCRs, are trace amine associated 
receptors (TAAR), all of which were significantly down regulated when cells were 
exposed to glucolipotoxicity for 72h, many of them infinitely. Whilst solo treatments 
of either high sugar or high fat, also had significant effects in reducing TAAR members 
gene expression, a combined treatment of both high sugar and fat had the largest 
effect across all TAAR family members. This therefore identified TAARs as potential 
prime contenders to play a role in glucolipotoxicity driven β-cell dysfunction, and 
particularly diminished insulin secretory capability, which is a main hallmark of type 
2 diabetes. 
TAARs were first identified in 2001 (Borowsky, et al. 2001; Bunzow, et al. 2001), as 
receptors for trace amine compounds tryptamine, 2-phenylethylamine and p-
tyramine. However, the term trace amine was fashioned much earlier in the year 
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1974 as a way to distinguish between endogenous monoamine compounds that had 
low tissue concentrations (as low as ~100nM) from the more abundant (100-fold 
higher)  structurally similar neurotransmitters (Berry 2004; Boulton 1974). The novel 
GPCR identified in the cDNA of a rat pancreatic tumour cell clonal line in 2001 
(Bunzow, et al. 2001) was termed trace amine associated receptor 1 (TAAR1). This 
receptor has low expression levels in many tissue types, however its expression is 
uniquely abundant in β-cells (Regard, et al. 2007; Raab, et al. 2016). This was 
somewhat overlooked when TAAR1 was first identified yet has now alerted many to 
its potential role in glucose homeostasis.  
In humans, the TAAR genes are located on chromosome 6q23.2 (Borowsky, et al. 
2001; Bunzow, et al. 2001) of which there are six functional genes (TAAR1, 2, 5, 6, 8 
and 9) and three pseudogenes (TAAR3, 4 and 7). Mice have fifteen TAAR genes and 
one pseudogenes, whilst rats have seventeen TAAR genes and two pseudogenes 
(Lindemann, et al. 2005; Lindemann and Hoener 2005). Work carried out in 2006 
demonstrated that essentially all TAAR family members, bar TAAR1, were localised 
to the olfactory epithelium and functioned as olfactory receptors with minute 
(usually undetectable) protein expression in other tissues, and is therefore why as a 
result, there is limited literature on other TAAR family members to that of TAAR1 
(Liberles and Buck 2006; Maguire, et al. 2009; Horowitz, et al. 2014). 
Similarly, to the well characterised type 2 β-adrenergic receptor, TAAR1 couples to 
the stimulatory and inhibitory G α-proteins; Gαs and Gαi. These proteins differentially 
regulate adenylyl cyclase’s which in turn converts ATP to cAMP (Rosenbaum, et al. 
2009a; Sotnikova, Caron and Gainetdinov 2009). It has therefore been shown that 
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TAAR1 stimulation with known ligands increases intracellular cAMP (Wainscott, et al. 
2007; Barak, et al. 2008). Unlike TAAR1, all other TAAR family members in the 
olfactory epithelium have been shown to signal via Golf proteins, however, likewise 
these proteins also associate with adenylyl cyclases and can therefore also regulate 
cAMP production (Ferrero, et al. 2012a; Zhang, et al. 2013). As cAMP is a known 
enhancer of stimulated insulin secretion through both PKA dependent and 
independent mechanisms (Seino and Shibasaki 2005; Malaisse and Malaisse-Lagae 
1984), GPCR regulation of adenylyl cyclases have huge potential as a therapeutic 
strategy for type 2 diabetes where β-cells have started to fail and insulin secretion is 
diminished. Moreover, MIN-6 β-cell administration with the TAAR1 ligand 3-
iodothyronamine markedly enhanced insulin secretion (Regard, et al. 2007). TAAR 1 
activation with a selective agonist (RO5166017), increased glucose stimulated insulin 
secretion in both clonal β-cells (INS-1E) and human islets as well as elevating mice 
plasma PYY and GLP-1 levels. The same selective agonist also improved glucose 
tolerance in diabetic db/db mice and reduced body weight and food consumption in 
diet-induced obese mice (Raab, et al. 2016). These studies therefore suggested that 
TAAR1 has potential as a therapeutic target to treat type 2 diabetes, however, other 
members of the TAAR family have scarcely been studied for their potential use. 
Archetypal trace amines such as p-tyramine and 2-phenylethylamine are synthesised 
endogenously as the by-product of monoamine neurotransmitter production after 
decarboxylation of precursor amino acids via L-amino acid decarboxylase 
(Gainetdinov, Hoener and Berry 2018). Synthesis is not limited as previously thought 
to neuronal cells, and L-amino acid carboxylase has been reported in many tissue 
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types, including importantly, the pancreas  (Lindstrom and Shelin 1983; Rorsman, et 
al. 1995). These class of amines are promiscuous in their receptor affinity with the 
majority of the whole family of TAARs having a known amine ligand. 
In order to investigate the potential of these receptors as novel drug development 
targets, amines that bind to the wider range of TAAR family members were studied 
for their affect upon cAMP production, and importantly, insulin secretion in INS-1 β-
cells and primary ex-vivo mouse islets. Pharmacological studies in both mice and 
humans demonstrate that that p-tyramine and 2-phenylethylamine activate both 
TAAR1 and TAAR4 (Borowsky, et al. 2001; Berry, et al. 2017; Pei, Asif-Malik and 
Canales 2016). Isopentylamine is described as a ligand for TAAR3 (Liberles and Buck 
2006), whilst agmatine is only reported as an agonist for TAAR13c which is only 
reported to be expressed in zebrafish (Li, et al. 2015). All of these compounds 
increased cAMP and this was reflected by an increase in insulin secretion from INS-1 
β-cells. This was further validated, as the modest non-significant increase in insulin 
secretion exhibited from agmatine administration, was mirrored by also having the 
smallest effect on cAMP accumulation. 
The commercially available antagonist EPPTB (previously called RO5212773) is 
selective against TAAR1 and showed a negative, albeit very minor effect on cAMP 
accumulation and insulin secretion. Due to the lack of other antagonists, 
characterising EPPTB is difficult. It is still unclear whether EPPTB is an antagonist or 
more likely an inverse agonist to TAAR1 (Bradaia, et al. 2009; Stalder, Hoener and 
Norcross 2011). N,N-dimethylcyclohexylamine activates TAAR7, including the mouse 
and rat paralogs of TAAR7b, 7f, 7b and 7d (Ferrero, et al. 2012a) and TAAR16e in 
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zebrafish (Li, et al. 2015). N,N-dimethylocytlamine was reported to similarly activate 
TAAR7 including the paralogs TAAR7e, 7f and 7h (Ferrero, et al. 2012a). Both of these 
N,N-dimethylalkyamines had no, or adverse effects on cAMP accumulation and 
therefore had no effect on stimulated insulin secretion. 
As shown from the phylogenetic tree of TAAR evolution (figure 5.9), TAAR1-4 form 
one of the two major clades and appear to be tuned to primary amines such as p-
tyramine and 2-pheylethylamine. The TAARs 5-9 that fall on the other main arm of 
the tree are more tuned to tertiary amines. This would therefore suggest that there 
is a genetic ancestry of functional ability within this family via primary amine binding 
to regulate cAMP production from ATP by adenylyl cyclase activation (Ferrero, et al. 
2012a). As presented here, only amines that are known ligands to receptors one to 
four had a positive effect on both cAMP and insulin secretion, whilst the tertiary 
amines, N,N-dimethylalkyamines, that bind to TAAR7 had no positive effect 
whatsoever.  
Within this body of work, agmatine is the only exception to the rule of increasing 
cAMP and insulin secretion whilst not hitting the receptors on the primary branch of 
the tree. As mentioned previously, agmatine is only thought to bind to TAAR13c 
which is reported to currently be expressed solely in zebrafish (Li, et al. 2015). 
TAAR13c does however share a conserved binding site with TAAR6 and TAAR8, which 
were shown to fall on the branch of the tree that had no effect on insulin secretion. 
However, TAAR13c itself despite this, does fall on the same branch of the 
phylogenetic tree as receptors 1-4 (Hussain, et al. 2013). Whilst agmatine is known 
to have no effect on TAAR1 signalling (Hu, et al. 2009), it is  conceivable that agmatine 
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could bind to one of the other receptors on the conserved mammalian branch of the 
phylogenetic tree capable of adenylyl cyclase activation and is just yet to be fully 
characterised. 
The work reported here is consistent with TAAR signalling reported in the literature, 
however it is not without its complications as a novel therapeutic strategy. Adenylyl 
cyclases (ADCY) have 10 different isoforms, of which 9 are regulated by GPCRs 
coupled to Gαs or Gαi (Tengholm and Gylfe 2017). Consistent with previous literature 
that suggests that a 48-72h β-cell exposure to glucotoxic hyperglycaemia can alter 
ADCY8 expression in both rat and human islets (Roger, et al. 2011), and 48h exposure 
to 0.5mM palmitate can reduce ADCY9 and ADCY5 in human and mice isolated islets 
respectively (Tian, et al. 2015) resulting in a reduction in cAMP accumulation and 
glucose stimulated insulin secretion, data here presents that both ADCY5/6 and 
ADCY9 were significantly downregulated in INS-1 β-cells exposed to glucolipotoxicity 
for 72h. This reduced adenylyl cyclase protein expression combined with reduced 
expression of TAARs mentioned previously would culminate in a reduction in the 
positive Gαs pathway signalling and an increase in Gαi signalling as shown in the 
MetaCore network analysis map. This would therefore result in reduced cAMP 
production and loss of cAMP augmented insulin secretion within the condition. This 
is in agreement with our data, whereby the positive effect of our ligands on 
stimulated insulin secretion was lost when INS-1 cells were cultured in 
glucolipotoxicity for 72h in response to decreased expression. Whilst this may 
therefore appear as the potential protective action of TAARs are lost when exposed 
to glucolipotoxicity, and therefore impractical for diabetic patients in a state of 
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hyperglycaemia and hyperlipidaemia, it is important to note that a positive feedback 
loop of TAAR agonist induced increase in TAAR expression has been reported in other 
cell types. A 6h exposure to the placental cell culture line BeWo with 0.1-0.01nM of 
the endogenous trace amines 3-iodothyromine and triiodothyronine increased 
TAAR1 expression. The selective agonist RO5203548 at the higher concentration of 
0.1nM also has a significant effect on increasing TAAR1 expression via Western blot 
analysis (Stavrou, et al. 2018). Likewise, in T-cells, incubation with the 100 µM of the 
non-selective agonist methamphetamine for 6h drastically increased TAAR1 mRNA 
~200-fold compared to the untreated control human peripheral blood mononuclear 
cells. This work also demonstrated that a longer-term treatment (24h) of either 
100µM 2-phenylethylamine, 100µM p-tyramine or 100µM methamphetamine all 
significantly increased TAAR1 protein expression in human T-cells measured via 
fluorescence (Sriram, et al. 2016). If a similar response can occur in β-cells with a 
longer timed exposure to endogenous trace amines than the 2h shown here, TAAR 
agonists administration may represent a viable treatment to overcome glucolipotoxic 
driven diminished TAAR expression, and then have a positive effect on augmenting 
insulin secretion. This is an incredibly exciting and promising area for future 
systematic research and characterisation.  
There are already numerous treatment strategies to treat the failure of insulin 
secretion in overt diabetes. Sulphonylurea compounds were first introduced as a 
prescribed medication in the 1950s with the sole purpose of augmenting insulin 
secretion, and these remain key pharmacotherapy compounds 70 years on for the 
regulation of glucose homeostasis within the condition. However, recent safety 
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concerns about sulphonylurea side effects have arisen in recent years resulting in 
patient weight gain and hypoglycaemia, all of which are detrimental to the longevity 
of treatment (Sola, et al. 2015). Additionally, like most pharmacotherapy 
intervention tools, they become less effective over time and therefore it is imperative 
to constantly discover novel targets that action via different mechanisms to increase 
stimulated insulin secretion, not exhausted by pre-existing treatments. Unlike 
sulphonylureas, administration of TAAR agonists offer significant additional benefits 
in comparison to previous treatments as they not only promote weight loss but have 
also shown to reduce binge eating phenotypes (Raab, et al. 2016; Revel, et al. 2013; 
Ferragud, et al. 2017). TAARs also function through a completely separate 
mechanism. Sulphonylureas increase the exocytosis of insulin-containing secretory 
granules by the binding and closing of β-cell KATP channels. This channel closure 
causes the cell membrane to depolarise resulting in Lc-type Ca2+ channels opening 
and calcium influx and insulin secretion (Proks, et al. 2002). TAARs however, effect 
insulin secretion via the same mechanism as the increasingly popular 
pharmacotherapy treatment; incretin mimetics.  
Incretin mimetics stimulate cell membrane incretin receptors (glucagon-like peptide-
1 receptor), which are GPCRs linked to adenylyl cyclases. This, similar to the data 
reported here, increases cAMP, reflected by an increase in stimulated insulin 
secretion (Drucker 2006; Holst 2007). DPP4 inhibitors or gliptins as they are 
sometimes referred as, similarly increase stimulatory GPCR signalling, amplifying 
cAMP and therefore insulin secretion. However, they do this by inhibiting enzymatic 
hydrolysis of endogenous incretins, increasing their intracellular concentrations 
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causing a more pronounced stimulatory effect (McIntosh, et al. 2005). Incretin 
mimetics are also not without their problems however. Not only does 
hyperglycaemia significantly reduce incretin receptor expression, they also need to 
be administered by injection which can often be unpopular with patients (Xu, et al. 
2007). The fact that incretin receptors are downregulated by hyperglycaemia and still 
has a marked effect on amplifying insulin secretion when treated with incretin 
mimetics or DPP4 inhibitors, offers more validity to TAAR as a potential strategy as 
their expression is also downregulated by glucolipotoxicity but may therefore still 
exhibit positive functionality with what receptors are expressed. 
As current therapies utilise adenylyl cyclase activation to increase insulin secretion, 
olfactory receptors may too provide a fresh therapeutic strategy to treat diabetes 
induced failed insulin secretion, as they too have the ability to couple G-proteins 
associated to adenylyl cyclases. Recently olfactory receptors shown to be expressed 
in MIN6 β-cells promoted glucose stimulated insulin secretion when stimulated with 
odorants, suggesting a chemo-sensory function in β-cells to regulate glucose 
homeostasis that could be targeted for therapeutic intervention. This work did 
however suggest a mechanism independent of Golf-cAMP-PKA, but this work only 
investigated two receptors out of hundreds of possible candidates (Munakata, et al. 
2018). Therefore, further research is required to truly understand olfactory receptors 
and their mechanism(s) of action. Olfactory and TAAR ligands can also be 
administered orally, instead of via subcutaneous injection, thereby offering another 
benefit over some other treatment options. 
 201 
 
In conclusion, whilst exposure to glucolipotoxicity decreases expression of TAARs, 
adenylyl cyclases, and olfactory receptors alike, stimulation of TAAR 1-4 in control 
conditions lead to a significant increase in cAMP accumulation and enhancement of 
insulin secretion. This ability was lost by a 72h GLT incubation, insinuating TAARs 
likely contribute to the pathophysiology of type 2 diabetes. Regardless of this, 
current, and more importantly, new treatment therapies that regulate cAMP 
production via adenylyl cyclase activation through stimulation of heterotrimeric G-
protein coupled receptors have the potential to be effective treatments to offset the 
insulin secretion deficiency of the type 2 diabetic pathophysiology.  
5.4. Future Work 
As mentioned previously, future work will investigate if a more chronic exposure 
(longer than 2h) to endogenous trace amines that had a positive effect in the body 
of work presented here (p-tyramine, 2-phenylethylamine, isopentylamine and 
agmatine) can have a positive feedback loop on TAAR expression in β-cells that is 
diminished in response to glucolipotoxicity. If TAAR expression can be reversed by 
longer periods of amine administration, the positive effect presented here on both 
cAMP production and therefore insulin secretion in control conditions could be 
retained even in the face of toxic high sugar and high fat conditions. If this is the case, 
in-vivo studies with long term oral administration of trace amines on high fed 
spontaneously diabetic mice may be carried out to investigate TAAR expression 
changes and effect on glucose homeostasis in a full animal model of diabetes could 
be observed. If a positive effect is seen on both TAAR expression, glucose tolerance, 
food consumption, fasting plasma glucose and glycated haemoglobin levels, this then 
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makes TAAR a worthy and viable candidate for a treatment strategy in type 2 diabetic 
human patient trials.  
In parallel to this future work will also aim to validate the illumina HiSeq olfactory 
receptors expression findings via qRT-PCR and Western blotting, as well as 
researching the mechanism(s) of olfactory signalling. If, as thought, olfactory 
receptors also couple to Golf signalling pathways with the ability to augment cAMP 
production via adenylyl cyclases, then this may too represent another potential 
treatment strategy to augment insulin secretion in response to glucolipotoxicity. 
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6. General Discussion 
and Conclusions 
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6.1. General Discussion 
Diabetes mellitus is a polygenic metabolic disorder that is characterised by the 
synergistic failing of insulin secretion from pancreatic β-cells and decreased insulin 
sensitivity at target tissues such as skeletal muscle, thereby resulting in a state of 
hyperglycaemia. Type 2 diabetes is the most common classification accounting for 
~90% of all incidences and is typically developed over many years in response to 
numerous contributing risk factors ranging from genetics, to smoking, to the main 
risk contributor; obesity and high sugar and fat diets (Wu, et al. 2014). Global 
diabetes prevalence is on the rise and is currently thought to affect over 425 million 
people worldwide, costing 1.8% of the world’s total GDP (Bommer, et al. 2017). 
Insulin resistance in response to chronic exposure to toxic concentrations of sugar 
and fat is normally the first sign on type 2 diabetes onset (Petersen, et al. 2007), 
followed by β-cell adaptation resulting in increased insulin production and secretion 
to compensate and maintain healthy blood sugar levels. However, prolonged 
exposure to high glucose and fat concentrations results in amplified oxidative and ER 
stress, and increased circulating toxic FFA’s culminating in β-cell failure, death and 
resultant loss of glycaemic control. Downstream complications of this can be fatal 
ranging from nephropathy and retinopathy to cardiovascular disease 
(Papatheodorou, et al. 2016). Numerous anti-diabetic medications exist and are 
prescribed to tailor the individual patient’s condition. However, like most, these 
treatments lose effectiveness over time, and it is therefore incredibly important to 
continually identify and develop new targets and strategies separate to mechanisms 
of those already defined to combat the condition. 
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The aim of this thesis was to identify novel targets and treatments for type 2 diabetes, 
investigating changes in stimulated insulin secretion using a model of 
glucolipotoxicity in INS-1 β-cells. Clonal INS-1 β-cells were cultured in RPMI-1640 
standard growth media supplemented to 28mM glucose and 200µM oleic and 
200µM palmitic acid for 3 or 5 days to mimic a glucolipotoxic state. Both palmitic acid 
and oleic acid were used to more wholly represent the human diet, with palmitic 
being the most abundant saturated FA and oleic monounsaturated FA, allowing a 
truer representation of β-cell pathophysiology in response to type 2 diabetes onset 
(Ricchi, et al. 2009). Previous published and unpublished research from the Turner 
research group has demonstrated that this model of glucolipotoxicity dosed for 3 or 
5 days in INS-1 cells was sufficient to inhibit stimulated insulin secretion (a hallmark 
of type 2 diabetes) whilst not effecting cell viability (Marshall, et al. 2007), therefore 
confirming it as a valid model to assess glucolipotoxic mechanisms in INS-1 β-cells 
with the aim to identify new treatments that can inhibit or reverse the damaging 
consequences. 
Data shown in Chapter 3 demonstrated the damaging effect of glucolipotoxicity, and 
carnosine’s potential as a treatment for type 2 diabetes. Consistent with the 
literature, 5 day glucolipotoxic exposure was shown to increase reactive oxygen, 
nitrogen, and carbonyl species, which in turn increased 4-HNE and 3-NT protein 
adduct formation. The reactive carbonyls can form adducts on key cellular proteins 
which can result in cellular function perturbation (Ellis 2007). Glutathione is one of 
the most suited enzymes to detoxify one such reactive carbonyl; HNE (Tiedge, et al. 
1997). However, β-cells have much lower glutathione expression levels compared to 
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other tissues making them much more susceptible to oxidative stress related damage 
by reactive carbonyls (Robertson and Harmon 2007). Therefore 5 day exposure to 
glucolipotoxicity and ensuing oxidative stress coupled with β-cells low anti-oxidant 
defence system culminated in significantly diminished stimulated insulin secretion. 
Some recovery of cellular function is observed when cells were removed from the 
toxic environment, however it is likely the low capacity of the anti-oxidant defence 
system limits this to only the partial recovery exhibited. Therefore, to offset the 
damaging effects of glucolipotoxicity-driven reactive species other protective 
compounds are required.  
Carnosine is an endogenous dipeptide of β-alanine and L-histidine ingested primarily 
from red meat, but this is also available as a dietary supplement. Carnosine has 
already been shown to increase fasting insulin and lower insulin resistance, thereby 
increasing glucose tolerance (de Courten, et al. 2016). It has also been demonstrated 
to lower fasting glucose in obese individuals when ingested as a component of a 
dietary supplement alongside cinnamon and chromium (Liu, et al. 2015). It was more 
recently shown to be an effective scavenger of reactive carbonyls in a rodent model 
of retinopathy (Albrecht, et al. 2017), although there was no direct investigation of 
carnosine function on β-cells in the literature. Data presented here shows that 
carnosine is an effective scavenger of reactive species, as a 1h acute treatment was 
able to significantly reduce reactive species detection. A longer exposure of 
carnosine over 5 days was also able to reverse glucolipotoxic driven increases in iNOS 
expression, as well as reversing glucolipotoxic 3-NT and 4-HNE protein adduction. 
This reactive metabolite inhibition resulted in significant increases in insulin secretion 
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both in vitro and in vivo.  Importantly a 2 day carnosine treatment after 3 days of 
glucolipotoxic exposure was shown to reverse the damage on the insulin secretory 
pathway, suggesting carnosine can act through two different methods of action: 1) 
scavenge reactive species directly before they can have downstream toxic effects and 
2) sacrificially react with downstream carbonyls forming non-reversible less reactive 
adducts (Song, et al. 2014). Carnosine also exhibited a similar function in C2C12 
skeletal muscle where a 1h and 5 day treatment period decreased reactive species 
and increased insulin sensitivity respectively. Carnosine can act via a multitude of 
functionalities in numerous tissue types and therefore represents a promising agent 
to combat type 2 diabetes alongside pre-existing treatments that aim to augment 
insulin secretion in β-cells and increase insulin sensitivity and resultant glucose 
uptake in skeletal muscle.  
This work was also able to demonstrate that INS-1 β-cells express the enzyme 
responsible for carnosine synthesis, thereby making β-alanine supplementation and 
increased endogenous carnosine synthesis a potentially viable treatment option. β-
alanine is already extensively researched for its positive role in enhanced skeletal 
muscle cellular performance in response to physical activity (Hill, et al. 2007) and 
work here reports that β-alanine supplementation can elicit a protective action 
against glucolipotoxic driven stress. However this function is not directly instigated 
by β-alanine, as a 1h dose had no effect on reactive species, yet a 5 day exposure 
period significantly reduced their detection. This would suggest β-alanine’s 
‘scavenging’ action is a result of its utilisation to form carnosine, which can then elicit 
a protective outcome. HPLC experimentation in collaboration with Dr James (NTU) 
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alone was unable to confirm this theory as carnosine concentrations remained 
consistent in control and with β-alanine supplementation, which may have been a 
result of immediate carnosine synthesis and consumption via reactive species 
sequestering. Further research is therefore required to support this hypothesis. 
Nevertheless, a 5 day β-alanine supplementation resulted in significant increases in 
stimulated insulin secretion and a significant reversal of glucolipotoxicity-mediated 
inhibition of insulin secretion, and may therefore represent a valid agent to combat 
the onset of type 2 diabetes.  
Carnosinase-2; the enzyme responsible for carnosine hydrolysis within tissues was 
also shown to be expressed in INS-1 β-cells. To combat rapid carnosine hydrolysis by 
this enzyme, in collaboration with Dr Garner and team in the Department of 
Chemistry, NTU, carnosine-like compounds were identified in the MayBridge 
compound library using in silico analysis, initially based on structural shape and 
chemistry (ROCS), before threshold analysis for percentage fit into the active site of 
carnosine hydrolysis on the enzyme carnosinase-2 in GOLD. Compounds that had a 
similar structure and chemical makeup as carnosine, with a high enough percentage 
fit to bind with the carnosinase-2 active site, yet low enough to avoid hydrolysis 
thereby acting as inhibitors, were purchased. Disappointingly, of the 9 compounds 
that were purchased, 5 were toxic to INS-1 cells, whilst the other 4 exhibited no 
abilities to reduce reactive species in -cells or influence insulin secretion. In contrast, 
these same compounds exhibit a pronounced effect in skeletal muscle in terms of 
reducing glucolipotoxic driven reactive species and increasing insulin sensitivity. This 
is not so surprising when one considers the endogenous concentrations of carnosine 
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in the different tissue types. These compounds were selected to act as carnosine-2 
inhibitors thereby allowing endogenous carnosine to have a larger effect that normal 
in reducing glucolipotoxic stress. As endogenous carnosine is as high as 5-8mmol/L 
in skeletal muscle (Derave, et al. 2010), yet as low as preliminary data in this chapter 
would suggest (within the µM range) then these compounds potentially still offer 
protective actions in a full physiological context. 
As the aim of the thesis was to identify novel targets for the treatment of type 2 
diabetes, a transcriptomic approach was also used to identify genes and proteins that 
contribute to glucolipotoxic inhibition of insulin secretion. Building from previous 
microarray datasets obtained in the Turner research group, Illumina-HiSeq gene 
expression analysis was utilised to characterise changes in the INS-1 β-cells 
transcriptome exposed to glucolipotoxicity.  RNA isolated from INS-1 cells cultured in 
glucolipotoxic media for 3 days identified G-protein coupled receptors (GPCR) as the 
specific protein class with the highest statistically significant gene perturbation 
compared to control. One such family of GPCRs with particularly high gene 
expression alterations were trace amine associated receptors (TAARs), of which all 
15 that are expressed in the rat transcriptome were downregulated by 
glucolipotoxicity. TAAR gene and protein downregulation was confirmed via qRT-PCR 
and Western blot, establishing the whole family as prime contenders to contribute 
to glucolipotoxic damaging downstream consequences.  
TAAR1 couples to the stimulatory and inhibitory G α-proteins; Gαs and Gαi which 
regulate adenylyl cyclases, the protein responsible for ATP conversion to cAMP 
(Rosenbaum, Rasmussen and Kobilka 2009b; Sotnikova, et al. 2009). As cAMP is 
 210 
 
known to potentiate secretagogue-stimulated insulin secretion through both PKA 
dependent and independent mechanisms (Seino and Shibasaki 2005; Malaisse and 
Malaisse-Lagae 1984), modulation of GPCR-mediated cAMP pathways is an active 
area of emerging type 2 diabetic therapeutic investigation.  Work in chapter 5 
demonstrated that stimulation of TAARs with endogenous primary amine ligands 
increase cAMP accumulation, thereby resulting in enhanced stimulated insulin 
secretion in both cell culture and primary ex vivo mouse islets. Interestingly, 
stimulation with tertiary amines had no effect, which may suggest a conserved 
genetic ancestry for TAAR regulation of adenylyl cyclase, as primary amines stimulate 
receptors 1-4, whilst tertiary amines stimulate receptors 5-9 (figure 5.9) (Ferrero, et 
al. 2012b). Further data presented in this chapter however, also indicated that 
reduced TAAR and adenylyl cyclase protein expression in response to 
glucolipotoxicity expectantly diminishes their ability to influence glucose metabolism 
by losing the ability to enhance insulin secretion. TAARs should not be discredited 
though, as recent literature suggests that longer term exposure of TAARs to their 
ligands reverses loss of protein expression in human T-cells (Sriram, et al. 2016), 
which if true for pancreatic β-cells may represent a viable treatment option to 
overcome glucolipotoxic driven diminished protein expression and resultantly enable 
the amplification of cAMP augmented stimulated insulin secretion. 
 
6.2. Conclusions 
This thesis identified that the dipeptide carnosine has the ability to inhibit and 
reverse the damaging effects of glucolipotoxic driven cellular stress in β-cells 
 211 
 
associated with type 2 diabetes, thereby resulting in enhanced insulin secretion. 
Carnosine treatment was also shown to increase insulin sensitivity and therefore 
glucose uptake in a skeletal cell model through what we believe is the same 
scavenging mechanism. This dietary supplement is therefore a potential agent that 
could improve patient prognosis via increased blood sugar level management. 
 β-alanine, one amino acid constituent of carnosine was also shown to increase 
insulin secretion and reduce glucolipotoxic driven reactive species in INS-1 β-cells 
when dosed for longer periods of time suggesting a potential protective action 
derived from its utilisation to form carnosine intracellularly. Carnosine derived 
compounds were also screened for their potential to act as carnosinase-2 inhibitors 
and thereby improve control of glucose homeostasis via this mechanism. However, 
these were unsuccessful in terms of β-cell physiology, but potential still exists for 
these compounds in tissues where endogenous carnosine concentrations are higher. 
Further investigation is required though. 
This body of work through a transcriptomic approach also identified that 
glucolipotoxic exposure decreases expression of the GPCR family TAARs, as well as 
olfactory receptors and adenylyl cyclases alike, yet stimulation of TAARs 1-4 in 
control conditions augmented cAMP production and insulin secretion, which was lost 
when INS-1 β-cells were exposed to glucolipotoxicity. Therefore, downregulation of 
GPCR signalling through these families likely contributes to glucolipotoxic inhibition 
of insulin secretion, and therefore marks these proteins as future potential treatment 
targets for type 2 diabetes. 
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7. Future Directions 
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7.1. Results 
As detailed in chapter 5, utilising the RNAseq dataset, GPCRs (TAARs and olfactory 
receptors) were identified as being differentially expressed in INS-1 β-cells when 
exposed to glucolipotoxicity for 72h. This alteration in gene expression was validated 
via qRT-PCR and Western blot and was shown to have a significant functional impact 
on the insulin secretory pathway. 
Carrying on from this work, non-biased enrichment analysis of the full RNAseq data 
sets between control and glucolipotoxic conditions identified cell adhesion and 
extracellular matrix remodelling as key pathways of dysregulated gene expression 
following exposure of INS-1 β-cells to high glucose and fatty acids for 72h (Table 7.1). 
As shown in Table 7.1, cell adhesion and ECM enrichment pathway maps ranked 
second, third and eighth for statistically significant changes in gene expression, with 
p values of 2.365E-09, 2.815E-09 and 7.989E-06 and similarly small false detection rates 
when comparing control gene expression to 3-day glucolipotoxic exposure. 
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Enrichment by pathway maps    
# Maps Total 
gene 
number 
p Value Min FDR 
1 Immune response - T cell co-signalling 
receptors, schema 
55 9.980E-12 8.184E-09 
2 Cell adhesion_ECM remodelling 53 2.365E-09 7.695E-07 
3 Cell adhesion_Cell-matrix 
glycoconjugates 
38 2.815E-09 7.695E-07 
4 Protein folding and 
maturation_Bradykinin / Kallidin 
maturation 
32 1.478E-07 3.030E-05 
5 Rheumatoid arthritis (general 
schema) 
50 1.620E-06 2.657E-04 
6 Blood coagulation_Blood coagulation 39 2.137E-06 2.920E-04 
7 Role of cell adhesion in vaso-occlusion 
in Sickle cell disease 
43 7.313E-06 8.188E-04 
8 Cell adhesion_Integrin inside-out 
signalling in neutrophils 
77 7.989E-06 8.188E-04 
9 Development_Neural stem cell 
lineage commitment (schema) 
38 9.976E-06 9.089E-04 
10 Development_BMP7 in brown 
adipocyte differentiation 
39 7.563E-05 6.202E-03 
Table 7. 1; Pathway map enrichment analysis report of RNAseq Data.  
Using non-biased enrichment analysis, the top 10 statistically significant pathway 
maps when comparing control to 3 day glucolipotoxic exposure RNAseq data were 
ordered along their false detection limits. 
 
In response to this, to further investigate the role of extracellular matrix changes in 
glucolipotoxic conditions, MetaCore, an integrated knowledge database, was again 
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utilised to generate a ranked pathway interactome linked to table 7.1 based on the 
extent of dysregulation. The pathway map linked to ECM remodelling (Figure 7.1) 
identified 5 cellular membrane proteins as being significantly downregulated when 
INS-1 β-cells were exposed to glucolipotoxicity for 72h. These particular proteins 
have been singled out initially due to their cell membrane residency, which makes 
them more amenable for further study (in comparison to extracellular matrix 
proteins) when using tissue culture clonal cell lines. These proteins are the matrix 
metalloproteins (MMP) 14, MMP15 and MMP16, the adhesion receptor CD44 and 
the tyrosine kinase ErbB4. 
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Figure 7. 1; Glucolipotoxic driven changes in extracellular matrix remodelling 
interactome.  
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Illumina HiSeq data was incorporated into the MetaCore network analysis 
programme (Thomson Reuters - http://genego.com). The blue thermometers 
represent the level of significant downregulation of gene expression (P<0.05), whilst 
the red thermometers indicate the level of significant upregulation of gene 
expression between INS-1 β-cells cultured in control or glucolipotoxic media for 72h. 
 
Figure 7.2 indicates the RNA read counts in control and GLT conditions of the 5 
implicated membrane proteins. Read counts were significantly reduced in 72h 
glucolipotoxicity by 37.2 ± 1.3% (p=0.001), 38.3 ± 13.2% (p=4.67e-6), 98.1 ± 1.9% 
(p=9.55e-9), 99.1 ± 0.9% (p= 7.89e-13) and 98.1 ± 0.9% (p=8.68e-10) for MMP15, 
MMP16, MMP14, CD44 and ErbB4 respectively. 
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Figure 7. 2; Illumina HiSeq RNA expression data for ECM membrane proteins 
dysregulated by GLT.  
INS-1 cells were cultured for 72h in standard growth media or media supplemented 
to 28mM glucose and 200µM oleic acid and 200µM palmitic acid. RNA was extracted, 
and quality assessed before Illumina HiSeq sequencing and analysis was undertaken. 
Data is expressed as mean RNA read counts per condition of MMP15, MMP16, 
MMP14, CD44 and ErbB4 ± SEM, from 3 independent RNAseq analyses per condition. 
p<0.005 v control 
 
In order to validate these RNAseq findings and therefore the interactome, 
independent qRT-PCR analysis was performed for the genes MMP15, MMP16, 
MMP14, CD44 and ErbB4. INS-1 cells were therefore cultured in control or GLT media 
for 72h prior to RNA extraction, cDNA synthesis via reverse transcription and qRT-
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PCR analysis (Figure 7.3). A 3 day incubation in GLT caused MMP15 gene expression 
to significantly decrease by 81.2 ± 2.0% (p=1.14e-6), MMP14 gene expression to 
significantly decrease by 48.1 ± 13.5% (p=0.012) and ErbB4 gene expression to 
significantly decrease by 60.2 ± 20.0% (p=0.02). Unfortunately, due to time 
constraints and availability of reagents, only one result was obtained for CD44 and 
MMP16. However, these preliminary findings for these two gene targets suggests a 
similar pattern of glucolipotoxic driven downregulation of gene expression consistent 
with the RNAseq dataset. 
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Figure 7. 3; Glucolipotoxic changes of qRT-PCR expression data of ECM implicated 
proteins.  
INS-1 cells were cultured in control or GLT media for 72h before RNA extraction and 
qRT-PCR analysis performed using primers and cycle conditions detailed in materials 
and methodology section. Data is expressed as fold change in RNA expression of 
MMP15, MMP16, MMP14, CD44 and ErbB4 ± SEM compared to control using 
comparative delta delta Ct (ΔΔCT) method from 3 independent experiments (MMP15, 
MMP15 and ErbB4). One repeat for MMP16 and CD44.  *p<0.05 ***p<0.005 
7.2. Discussion and Future Work 
Utilising the Illumina HiSeq RNA sequencing data, the identification of extracellular 
matrix remodelling was identified as one of the most significantly dysregulated 
cellular events when INS-1 β-cells are exposed to high concentrations of glucose and 
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fatty acids for 72h. This was partially validated via qRT-PCR expression data, 
confirming downregulation of gene expression of the membrane proteins MMPs, 
CD44 and ErbB4 that featured in the network map. 
The extracellular matrix (ECM) is a non-cellular network of structural proteins that 
provide a flexible three-dimensional scaffold for the tissue structure and connective 
junctions, as well as providing chemical and physical cues for migration, 
differentiation and growth. The ECM is constantly undergoing controlled remodelling 
to regulate tissue homeostasis and the dysregulation of ECM composition, protein 
abundance, structure and loss of elasticity has been implicated in numerous 
pathological conditions such as fibrosis and various cancer types (Bonnans, Chou and 
Werb 2014). The ability for β-cells to communicate via the extracellular matrix and 
connexin channels is also vital to synchronised insulin secretion. -cells not coupled 
with connexin junctions show poor insulin gene expression and secretion in response 
to glucose compared to coupled β-cells (Meda, et al. 1990). If the ECM, and therefore 
tissue communication, is dysregulated in response to glucolipotoxicity as preliminary 
data would suggest, this is likely to contribute to the failure of β-cell insulin secretion 
witnessed in type 2 diabetes. 
MMPs are the main enzymes involved in ECM degradation, an initial key component 
of the remodelling process. MMPs are activated via proteolytic cleavage from other 
MMPs or oxidation by reactive species and are then able to degrade all known ECM 
proteins (Lu, et al. 2011). As reactive species are a hallmark of obesity and type 2 
diabetes onset, MMP expression and activity is expected to increase. MMP2 and 
MMP9 which have been researched in type 2 diabetes particularly attack laminin, 
 222 
 
fibronectin, and collagen IV in blood vessels in cerebrovascular disease (Mun-Bryce 
and Rosenberg 1998). However, the relationship between MMP and hyperglycaemia 
and hyperlipidaemia are much more complex. Blood concentrations of MMP2 and 
MMP9 have been reported to be increased in type 2 diabetic patients (Signorelli, et 
al. 2005), however, conflicting data suggest the opposite of decreased MMP 
concentrations in type 2 diabetic patients (Sampson, et al. 2004; Lewandowski, et al. 
2011). Whilst these studies investigate blood concentration as opposed to solely β-
cell concentrations, the latter studies would agree with our findings that chronic 
exposure to high glucose and high fat decrease MMP expression. There is currently 
no published link between MMP derived ECM dysregulation and β-cell failure, 
however any disruption to ECM remodelling or loss of coordinated function via 
connexin channels in response to high glucose and fat may contribute to 
glucolipotoxic driven loss of insulin secretion, but further investigation into this 
would be required. 
Similarly, our enriched interactome suggests that the majority of members of the 
collagen family are highly downregulated in response to glucolipotoxic exposure. 
Various studies have already demonstrated the beneficial function of culturing β-
cells on ECM gel environments containing collagen I and IV. Both β-cell survival and 
insulin secretion was promoted with specific extracellular protein concentrations 
suggesting a role of ECM interaction and signalling between cells in the insulin 
secretory pathway (Nagata, et al. 2001; Weber, Hayda and Anseth 2008). If collagen 
is downregulated in response to glucolipotoxic exposure as preliminary data suggests, 
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this may contribute to the loss of ECM remodelling and consequentially insulin 
secretion. 
The membrane protein CD44 was also shown to be downregulated and linked to 
actin cytoskeletal remodelling via moesin. Actin is a key regulator of insulin secretion 
as it transiently depolymerises in response to glucose allowing nearby insulin granule 
access to the membrane (Thurmond 2007). It also facilitates transport of intracellular 
granules to replenish the readily releasable pool where they can dock with SNARE 
proteins. As CD44 was downregulated when exposed to GLT for 72h, future work that 
was beyond the scope of this PhD will aim to knock down CD44 and look at the 
functional consequences on the insulin secretory pathway. The aim is to determine 
if CD44 is a regulator of glucose stimulated actin reorganisation and whether its loss 
contributes to glucolipotoxic inhibition of insulin secretion.  
In conclusion, this preliminary data suggests that glucolipotoxicity alters both 
extracellular matrix remodelling and cytoskeletal remodelling which may play a key 
role in the dysregulation of insulin secretion in type 2 diabetes and this, alongside 
other future research avenues discussed at the end of chapters 3, 4 and 5 will be the 
basis for future work. 
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Appendices 
Appendix 1 
Target Species Forward Primer Reverse Primer 
TAAR1 Rat 
GAAGGAGTTGAGGAG
CAGTATC 
AAGACGTCATGAATG
CCAGTA 
TAAR2 Rat 
AATGACTATTCCGGTC
GTCAAG 
CCATCAGCATAAGCCT
CTGAA 
TAAR3 Rat 
GGTATGCAGAGCTAC
GAGATTC 
CATGATGGAGCCAGG
AGTAAA 
TAAR4 Rat 
CATGATCGGAGCGAT
AGTGATG 
GTGGTAGCCATGGAG
AGAATAAG 
TAAR5 Rat 
CTCCAAGTTCACAGTC
AGGATAG 
GTAGAGAAAGAAGGC
AGTGTAGG 
TAAR6 Rat 
CAGGAATTTGCATCAG
CATCTC 
CTCCAGGCCATCAGCA
TAAA 
TAAR7b Rat 
TCTGCTCTCAGCCTCA
TCTA 
CCAAAGCCAAAGACT
GCATAAA 
TAAR9 Rat 
CCAAGTTCACCATTTC
GGTTTC 
CTCGTTGGCTCCTGTG
TAAA 
ErbB4 Rat 
AGTGGTCTGTCATTGC
TTATCC 
TGCTGTTGTCCGTGAT
GTAG 
MMP14 Rat 
GGTGTGTGTCCAACCC
TATTT 
GGATGGAAGAGAAGC
AGATGAC 
MMP15 Rat 
CTAGACTGCCCATGTT
CTCTTT 
GACCTCTGGTACCCTA
GTATGT 
MMP16 Rat 
GGACCAACAGACCGA
GATAAAG 
ACCAATACAAGGAGG
CCATAAG 
CD44 Rat 
GCCTGGTACGGAGTC
AAATAC 
TCATCAATGCCTGATC
CAGAAA 
GAPDH Rat 
CATCTCCCTCACAATT
CCATCC 
GAGGGTGCAGCGAAC
TTTAT 
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